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ABSTRACT
SYNTHESIS OF FUNCTIONAL COPOLYMERS VIA AQUEOUS RAFT
POLYMERIZATION FOR BIOCONJUGATION AND TARGETED
DELIVERY OF SMALL INTERFERING RNA
by Adam Wesley York
May 2010
The versatility of reversible addition-fragmentation chain transfer (RAFT)
polymerization has moved this controlled radical technique to the forefront of copolymer
construction for bioapplications including polymeric drug/gene delivery vehicles.
Strengths of the RAFT process include the capacity to control the polymerization of a
wide variety of vinyl monomers under mild conditions, its tolerance to numerous
chemical groups that allow the preparation of functional copolymers for facile
modification, and the range of copolymer architectures with predetermined end group
functionalities which may be synthesized. Given these strengths, RAFT polymerization
was utilized in this research to synthesize functional/reactive copolymers for
bioconjugation and targeted delivery of small interfering RNA (siRNA).
The first section describes the successful aqueous RAFT polymerization of water
soluble, biocompatible N-(2-hydroxypropyl)methacrylamide-b-N-[3-(dimethylamino)
propyl] methacrylamide (HPMA-b-DMAPMA) block copolymers and subsequent chain
end conjugation. Well-defined, HPMA-b-DMAPMA copolymers were synthesized in
the presence of the carboxylic acid containing chain transfer agent, 4-cyanopentanoic
acid dithiobenzoate (CTP; C1), and the initiator 4,4’-azobis(4-cyanopentanoic acid) (V501; I3). Following copolymer characterization, bioconjugation methods to both the α-
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and -chain ends were developed. First, a facile method for the amine functionalization
of the thiocarbonylthio -chain end was developed. The key to labeling the -chain end
of HPMA-b-DMAPMA is to first reduce the dithioester chain end with the reducing
agent NaBH4 and then functionalize the resulting polymeric thiol with a primary amine
through a disulfide exchange reaction with cystamine. It was demonstrated that this
disulfide exchange reaction is efficient and that the amine-functionalized HPMA-bDMAPMA can be easily labeled with an amine-reactive fluorescein fluorophore. Primary
amines were detected via a ninhydrin assay while fluorescein conjugation was analyzed
via UV-vis spectroscopy. Building on the success of this end group conjugation, the
focus was then turned to the conjugation of folate, a cancer cell targeting moiety, to the
α-terminal chain end of HPMA-b-DMAPMA copolymers for targeted siRNA delivery.
The carboxylic acid α-chain ends of the block copolymers were activated via
carbodiimide chemistry to form an activated ester that was subsequently modified with an
amine and folate containing PEG. However, poor conjugation yields, determined via
UV-vis spectroscopy and MALDI-ToF mass spectrometry, to the α-terminal chain ends
led to the development of an alternate synthetic pathway for folate conjugation.
The second section concerns the cell specific delivery of small interfering
ribonucleic acid (siRNA) using well-defined multivalent folate-conjugated block
copolymers. Primary amine functional, biocompatible, hydrophilic-b-cationic copolymers
were synthesized via aqueous RAFT polymerization. HPMA, a permanently hydrophilic
monomer, was copolymerized with a primary amine containing monomer, N-(3aminopropyl)methacrylamide (APMA). Poly(HPMA) confers biocompatibility, while
APMA provides amine functionality, allowing conjugation of folate derivatives. HPMA-
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s-APMA was chain extended with a cationic monomer, DMAPMA, to promote
electrostatic complexation between the copolymer and the negatively charged phosphate
backbone of siRNA. Notably, the HPMA polymer block stabilizes the neutral complexes
in aqueous solution, while APMA allows the conjugation of a targeting moiety, thus,
dually circumventing problems associated with the delivery of genes via cationically
charged complexes (universal transfection). As demonstrated through zeta potential,
fluorescence microscopy and gene down-regulation studies, this tailored copolymer
allows formation of neutral complexes that can be specifically delivered to cancer cells
that over-express folate receptors.
In the third section, a well-defined HPMA-s-APMA copolymer, synthesized via
RAFT polymerization, was utilized for the rational design of multiconjugates containing
both a gene therapeutic, siRNA, and a cancer cell targeting moiety, folate. After isolating
HPMA-s-APMA, a small fraction of the pendent primary amines were converted to
activated thiols utilizing N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP),
providing a copolymer with two distinct reactive sites for both thiol containing
compounds and activated esters. Characterization of the intermediates was performed by
ASEC-MALLS and 1H NMR and UV-vis spectroscopy. Conditions for the
bioconjugation of both 5’-thiolated siRNA and modified folic acid were developed and
carried out in two separate steps. It was demonstrated that this pathway provides a facile
and robust route for producing well-defined targeted siRNA delivery vehicles. In
addition, siRNA release through disulfide cleavage was demonstrated under intracellular
conditions, while the presence of attached folates allows for site-directed delivery to
cancer cell lines that over-express folate receptors. Conjugation reactions and subsequent
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siRNA release were confirmed by polyacrylamide gel electrophoresis and UV-vis
spectroscopy.
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CHAPTER I
INTRODUCTION
Significant progress in controlled radical polymerization (CRP) techniques offers
vast opportunities for developing novel polymeric materials for drug/gene delivery
applications. Carriers synthesized via CRP will undoubtedly impact the future diagnosis
and treatment of infectious and genetic diseases. Specifically, one such CRP technique,
reversible addition-fragmentation chain transfer (RAFT) polymerization, allows
unprecedented latitude in the synthesis of water-soluble architectures with precise
dimensions and appropriate functionality for multiconjugation and targeted delivery of
diagnostic and therapeutic agents.
Prior to development of CRP methods, limited synthetic tools were available to
polymer chemists for the construction of drug delivery vehicles, even though Ringsdorf
and others had eloquently proposed targeted model systems.1,2 Control of (co)polymer
architecture, molecular weight and molecular weight distribution, placement of reactive
structopendant or structoterminal functionality, and solubility/dispersion in biologically
relevant media were obstacles inherent to existing polymer technology. For example,
block and star copolymer architectures with appropriate functionality could only be
achieved via anionic, cationic, or group transfer chain growth polymerization techniques
with limited types of monomers, often requiring protecting group chemistry, under
stringent reaction conditions.3-5 Fortunately, rapid development in CRP now allows
control over a number of necessary design criteria for (co)polymers utilized in biological
applications including drug/gene delivery.
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Recently, CRP has been exploited as an instrument in the field of gene (DNA or
RNA) delivery, and more specifically for the delivery of small interfering ribonucleic
acids (siRNA).6-12 Polymers designed for gene delivery must provide multiple functions
that include housing of the gene, facile surface modification for targeting and or gene
attachment, gene protection from degradation, and reasonable manufacturing costs. In
addition, the polymeric carrier must circumvent several extra- and intracellular issues that
present significant challenges in the successful delivery of genes. These include increased
serum stability and circulation in the blood stream, specific cellular binding, endosomal
release, cytoplasm transport, and release of the gene.13 Although many challenges remain
for effective gene delivery, RAFT polymerization presents a unique opportunity to
rationally design copolymers with appropriate requisites not only for gene delivery but
also the delivery of other therapeutics and diagnostics. In the following sections, the
details of the RAFT process will be highlighted as well as its utility in constructing viable
polymer-conjugate vehicles for targeted drug/gene delivery and its future in siRNA
delivery.

Reversible Addition-Fragmentation Chain Transfer (RAFT) Polymerization
The main CRP techniques include stable free radical polymerization (SFRP),4
atom transfer radical polymerization (ATRP),5 and RAFT polymerization.3,14-17 The key
to CRP is the established equilibrium between active and dormant radical species that
allows controlled growth of polymer chains. In addition, a sufficiently low concentration
of active radicals is maintained thus minimizing termination. The reversible equilibrium
for the three major CRP techniques is illustrated in Scheme I-1.18 In SFRP, dormant

3
polymeric alkoxyamines undergo homolytic cleavage to produce a propagating radical
and a persistent nitroxide radical (here 2,2,6,6-tetramethylpiperidinyl-1-oxyl (TEMPO) is
chosen). The propagating chain can then add monomer and recouple with the persistent
radical reverting back to the dormant chain. In ATRP, reversible cleavage of a covalently
bound halide is accomplished via a redox process catalyzed by a transition metal complex
(i.e., Cu, Ru, Fe or other). The oxidized complex, like the nitroxide in SFRP, serves as
the persistent species readily accessible for recombination with the propagating species.
For details on SFRP or nitroxide mediated polymerization (NMP) and ATRP the reader
is referred to comprehensive reviews written by Hawker, Bosman and Harth4 and
Matyjaszewski et al.,5 respectively. In RAFT, a degenerative addition-fragmentation
process occurs between a propagating chain and a thiocarbonylthio compound. Chain
extension occurs by addition of monomer to the propagating radical. Ideally, the
intermediate radical produced is not involved in propagation and should not irreversibly
terminate to achieve a controlled/living polymerization.
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Scheme I-1. Mechanism for chain extension and block formation showing equilibrium
between dormant and active chains for SFRP, ATRP, and RAFT methods.18

Due to the control afforded by CRP methods the synthesis of complex
(co)polymer architectures is now feasible, a notable limitation of conventional free
radical polymerization. Examples of such complex structures are illustrated in Figure I-1.
Polymer architectures of special interest for delivery applications are statistical, block,
and star copolymers because of their utility in preparing polymer prodrugs and polymeric
drug/gene delivery vehicles (i.e., interpolyelectrolyte complexes (IPECs), micelles and
vesicles).
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Homopolymer

AB Statistical copolymer

AB Alternating copolymer

AB Diblock copolymer
AB Graft copolymer

ABA Triblock copolymer

ABC Triblock copolymer

Star (co)polymer

Figure I-1. (Co)polymer architectures accessible by CRP techniques.

While each of these CRP techniques has its inherent advantages and limitations,
the RAFT process is arguably the most amenable to controlled delivery applications due
to the variety of functional monomers that can be directly polymerized in water without
requiring protecting group chemistry. Furthermore, both structopendant and
structoterminal (α and ω) functionality can be precisely incorporated for subsequent
bioconjugation reactions. These elements make RAFT attractive for the synthesis of
intelligently designed polymers, such as self-assembled, responsive or reactive
copolymers, useful in numerous biologically relevant applications.

6
RAFT Polymerization Mechanism
RAFT polymerization was first introduced by the Australian CSIRO group in
1998.14,17,19 As proposed by the CSIRO group, the RAFT mechanism operates under a
degenerative chain transfer process and is outlined in Scheme I-2. RAFT polymerization
is similar to conventional free radical polymerization the only difference being the
presence of a mediating species known as the chain transfer agent (CTA). As with other
controlled ―pseudo-living‖ polymerization techniques, the rate of initiation should be
greater than the rate of propagation resulting in the initiation of all polymer chains prior
to propagation. Propagation proceeds through the controlled addition of monomer with
minimal termination and traditional chain transfer events. Thus, a successful RAFT
polymerization will yield narrowly dispersed (co)polymers with controlled molecular
weight and (co)polymer architecture.
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Scheme I-2. The RAFT mechanism.3,16,17,20

Initiation. As with all free radical polymerizations, radicals must either be added
or generated in the reaction medium in order to start the polymerization. RAFT
maintains control over the radicals during the polymerization due to the presence of the
CTA. Typically, the initial initiator concentration is judiciously selected to ensure that
the number of CTA molecules is greater than the number of free radicals ([CTA] > [I])
during the polymerization. The concentration of free radicals is dictated by the
dissociation rate constant (kd) while the number of chains is primarily controlled by the
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CTA concentration. The rate of initiation, Ri, is the same as conventional radical
polymerization and is defined as:
𝑅𝑖 = 2𝑘𝑑 𝑓[𝐼]

(1)

where  and [I] are the initiator efficiency and initiator concentration, respectively.
RAFT polymerizations are generally initiated using thermal initiators (e.g. azo initiators)
although there are reports using photoinitiators,21,22 radiation,23-25 and plasma.26
CTA activation / initialization. The generated free radical species (1) may add to
monomer (M) to form the radical species 3 or to the reactive C=S double bond of the
CTA (2) to yield the intermediate radical species 4 (step II, Scheme I-2). Free radical
species 3 can continue to propagate adding more monomer or add to the RAFT CTA (2).
Upon addition across the C=S group (kadd) of the CTA, the intermediate radical species 5
is formed. This intermediate radical can fragment in either direction to regenerate species
3 (kfrag) or expel R (7) (k). Through appropriate selection of CTA, the formation of free
radical species 7 and a new RAFT agent 6 will be favored over species 3. This allows for
reinitiation of the polymerization (ki) through the addition of monomer to form species 8.
Similarly, the radical initiating species 1 can add directly to the CTA (2) to yield the
intermediate radical species 4. As is the case with intermediate radical 5, 4 can fragment
to reform the initiating species 1 or expel R (7). Ideally, adduct 7 will add monomer
resulting in the formation of oligomeric radical species 8.
The period of CTA activation/initialization, also known as the pre-equilibrium, is
typically the time it takes for all R groups to fragment (7) and reinitiate polymerization
resulting in the formation of the oligomeric radical species 8.15-17,27 This process is
governed by the magnitude of the addition and fragmentation rate constants kadd, kfrag, k,
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and k- shown in step II, Scheme I-2. The simplified form of this reversible process is
shown in Scheme I-3 and the forward chain transfer constant (Ctr)3,17 can be defined
mathematically as:
𝐶𝑡𝑟 =

𝑘 𝑡𝑟

(2)

𝑘𝑝

where kp is the rate constant of propagation and ktr is defined as
𝑘𝑡𝑟 = 𝑘𝑎𝑑𝑑

𝑘𝛽

(3)

𝑘 𝑓𝑟𝑎𝑔 + 𝑘 𝛽

and the ratio of rate constants, (kβ/(kfrag + kβ), dictates how the intermediate radical (4 or
5) partitions between starting materials (1 or 3) and products (6, 7, or 9). Similarly, the
reverse chain transfer constant (C-tr)3,17 is written as:
𝐶−𝑡𝑟 =

𝑘 −𝑡𝑟

(4)

𝑘𝑖

where ki is the rate constant of reinitiation and k-tr is described as
𝑘−𝑡𝑟 = 𝑘−𝛽 𝑘

𝑘 𝑓𝑟𝑎𝑔
𝑓𝑟𝑎𝑔

(5)

+ 𝑘𝛽

and the ratio of rate constants, (kfrag/(kfrag + kβ), dictates how the intermediate radical (4
or 5) partitions between starting materials (6, 7, or 9) and products (1 or 3). These
equations are derived assuming a steady-state approximation and that the only reaction
the intermediate radical can participate in is fragmentation (i.e., no side reactions).3,17,28
Again, this pre-equilibrium is controlled by the ability of the R group to fragment and
reinitiate polymerization.
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Scheme I-3. Simplified mechanism for the CTA activation/initialization in RAFT
polymerization.
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In order to fully appreciate the RAFT mechanism, it is important to know that the
number of CTA molecules (2) is greater than the number of radical species (1)
throughout the polymerization. Therefore, the number of radicals in the system is
dictated by the amount of initiator added while the number of chain ends is
predominately controlled by the concentration of CTA.16,17 Given the reversibility of the
RAFT mechanism, activation of a large number of CTA molecules by a small number of
initiator fragments is possible. As such, nearly all chains are initiated by R (7) while
initiator generated chains are minimal.16
Main Equilibrium. The majority of propagation in RAFT polymerization takes
place in step III of Scheme I-2, which is typically referred to as the main equilibrium.
This step is a degenerative chain transfer process that establishes a rapid equilibrium
between the dormant thiocarbonylthio species (10) and the active propagating polymeric
radicals (Pn and Pm).3,16,17,29 The addition of the propagating radicals (kaddP) to the
dormant thiocarbonylthio species (10), also known as a macroCTA, results in the
formation of the intermediate radical species (11). This intermediate radical can then
fragment (kfragP) in either direction giving all polymer chains equal chances to grow,
resulting in uniform chain growth and thus narrow polydispersities. In the main
equilibrium, the R group is transformed from a small molecule to either an oligo- or
polymeric species. As such, the incoming radical species is similar to that of the R
group. Therefore, the rate of fragmentation in the main equilibrium (kfragP) is different
from that of the CTA initialization/activation step (kβ). Given the similarity of R groups
in the main equilibrium, the fragmentation rate for the intermediate species (11) is
assumed to be the same in either direction. Therefore, Equation 3 for ktr from the CTA
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initialization/activation step can be reduced to Equation 6, indicating that half of the
additions of radical species are effective chain transfer events.28

𝑘𝑡𝑟 =

𝑘 𝑎𝑑𝑑
2

(6)

The extent of monomer consumption in the main equilibrium varies depending on
polymerization conditions such as reaction time, as well as relative CTA and monomer
concentrations.16,30 Upon completion or the deliberate quenching of the polymerization,
the vast majority of polymer chains retain the thiocarbonylthio functionality. The
retention of this ―living‖ chain end allows the polymer or macroCTA to be isolated and
subsequently chain extended with a second monomer for the synthesis of block
copolymers.
Termination. As with all free radical polymerizations termination events can still
occur in RAFT polymerization. These events happen through radical-radical coupling or
disproportionation. In addition, it is also possible that the intermediate radical species (4,
5 and 11) can undergo irreversible coupling reactions under certain conditions.31-37 Such
reactions would result in loss of CTA throughout the system leading to higher than
expected molecular weights. However, excellent control over the molecular weight can
be achieved if CTA, monomer, initiator, reaction conditions, and conversion are
appropriately chosen. Typically, in well designed RAFT experiments, high [CTA]o/[I]o
ratios are chosen to greatly suppress termination events. In addition, excessive
polymerization times should be avoided when retention of the thiocarbonylthio moiety is
desired. Stopping the polymerization at moderate conversions lowers the chance of
termination, thus preserving the thiocarbonylthio chain end.
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RAFT Chain Transfer Agent
The key to RAFT polymerization and control over molecular weight is the
thiocarbonylthio moiety of the CTA. Various thiocarbonylthio groups have been
reported in the literature and can be classified into the following categories:
trithiocarbonates,38-41 dithioesters,3,29,42-52 xanthates,53 and dithiocarbamates.54 The two
main functionalities of the CTA, as previously mentioned, are the R group, which must
be a good leaving group and able to efficiently reinitiate polymerization, and the Z group,
which both activates the carbon-sulfur double bond towards radical addition and has a
stabilizing/destabilizing effect on the intermediate radical. The choice of the R group, Z
group, and monomer is not arbitrary and must be carefully made in order to achieve a
successful RAFT polymerization. The generic structure of the CTA was previously
shown in Scheme I-2 as compound 2. Some common examples of CTAs used in RAFT
polymerization are shown in Figure I-2. The most commonly utilized thiocarbonylthio
compounds in current literature are dithioesters (Z = alkyl or aryl) or trithiocarbonates (Z
= S-alkyl), although xanthates (Z = O-alkyl) and dithiocarbamates (Z = N,N-dialkyl) are
still periodically employed.
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successfully employed in RAFT polymerization.
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The R group. In order to achieve a successful RAFT polymerization the R group
must be an effective homolytic leaving group and be able to efficiently reinitiate
polymerization.3,16,17,20 Reinitiation involves addition of R (7) to monomer during the
CTA activation/initialization stage (step II, Scheme I-2). The stability of the fragmented
R group plays a crucial role in RAFT kinetics. If the homolytic leaving group is too
stable, the fragmentation will be fast and efficient but reinitiation will be poor. This
causes significant induction periods that result in little or no polymerization. On the
other hand if the R group is a poor homolytic leaving group in relation to the propagating
chain, poor control over the polymerization is observed.3,20 In addition, the lifetime of the
intermediate radical (5) is strongly influenced by the nature of the R group. For example,
stability, polarity and steric bulk of the R group influence the rates of fragmentation and
reinitiation.3,16,20 In general, R groups with electron withdrawing moieties will produce a
more stable radical upon fragmentation.
The Z group. The nature of the Z group strongly influences the reactivity of the
carbon-sulfur double bond towards free radical addition and the stability of the
intermediate radical species (5, 11).55,56 The rate of chain transfer (ktr) to the CTA can be
modified through manipulation of the Z group. Employing radical stabilizing Z groups
gives a higher probability that propagating chains will add across the carbon-sulfur
double bond, thus limiting the number of monomer units added between chain-transfer
events. However, over-stabilization by the Z group leads to longer lifetimes and higher
concentrations of the intermediate radical species. High intermediate radical
concentrations could possibly lead to self termination reactions or with other active
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radicals. Over-stabilization also leads to poor R group fragmentation causing slow
polymerization rates and increased induction periods.27,57
In general, dithioesters, especially when Z = phenyl (i.e., dithiobenzoates) (C1C4, C6), have the highest chain transfer constants compared to other thiocarbonylthio
species, shown in Figure I-2.16,17 Although dithiobenzoates have a higher reactivity
toward free radical addition, they can lead to significant polymerization retardation
because of increased radical stabilization. This effect is more apparent when
dithiobenzoates are employed with more reactive vinyl monomers (higher kp), such as
acrylamides. Trithiocarbonates on the other hand are less reactive than dithioesters
towards radical addition, but have lower retardation rates and can still provide control
over the polymerization.17 Therefore, trithiocarbonates are generally employed when
polymerizing more reactive vinyl monomers (i.e., acrylamides). As a general rule of
thumb, the rate of radical addition (kadd) to the carbon-sulfur double bond is highest for Z
= alkyl or aryl (dithioesters) and Z = S-alkyl (trithiocarbonates) and lower when Z = Oalkyl (xanthates) or Z = N,N-dialkyl (dithiocarbamates). The lower rate of radical
addition for xanthates and dithiocarbamates, relative to dithioesters and trithiocarbonates,
is due to the zwitterionic canonical forms that arise from interaction of the oxygen or
nitrogen lone pairs with the C=S double bond.16,17 However, the addition of electron
withdrawing substituents on Z, as shown for benzyl 1-pyrrolecarbodithioate (C15) in
Figure I-2, reduces this interaction thus enhancing its reactivity towards radical
addition.55 The subsequent rate of fragmentation (kβ), homolytic cleavage of the R group,
depends largely on the nature and stability of the intermediate radical relative to the
resultant nature and stability of the fragmented R group (R).
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Kinetic Behavior
The success of RAFT polymerization relies heavily on the rate of chain transfer
(ktr) and the lifetime of the intermediate radical. Optimization of these two kinetic
parameters leads to suppression of radical-radical termination and rapid radical transfer
between active propagating chains (chain end radical) and dormant chains
(thiocarbonylthio chain end), two requisites for controlled polymerization. Ideally,
RAFT polymerization should have very similar rates to conventional radical
polymerization. However, observed polymerization rates for many RAFT systems are
retarded when compared to the equivalent conventional radical polymerization system.
Induction periods, time before substantial propagation starts, and propagation rate
retardations, due to low concentration of propagating radicals, are commonly observed in
RAFT polymerization giving rise to polymerization retardation.27,56 Induction periods
are experimentally observed as a deviation from linearity at early polymerization times in
the pseudo first-order rate kinetic plot.56 Two explanations for this induction period have
been attributed to A) slow fragmentation of the intermediate radical adduct (4 or 5) or B)
poor reinitiation (addition to monomer) by the fragmented R group (R; species 7).57,58
For example, Barner-Kowollik and coworkers observed an induction period in the RAFT
polymerization of styrene with cumyl dithiobenzoate (CDB; C2) as the CTA and a cumyl
radical as the initiator.59 This period was attributed to a long-lived intermediate radical
(Figure I-3) (explanation A above) resulting in slow fragmentation and thus prolonging
the CTA activation/initialization step. Several groups have reported that long-lived
intermediate radicals can be destabilized, thus reducing the induction period, by utilizing
CTAs with less stabilizing Z groups (i.e., benzyl vs. phenyl).3,17,55,56
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Figure I-3. Proposed intermediate radical responsible for the observed inhibition period
in the polymerization of styrene with CDB (C2) as the CTA.

On the other hand, Donovan and coworkers correlated the observed induction
period to poor reinitiation efficiency by the R group (explanation B above).58 This was
demonstrated in the RAFT polymerization of dimethylacrylamide (DMA; M2) in the
presence of two CTAs with different R groups and hence different rates of reinitiation.
When utilizing CDB (C2) as the CTA, an induction period was observed and attributed to
slow reinitiation or addition to DMA by the fragmented cumyl radical. Alternatively,
when employing a CTA with an R group that replicates the DMA propagating chain end,
the induction period was eliminated.
Rate retardations in RAFT polymerization are often due to a low concentration of
propagating radicals/active chain ends. This retardation is highly dependent on
monomer/CTA pairings, typically those that give very stable intermediate radicals, as
well as the initial concentration of CTA employed.3,27 The CTA structure plays a crucial
role in the stability and hence the lifetime of the intermediate radical (4, 5 and 11).
Therefore, CTAs that provide highly stabilizing Z groups tend to give intermediate
radicals with longer lifetimes, which in turn lead to higher rates of retardation.57,60-66 The
biggest debate in the literature is the lifetime and fate of this intermediate radical.
Several groups argue that rate retardation arises from a long lived intermediate radical
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species,57,60-68 while others believe that the intermediate radical is consumed in
bimolecular termination reactions.31-37 Due to this ongoing controversy, an IUPAC task
group has addressed, in detail, the different rate retardation theories for RAFT
polymerizations utilizing dithiobenzoate CTAs.27 The reader is referred to this report for
further information. Even though this controversy remains, the ability of the RAFT
process to provide (co)polymers with advanced architectures and well-defined molecular
weights is undeniable.3,16-18,20,69
Molecular Weight Control
In an ideal RAFT polymerization, all chains are initiated by the R group of the
CTA; however, a small amount of initiator is required to start the polymerization. Since
most chains are initiated by the R group the molecular weight of the polymer can
essentially be predicted by controlling the monomer to CTA ratio.3,15-18,20,69 In RAFT
polymerization, the molecular weight evolves linearly with conversion and can be
predicted by Equation 7 in which Mn,th is the theoretical molecular weight, [Monomer]o is
the initial monomer concentration, [CTA]o is the initial CTA concentration,  is the
initiator efficiency factor, [I]o is the initial initiator concentration, kd is the rate constant
of initiator decomposition, t is time,  is the monomer conversion, MWmonomer is the
molecular weight of the monomer, and MWCTA is the molecular weight of the CTA.3,70

𝑀𝑛,𝑡 =

[𝑀𝑜𝑛𝑜𝑚𝑒𝑟 ]𝑜

[𝐶𝑇𝐴]𝑜 + 2𝑓 𝐼 𝑜 (1−𝑒 −𝑘 𝑑 𝑡 )

× 𝜌 × 𝑀𝑊𝑚𝑜𝑛𝑜𝑚𝑒𝑟

+ 𝑀𝑊𝐶𝑇𝐴

(7)

As previously mentioned the amounts of initiator derived chains are negligible allowing
Equation 7 to be simplified to Equation 8.3
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𝑀𝑛,𝑡 =

[𝑀𝑜𝑛𝑜𝑚𝑒𝑟 ]𝑜
[𝐶𝑇𝐴]𝑜

× 𝜌 × 𝑀𝑊𝑚𝑜𝑛𝑜𝑚𝑒𝑟

+ 𝑀𝑊𝐶𝑇𝐴

(8)

Positive deviations in Mn,th imply incomplete usage of CTA, while negative deviations
imply that initiator derived chains are significant and Equation 7 should be used.3,17,20
Generally, high [CTA]o/[I]o ratios are chosen in order to negate the number of initiator
derived chains. However, appropriate monomer/CTA combinations as well as other
polymerization conditions (i.e., temperature, solvent) must also be carefully selected to
maintain molecular weight control.
It is apparent from Equation 8 that a specific molecular weight or chain length can
be targeted by stopping the polymerization at a predetermined time. This control allows
the synthesis of homo- or block (co)polymers with ―tuned‖ dimensions, making RAFT
very attractive for applications requiring well-defined copolymers such as gene/drug
delivery. In addition to controlling the chain length, RAFT polymerization can provide
(co)polymers with advanced architectures including multi-block, star, graft, statistical,
alternating, as well as gradient (Figure I-1).3,16,71
RAFT Conditions and Monomers
RAFT polymerization is perhaps the most versatile CRP method because of its
robust nature and the ability to polymerize a wide range of monomers under mild reaction
conditions. To date, RAFT polymerizations have been performed in both organic and
aqueous media at temperatures ranging from room temperature (~ 22 °C) to 100
°C.3,16,17,39,72 It is important to note that when performing RAFT polymerization under
aqueous conditions, care must be taken in order to prevent hydrolysis and/or aminolysis
of the CTA. For example, Thomas and coworkers73 reported the successful aqueous
RAFT polymerization of acrylamide (AM; M1) demonstrating the importance of
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controlling the pH of the polymerization media. It was shown that under acidic
conditions narrowly dispersed polymers could be obtained while at pH 7 uncontrolled
polymerization and loss of CTA was observed. Since this seminal report, the controlled
polymerization of many water soluble monomers under acidic conditions has been
achieved via aqueous RAFT, including primary amine containing monomers that would
lead to the aminolysis of the CTA if acidic conditions were not utilized.6,9,15,42,43,72,74-78
Developing polymerization conditions that preserve the structural integrity of the
CTA is of significant importance not only for control over the polymerization but also for
retention of end group functionality. CTAs of particular interest for drug and gene
delivery are ones that allow for facile pre- or post-polymerization conjugation to
biological compounds. Examples of such CTAs, all of which contain a carboxylic acid,
C1, C7, C8, C9 and C10 are illustrated in Figure I-2. Polymers and copolymers prepared
with the above CTAs have α-carboxylic and ω-thiocarbonylthio functionalities which are
easily derivatized. The α-carboxylic acid allows for carbodiimide mediated
functionalization with bioactive compounds, for example those containing a primary
amine. Furthermore, the carboxylic acid of the R group can be activated with Nhydroxysuccinimide (NHS) prior to polymerization, allowing for facile bioconjugation,
as demonstrated by D'Agosto and coworkers in 2006.79 CTAs have also been synthesized
with functionalities other than carboxylic acids. For example, in 2007, Davis, Bulmus
and coworkers80 synthesized a novel trithiocarbonate that contained a polyethylene
glycol-substituted (PEGylated) Z group and a pyridyl disulfide R group that could be
easily functionalized with thiol containing compounds, in this case bovine serum albumin
(BSA). Recently, Sumerlin and coworkers81 demonstrated the RAFT polymerization of
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DMA-b-NIPAM (M2-b-M3) copolymers utilizing a trithiocarbonate with an azide
substituted R group. This allowed for post-polymerization modification of the α-chain
end with alkyne functional folic acid through ―click‖ chemistry. The development of end
group conjugations to RAFT-synthesized copolymers is a main objective of this
dissertation,82,83 which was researched concurrently with above reports, and will be
discussed in subsequent sections.
Thermal initiators, such as azo-based initiators (Figure I-4), are typically used to
initiate RAFT polymerizations; however other initiators such as organic peroxides or UV
initiators can also be utilized.3,29 Even though a small number of chains in RAFT are
initiator derived chains, it can be advantageous to use an initiator that has identical
functionality to that of the R group of the CTA. For example, McCormick and coworkers
frequently use this strategy by employing the water soluble azo initiator 4,4’-azobis(4cyanopentanoic acid) (V-501, I3) and 4-cyanopentanoic acid dithiobenzoate (CTP; C1),
which assures only carboxylic acid functionality at the -chain end of the resulting
polymers.6,9,43,77 2,2'-Azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride (VA-044;
I4) is water soluble and possesses a low decomposition temperature allowing for
polymerization of temperature-responsive polymers directly in water without
precipitation. For example, Convertine and coworkers 72 reported the room temperature
aqueous RAFT polymerization of the micelle forming block copolymer DMA-b-NIPAM
(M2-b-M3) that has potential for the uptake and release of hydrophobic drugs.
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Figure I-4. Diazo initiators commonly used in RAFT polymerization.

Reports of RAFT polymers for biomedical and pharmaceutical applications have
increased dramatically over the last few years,15,16,69,84-86 likely due to facile synthesis of
biologically relevant architectures with water solubility under mild conditions. Although
other CRP techniques can be conducted at mild temperatures in organic media, a wider
range of monomers has been successfully polymerized at room temperature in aqueous
media utilizing RAFT polymerization techniques.16,18 This allows, in principle, direct
block copolymer formation from thiocarbonylthio macroCTAs pre-functionalized with
biopolymers, for example, polysaccharides or polypeptides with less possibility of
degradation or denaturation at elevated temperatures or by organic media. Furthermore,
advances made in the RAFT process now allow the direct polymerization of
functional/reactive monomers without protecting group chemistries. The resulting
functional (co)polymers promote facile post-polymerization modification, in fewer
synthetic steps (i.e., no deprotection step), with biologically relevant species that lead to
well-defined biomolecule-polymer conjugates. In addition, RAFT polymerization does
not require the potentially toxic transition metal species and coordinating ligands required
by ATRP. Also of great utility in preparing targeted, controlled activity polymers is the
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aforementioned wide range of monomers that can be polymerized via the RAFT process
including neutral,38-40,47,48,51-54,77,87-92 cationic, 41-43,93-95 anionic, 44-46,96 and
zwitterionic47,48,97 monomers (Figure I-5). Given these distinctions, RAFT polymerization
has been employed to prepare biocompatible, hydrophilic (co)polymers for targeted gene
delivery in the work detailed in this dissertation.
Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA; M4) is a primary example
of an important polymer extensively studied as a non-viral carrier for anticancer drugs,
particularly doxorubicin (DOX).98-105 Although HPMA polymers have been shown to be
nonimmunogenic, they necessarily possessed broad polydispersities because they were
previously synthesized by conventional free radical polymerization techniques. In 2005
the McCormick research labs demonstrated the preparation of a well-defined nearmonodisperse PHPMA via aqueous RAFT polymerization.77 Several potentially useful
block copolymers, for biomedical applications, synthesized from monomers listed in
Figure I-5 will be discussed in subsequent sections; for example, DMA/NIPAM
(M2/M3) block copolymers form responsive micelles and HPMA/N-[3-(dimethylamino)
propyl]methacrylamide (DMAPMA; M7) block copolymers form interpolyelectrolyte
complexes with siRNA.
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Overview of Carriers for Targeted Therapeutic Delivery
Conventional delivery methods involve the administration of free pharmaceuticals
by various routes (i.e., oral, intravenous, topical, transmucosal, inhalation) to achieve a
desired therapeutic effect. Delivering drugs/genes by these methods typically causes the
drug to be distributed randomly throughout the host’s body. Furthermore, free
pharmaceuticals are readily cleared from systemic circulation through renal excretion and
can be inactivated by metabolic degradation.106-109 Due to these factors, a low percentage
of the initial dose reaches the site of action. If the therapeutic agent has minimal side
effects and can be delivered in large doses, then widespread body distribution and rapid
clearance may not be problematic. However, most drug/gene therapies are administered
to treat specific cells or tissues/organs and hence severe side effects can occur when the
drug accumulates in healthy tissue.108,109 Other issues related to the delivery of free
therapeutics are limited solubility and immunosuppression.106 These constraints have
provided researchers impetus for the development of therapeutic carriers that can address
conventional delivery issues.
In principle, intelligently designed therapeutic carriers for advanced delivery
applications can improve systemic circulation, lower toxicity, enhance solubility and
stability, inhibit unwanted metabolism (i.e., degradation), and increase specific tissue
accumulation of the drug/gene of interest.1,2,106,107,109 Several classes of carriers have been
developed and researched in order to optimize pharmacokinetics and physiochemical
properties of the delivered therapeutic agent. Examples of such carriers include viruses,
altered cells, liposomes, dendrimers, nanoparticles and polymers. These carriers can be
further generalized into viral and non-viral classes. While polymeric vehicles will be the
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main focus of this dissertation, other carrier systems will be briefly described in order to
lay the foundation for the impetus of this research.
Viral vectors are very effective at targeting and delivering therapeutic agents to
the cytoplasm or the nuclear envelope of the cell, since they are derived from altered or
recombinant viruses.13 However, shortcomings of viral vectors include the possibility of
an immunogenic response by the host, the high cost of manufacturing, and the lack of cell
specificity.13 Given these problems, a number of non-viral delivery systems with low
immunogenicity yet specific targeting have been considered. For example, conventional
liposomes have been utilized to sequester and transport chemotherapeutics,110
polynucleotides,111 and proteins.112 Although such systems can possess many requisite
requirements for improved delivery efficacy,113,114 disadvantages often are reported such
as limited solubility and partitioning, less than optimal pharmokinetics, and liposome
instability in the physiological environment.115
Recent research on polymeric vehicles has come from consideration of technical,
economic and safety issues. Polymer-based carrier systems include micelles,
polymersomes, polymer-drug conjugates, interpolyelectrolyte complexes, and
nanoparticles. A major goal of this dissertation is to prepare systems that mimic the
highly evolved trafficking and delivery efficiency of viral vectors while avoiding the nonspecific toxicity and immunogenicity issues discussed above. Several significant carrier
requirements are currently being addressed in the scientific community.84,85 For example,
it would be advantageous if the polymeric carrier could degrade or dissociate into low
molecular weight species capable of renal excretion. In the case of non-degradable
carriers, the carrier must be below a critical molecular weight to be efficiently
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excreted.116 As mentioned previously, the carrier must also efficiently associate with and
transport the therapeutic, provide reactive functionalities for targeting groups and or
drug/gene attachment, protect cargo from metabolic processes, and have low
manufacturing costs. In addition, the polymeric carrier must overcome several extra- and
intracellular barriers before successful therapeutic delivery is feasible. Serum stability,
enhanced blood stream circulation, specific cellular binding, endosomal release,
cytoplasm transport, and therapeutic release must be realized despite these hurdles for
sufficient therapeutic efficacy.13 Fortunately, progress made in CRP, and specifically
RAFT polymerization, provides significant opportunity to prepare narrowly dispersed,
well-defined polymeric carriers with the necessary design criteria for successful
therapeutic delivery. For example, RAFT polymerization allows precise control over the
size of the polymeric carrier which is vital for carriers relying on a passive targeting
mechanism while controlled incorporation of reactive functionalities for conjugation
reactions allows polymers to be tailored for active targeting applications.
Passive and Active Targeting
Several factors govern the dose size which can be safely administered to a patient.
Central to this discussion is the accumulation of the drug in the diseased versus healthy
tissue. Through site-specific delivery a high local concentration of the drug/gene can be
delivered to the site of action, thus, enhancing therapeutic efficacy and diminishing
adverse effects on healthy cells/tissues.117,118 Polymeric carriers can either actively or
passively guide the therapeutic to the targeted site.
Passively targeted carriers, primarily used in the treatment of cancer or specific
types of tumoral tissues, do not contain a directing moiety but rather rely on increased
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circulation time to accumulate within the intended site.119-123 The accumulation occurs
due to the enhanced permeability and retention (EPR) effect. This phenomenon exists
because capillaries around tumors have enhanced vascular permeability due to poorly
aligned endothelial cells and limited lymphatic drainage,117,120,124 leading to accumulation
of macromolecular species in tumoral tissue. Because normal tissue has fully developed
vasculature (i.e., less permeable to macromolecules) and can remove macromolecules by
lymphatic drainage, accumulation of macromolecules does not occur. The EPR effect
has been shown to increase therapeutic efficacy due to accumulation and subsequent
cellular uptake of polymeric carriers that were modified/loaded with anti-cancer
agents.99,101,105,117,125
Conversely, active targeting involves the attachment of a ligand to either the chain
end or backbone of the polymeric carrier. These ligands recognize certain cellular
receptors and thus direct the carrier to cellular sites containing the target receptor.
Targeting ligands include, but are not limited to, antibodies, antibody fragments,
vitamins, peptides, and carbohydrates. Utilizing targeting moieties is attractive because it
not only directs the therapeutic carrier to the cellular surface but the specific ligandreceptor interaction promotes internalization of the carrier through receptor-mediated
endocytosis.117 Endocytosis is the process of taking extracellular materials into the cell
through a vesicle known as the endosome. Endosomes are created when a portion of the
cellular membrane invaginates and separates from the rest of the cellular membrane.126
After internalization, the carrier can be released intracellularly, thus exposing the
drug/gene to the cytoplasm and allowing the drug/gene to carry out its intended
therapeutic effect.
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Although monoclonal antibodies and antibody fragments are frequently used for
active targeting of cancer cells,117,127-129 the vitamin folic acid, which is of particular
interest to this dissertation work, has also shown significant promise due to the overexpression of folate receptors on various cancer cell lines.130,131 Folate is an attractive
candidate for targeted controlled delivery because 1) it’s consumed in high quantities by
rapidly proliferating cells (i.e., cancer) due to its need in the metabolism of nucleotide
bases, 2) its ease in conjugation to therapeutic carriers, 3) its high affinity towards folate
receptors, and 4) the limited expression of folate receptors on non-cancerous cells.131
Cancerous cell lines that have been shown to over-express folate receptors include, but
are not limited to, ovarian, cervical, lung, breast, colon, kidney, and brain cancer.130,131
The relatively low number of accounts on functionalizing CRP polymers with folic acid
prior to this dissertation work,132 the ability to directly polymerize functional/reactive
monomers without protecting group chemistries and to precisely control the size of the
carrier via RAFT polymerization, and the facile modification of both α and  chain ends
provides precedence for developing folate-derivatized gene carriers via the RAFT process
for cancer therapy applications.

Polymeric Micelle Delivery Systems
One promising area for delivering therapeutics is the use of self-assembled
polymeric micelles. Although this is not the main focus of this dissertation work, it
deserves recognition and select examples have been included. The self-assembly of
block copolymers into micelles has been studied since 1984 in hopes of developing
therapeutic controlled release systems.2 In most stimuli-responsive micelles, one of the
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polymer blocks is rendered hydrophobic in response to an external stimulus,15,133 usually
a change in temperature, pH, or salt concentration (Scheme I-4).

Stimulus

Scheme I-4. Reversible micellization in response to an external stimulus.

The evolution of CRP methods has prompted the synthesis of a wide variety of
stimuli-responsive block copolymers with controlled block lengths.3,5,15,16,18,69,134 CRP
allows for the facile tuning of the hydrodynamic size, an important parameter when
designing micelles for drug delivery applications. Dimensions are typically in the
nanometer range which is suggested to be ideal for drug delivery through micrometer
sized capillaries.116
Several stimuli-responsive block copolymers have been synthesized via RAFT
polymerization, as well as other CRP techniques, and only a few examples will be
highlighted here. The reader is referred to reviews by Lowe and McCormick 15,16 and
McCormick and Sumerlin135 for further details regarding stimuli-responsive block
copolymers. Thermoresponsive block copolymers, utilizing N-alkyl acrylamide
monomers, deserve special mention since this area has been comprehensively studied for
potential therapeutic delivery.18,135 Most thermoresponsive polymers are synthesized
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utilizing NIPAM (M3) monomer since the resulting polymer possesses a lower critical
solution temperature (LCST) of 32 °C, close to physiological temperature, 37 °C.136-141
In 2000, the first RAFT polymerization of NIPAM in 1,4-dioxane was
demonstrated by Ganachaud and coworkers.51 Since this initial report, a large number of
laboratories have demonstrated the RAFT polymerization of NIPAM with various CTAs
in organic media.16,18 Using an appropriate initiator and CTA, the McCormick
laboratories reported the first room temperature aqueous RAFT polymerization of
NIPAM utilizing the diazo initiator and (I2) 2-ethylsulfanylthiocarbonylsulfanyl-2methyl propionic acid (EMP; C7) or 2-(1-carboxy-1-methylethylsulfanylthiocarbonylsulfanyl)-2-methylpropionic acid (CMP; C9) as chain transfer
agents.72 Significantly, this procedure allows polymerization at temperatures below the
LCST of PNIPAM which prevents polymer aggregation. In addition, diblock copolymers
were prepared by first polymerizing the hydrophilic monomer DMA (M2) followed by
chain extension with NIPAM. The transition from unimers to assembled micelles, as the
temperature was cycled between 25 °C and 45 °C, demonstrated reversible micellization.
This reversibility holds promise for the uptake and release of active agents and the
eventual elimination of the carrier from circulation provided the micelle-to-unimer
process can be controlled. In addition to thermoresponsive polymers, pH-responsive
polymers synthesized via RAFT have also been extensively studied and the reader is
referred to the literature for further details.15,16,44,45,76,142,143
Classical polymeric micelles are less than ideal, however, for delivery
applications since they dissociate into unimers when diluted below the critical micelle
concentration (CMC). Under physiological conditions, at high dilution, release kinetics
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for micelle-entrapped active agents would depend on the rate of the micelle-to-unimers
transition. However, micelle cross-linking can lead to greater control of pharmokinetic
release. A number of significant advances have been made in cross-linking micelles
since the seminal report by Wooley’s group in 1996.144 For thorough discussion the
reader is directed to extensive reviews of these structures, generally referred to as shell
cross-linked (SCL) micelles, which have recently been published by Armes and Read134
and McCormick and coworkers.69
Armes and coworkers 145 were the first to report SCL micelles that incorporated
stimuli responsive monomers (polymerized by group transfer polymerization) showing
promise for the rational design of SCL micelles for delivery purposes. However,
developments in CRP methods, especially RAFT and ATRP, have resulted in a wider
range of stimuli-responsive block copolymers that self-assemble in response to external
stimuli. Initially, SCL micelles were formed through the cross-linking of outer blocks,
thus requiring dilute micellar solutions to prevent inter-micelle cross-linking. This was
circumvented by Armes and coworkers 146 by utilizing responsive triblock copolymers in
which the middle block was cross-linked allowing the outer block to sterically inhibit
inter-micelle cross-linking.
To date, most literature reports have focused on non-reversible covalent crosslinking utilizing BIEE,146-148 carbodiimides,149-154 activated esters,155 divinyl sulfone,156 or
―click‖ chemistry.157 However, permanently cross-linked systems are unfavorable since
most SCL micelles are larger than the renal threshold limit, preventing excretion through
the kidneys. Reversibly cross-linked systems are more promising because the cross-links
can be cleaved by an external reagent causing molecular dissolution of the micelles, thus
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making excretion more probable. In that regard Li and coworkers 158 reported the
synthesis of reversible SCL micelles utilizing RAFT-synthesized triblock copolymers.
The activated monomer N-acryloxysuccinimide (NAS; M5), which can readily react with
primary amines, was incorporated into the inner block. The disulfide containing diamine
cystamine was used to cross-link the inner block resulting in reversible SCL micelles.
The RAFT-synthesized polyethylene oxide (PEO)-b-[DMA-s-NAS]-b-NIPAM (PEO-b[M2-s-M5]-b-M3) triblock copolymers formed micelles at elevated temperatures
(Scheme I-5). The shell of the micelle was then cross-linked with cystamine through the
statistically incorporated NAS groups. The reversibility of the polymer system was
monitored by dynamic light scattering (DLS) and the reduction of the cystamine disulfide
bond was achieved by addition of a reducing agent such as tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT). After reduction, the system could be crosslinked again by the addition of excess cystamine through a thiol-disulfide exchange
mechanism. It was shown that the rate of release of the model cardiovascular drug
compound, dipyridamole (DIP), from these SCL micelles can be easily controlled by
addition of a reducing agent at temperatures below the LCST of the PNIPAM block
(Figure I-6). When no reducing agent was present, the rate of release of the cross-linked
system was slower than that of the uncross-linked system at 37 °C, demonstrating the
potential usefulness of tailored stimuli-responsive copolymers in therapeutic delivery.
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Scheme I-5. Idealized representation of the reversible cross-linking of PEO-b-(DMA-sNAS)-b-NIPAM (PEO-b-[M2-s-M5]-b-M3) copolymer SCL micelle.158
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Figure I-6. A release study of the model cardiovascular drug dipyridamole from
reversible SCL micelles PEO-b-(DMA-s-NAS)-b-NIPAM (PEO-b-[M2-s-M5]-b-M3)
copolymer sensitive to reducing environments.158

Given the need for targeted delivery systems and the fact that SCL micelles could
deliver therapeutic agents, consideration should be given to modifying surfaces of SCL
micelles thorough conjugation of targeting moieties, peptides, proteins, or other
biological motifs. Wooley’s research group has made significant contributions to this
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area in recent years and has synthesized SCL micellar systems that have great potential
for increasing drug delivery efficacy. For example they reported the surface modification
of SCL micelles that were assembled with ε-caprolactone-b-acrylic acid (PCL-b-PAA)
copolymer synthesized by a combination of ring opening polymerization and ATRP,
followed by hydrolysis to obtain PAA from poly(tert-butylacrylate).150 The PAA shell
was approximately 50% cross-linked using carbodiimide chemistry leaving the remaining
carboxylic groups available for further modification. Later this group functionalized
these copolymers with both a fluorescent label and a protein transduction domain (PTD)
peptide.159 Despite the low percent of PTD peptide conjugation, the SCL micelles
displayed the ability to bind to cellular surfaces and subsequently cross the cellular
membrane, as shown by fluorescent confocal microscopy. Wooley and coworkers have
also successfully polymerized numerous diblock copolymer systems via ATRP or SFRP
capable of forming SCL micelles that have been surface modified with various
bioconjugates including folate,160 antigens,161 and integrin binding ligands.162 Methods
for conjugating such motifs to CRP (co)polymers are discussed in the following section.

Polymeric Prodrugs and Bioconjugates
Over the past three decades, biocompatible polymers have been extensively
studied and used to conjugate either therapeutic or diagnostic agents to either side chain
or chain end functionalities. As early as 1975, Ringsdorf 1 suggested design criteria for
such a system having four main components including a water soluble, biocompatible
backbone, a therapeutic agent, a spacer to separate the therapeutic agent from the
backbone, and a targeting moiety (Figure I-7). The conjugate of a therapeutic agent to a
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polymer through a linker, usually a degradable linker, is known as a polymeric prodrug.
These synthetic carriers can be targeted to specific cellular sites/tissues via the
aforementioned passive or active targeting methods.
Polymeric
Backbone

Drug

Targeting
Moiety

Degradable
Spacer

Figure I-7. Design criteria for polymeric prodrugs as suggested by Ringsdorf.1

Polymeric prodrug activity requires that the linked therapeutic agent either remain
active while conjugated or be released from the backbone once the carrier has reached the
targeted site. Until recently polymeric prodrugs were synthesized by non-controlled
polymerization methods, resulting in poorly defined polymers with broad molecular
weight distributions. This may not necessarily be a problem, providing the polymer is
biodegradable; otherwise the polymer must be sufficiently small to allow excretion
through the kidneys over time. It has been shown that linear polymers below 40 kDa, or
approximately 5 nm in diameter, are cleared readily through renal excretion.116 Therefore
it is desirable to produce non-biodegradable linear polymers near this limit to enhance
circulation, but excretion can occur over time. CRP techniques offer opportunities for
size selection since polymers with predetermined molecular weights can be easily
synthesized. Selecting the appropriate CRP method and monomers can provide
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(co)polymers with biocompatibility and reactive pendent and chain end functionality for
facile bioconjugation of therapeutics, targeting moieties and/or diagnostics.
Polymer Backbone Conjugation
Attachment of drugs or other biological species directly to a polymer backbone
has been the subject of extensive investigation.107 The presence of multiple reactive sites
along the backbone allows for high loading of biological agents (e.g. drugs, targeting
groups, vitamins). Furthermore, conjugation of multiple drugs and targeting moieties
allows the treatment of the ailment through multiple biological pathways leading to
higher inhibitory effects. Polymers with functional side chains can be prepared through
the polymerization of protected or unprotected monomers. In general, protected
monomers are employed when reaction conditions are unfavorable or impractical for the
direct polymerization of the unprotected monomer equivalent. However, deprotection
steps following polymerization can lead to incomplete protecting group removal or cause
other side reactions that affect the polymer backbone structure or other incorporated
comonomers.163 Due to these issues, the direct polymerization of unprotected monomers
is clearly a more attractive strategy.
Primary examples of backbone conjugation through the incorporation of
functional monomers can be found in the work published by Kopeček et al., Ulbrich et
al., and others who focused on the delivery of anticancer therapeutics using the
biocompatible polymer, poly(N-(2-hydroxylpropyl)methacrylamide)
(PHPMA).98,102,104,105,119,120,164-169 A potential problem with conventionally polymerized
HPMA (M4) containing copolymers is that of polydispersity, which can now be
circumvented by RAFT polymerization.77 In traditional controlled ―living‖ techniques,
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such as anionic, cationic and group transfer polymerization, the direct polymerization of
unprotected monomers is limited and generally requires protecting groups.163 The advent
of CRP and the development of polymerization conditions tolerant to various functional
groups (i.e., activated esters,155,158,170-174 primary amines,9,74,75,175,176 activated thiols,177,178
aldehydes,179 isocyanates180,181) now allows for the synthesis of narrowly dispersed
functional (co)polymers without protecting groups. Until recently, there were few reports
of the direct polymerization of unprotected monomers via RAFT polymerization, and
even less regarding the preparation of HPMA copolymer conjugates via CRP methods. A
major focus of this dissertation work, carried out prior to or concurrently with the above
literature references, was to adapt the aqueous RAFT process to copolymerize HPMA
with unprotected primary amine monomers to produce copolymers for subsequent
bioconjugation and gene delivery applications. Some examples of monomers with
reactive pendent functionality polymerized via CRP techniques are illustrated below
(Figure I-8).
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Activated ester monomers. Activated ester monomers polymerized by CRP
provide pendent functionality for attachment of drugs, targeting moieties, and compatible
entities. The copolymerization of pendent reactive monomers with hydrophilic
monomers allows the facile synthesis of water soluble multivalent polymeric prodrugs.
The polymerization of NAS (M5) or N-methacryloxysuccinimide (NMS; M6), for
example, has been achieved by both RAFT polymerization155,158,173 and ATRP.182 Müller
and coworkers182 successfully polymerized NMS via ATRP in organic media. The
pendent NMS units were reacted with specified quantities of the model compound,
glycine-glycine--naphtylamide hydrobromide. The remaining NMS units were then
functionalized with 1-amino-2-propanol, resulting in a water soluble PHPMA copolymer
conjugate. One potential drawback of synthesizing homopolymers of NAS or NMS is
that the resulting homopolymers are only soluble in dimethyl sulfoxide (DMSO) or
dimethylformamide (DMF).163 This solubility issue can be addressed through
copolymerization with other monomers or homopolymerizing activated ester monomers
with functionality other than N-hydroxysuccinimide (NHS). For example, Théato and
coworkers174 demonstrated the polymerization of pentafluorophenyl methacrylate in
dioxane via RAFT. Recently, Kane et al.173 successfully synthesized narrowly dispersed
HPMA-co-NMS (M4-co-M6) random copolymer via RAFT polymerization in organic
media (Scheme I-6). NMS had to be added gradually to the polymerization due to the
difference in reactivity ratios between HPMA and NMS to ensure uniform distribution of
the NMS monomer. The incorporation of the NMS monomer was kept between 20 and
28 %. Bioconjugation of a peptide that inhibits the assembly of anthrax toxin to HPMAco-NMS copolymer was demonstrated by the authors who reported a three orders of
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magnitude improvement in inhibition by the multivalent polymer bioconjugate relative to
the free peptide.
HPMA
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NMS
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Scheme I-6. Conjugation of an anthrax inhibitor peptide to a RAFT-synthesized HPMAco-NMS (M4-co-M6) copolymer.173

Primary amine monomers. Preparing (co)polymers with pendent primary amine
functionalities is attractive for various applications including drug carriers183 and
polymeric micelles and vesicles.184 However, the controlled polymerization of
monomers with primary amine groups has proven to be challenging and often requires
protecting groups.175 Fortunately, the rapid development of aqueous RAFT
polymerization now allows for the facile polymerization of primary amine containing
monomers without protecting group chemistry.9,16,69,74,75,78 This is significant given the
high reactivity of primary amines towards numerous functionalities (i.e., carboxylic
acids, isocyanates, aldehydes) allowing facile attachment of biorelevant species. The use
of ATRP to polymerize amine containing monomers proves to be difficult because ligand
displacement, used to stabilize the transition metal, by the growing chain can occur and
side reactions between the pendent primary amines with the halogen end group, both of
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which are required for successful ATRP.185 The successful polymerization of APMA
(M9) has recently been reported by the McCormick laboratories9,75,186 as well as
others.74,78 For example, Li and coworkers reported the successful homopolymerization
of APMA in a water/dioxane mixture utilizing CTP (C1) as the CTA with narrow PDIs.
The APMA homopolymers were chain extended with NIPAM (M3) and the resulting
block copolymers self-assembled into vesicles upon a temperature stimulus. The vesicles
structure was locked in place via interpolyelectrolyte complexation between the cationic
APMA block and an anionic homopolymer. It is important to note that the
polymerization of APMA needed to be performed under acidic conditions, as would be
the case with other primary amine monomers, to ensure amine protonation; therefore,
preventing aminolysis of the thiocarbonylthio moiety. Narain and coworkers78 and
Morgan et al.74 have also reported that the RAFT polymerization of primary amine
monomers (APMA and AEMA (M13)) should be performed under acidic conditions.
Recently, the McCormick laboratories synthesized statistical copolymers, via aqueous
RAFT, containing APMA repeats that were subsequently functionalized with activated
ester folates through post-polymerization modification for targeted delivery applications.9
Activated thiol monomer. The synthesis of polymers containing activated thiols
as pendent functionality is also extremely attractive given the role of thiols in biological
reactions. Thiols have been used extensively in the bioconjugation of peptides, proteins,
drugs, and thiol reactive dyes.187-190 Thiols have been shown to be efficiently reactive
towards other thiols (disulfide exchange), maleimides (thiol-ene reactions), and
iodoacetamides. The first controlled radical polymerization of the activated thiol
containing monomer pyridyldisulfide ethylmethacrylate (PDSM; M22) was reported by
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Thayumanavan and coworkers 191 utilizing ATRP and was later adapted to organic RAFT
polymerization by Bulmus, Davis, et al.177,178 PDSM was successfully polymerized
utilizing CTP (C1) as the CTA and azobisisobutyronitrile (AIBN; I1) as the primary
source of radicals, in DMF, yielding polymers with PDIs as low as 1.15.178 The PDSM
pendent functionality was shown to be reactive towards mercapto compounds, including
the tripeptide L-glutathione, resulting in mercapto-polymer conjugates linked through a
reducible disulfide bond. These polymers have significant potential in delivery based
applications due to the facile cleavage of disulfide bonds under reducing conditions.
Expanding on this research, Bulmus and coworkers recently reported the conjugation of
DOX to PDSM-b-HPMA (M22-b-M4) copolymer.177 Prior to conjugation, maleimide
functionality was introduced to DOX through an acid labile hydrazone bond. The
conjugation of maleimide-DOX and simultaneous cross-linking of PDSM-b-HPMA
copolymer into micellar assemblies was performed in a one-pot synthesis in the presence
of a reducing agent. Subsequent release of DOX from the disulfide micellar assemblies
was realized under acidic pH.
End Group Conjugation
The use of CRP polymers for end group conjugation has received significant
interest recently given the telechelic nature of CRP polymers and the facile
transformation of chain ends to functionalities reactive towards biomolecules. A recent
review by Haddleton et al. 192 discusses various bioconjugation reactions to polymer
chain ends prepared by CRP. Here a few systems have been selected to illustrate the
potential of these methods. Maynard’s group 193-195 utilized ATRP to produce
bioconjugates with controlled molecular weights and narrow polydispersities. They
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functionalized ATRP initiators with biotin, bovine serum albumin (BSA), and lysozyme
and subsequently polymerized NIPAM (M3) from modified ATRP initiators. The
resulting systems retained biological activity even after conjugation. At elevated
temperatures the PNIPAM segments collapse and the covalently attached bioconjugates
are rendered inactive. Possible applications of this and related work include enzyme
regulation or recovery.194,196,197 Stayton, Hoffman and coworkers198-200 have also
reported the bioconjugation of biotin to RAFT synthesized PNIPAM. They successfully
PEGylated biotin to the -terminal chain end199 by carbodiimide chemistry and to the terminal chain end198,200 by thiol-maleimide chemistry (Scheme I-7). It is important to
note that modification of the -terminal chain end with amines must be done carefully
since aminolysis of the -terminal thiocarbonylthio group can occur. This is easily
circumvented by the removal of the thiocarbonylthio moiety through one of several postpolymerization modifications.29,201 Hong et al.202 reported the synthesis of a biotinylated
CTA that was then used to directly mediate polymerization of HPMA (M4) and NIPAM,
by RAFT polymerization. The resulting biotinylated, temperature-responsive, water
soluble block copolymer was shown to self-assemble into polymeric micelles. Although
bioconjugates synthesized by these groups have yet to be used for drug delivery, the
potential of such modified polymers for drug or gene delivery is apparent.
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The ease in controlling end group functionalities through the proper selection of
CTA has arguably made RAFT polymerization the most used technique for chain end
modification through either pre- or post-polymerization reactions. One defining
characteristic of the RAFT process is the facile reduction of the -terminal
thiocarbonylthio chain end via reduction or aminolysis to yield a thio-terminal polymer
easily modified by chemistry commonly used in the biosciences.3,10,20,29,82,203-205 This
method also allows RAFT polymers to be functionalized with biological motifs at the terminal chain end, a process that has met with limited success in the past. McCormick
and coworkers first reported the in situ reduction of RAFT-generated polymers, directly
in water, to stabilize transition metal nanoparticles which have potential for
biodiagnostics.204,205 The facile transformation of the thiocarbonylthio moiety to a
polymeric thiol was also exploited by Oupicky and coworkers 206 for the direct
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conjugation of a maleimide functionalized biotin to a temperature responsive PEO-bNIPAM (PEO-b-M3) block copolymer. More recently, Bulmus et al. showed the
versatility of functionalizing the -terminal of RAFT-generated polymers through the
aminolysis of the thiocarbonylthio in the presence of 2,2’-dithiodipyridine (DTP) or ene
modified biomolecules yielding polymers with -terminal activated thiols or polymerbiomolecule conjugates (Scheme I-8).10 Homopolymers with activated thiol terminal
groups were modified with thiol containing biomolecules including a model hexapeptide
and oligonucleotide, while the in situ conjugation to homopolymers, in the presence of 2aminoethanol, included ene modified biotin and 6-O-methacryloylmannose. These end
group conjugation techniques are increasingly being utilized to produce polymeric
bioconjugates through the attachment of peptides, proteins, oligonucleotides or targeting
moieties for drug or gene delivery applications.
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Scheme I-8. ω-Terminal modification of RAFT-synthesized polymers via aminolysis in
the presence of 2,2’-dithiodipyridine (DTP) or ene modified biomolecules.
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Polyelectrolyte Complexes
Polyelectrolyte complexes resulting from the electrostatic interactions between
two oppositely charged macromolecules are being intensely pursued for gene delivery
applications. The most promising examples involve complexation between either
cationic homopolymers or hydrophilic-block-cationic copolymers and polynucleotides
such as DNA or RNA. The functional groups of the cationic polymer or copolymer
associate with the negatively charged phosphate backbone of polynucleotides.
Polyelectrolyte complexes, sometimes referred to as interpolyelectrolyte complexes
(IPECs) or block ionomer complexes (BICs), protect the complexed polynucleotide from
degradative enzymes, while remaining in the aqueous phase. In order to maintain
solubility or dispersability, the complex must maintain a net positive or negative charge
or be stabilized via a hydrophilic-co-cationic polymer.
As with other delivery vehicles, polyelectrolyte complexes used to deliver
polynucleotides (genes) must possess the aforementioned requirements and circumvent
any encountered extra- and intracellular barriers before efficient transfection can be
realized. Two fundamental problems the polymeric carrier must address are the gene
packaging and its stability/circulation in the bloodstream. Packaging and serum stability
are interrelated because gene packaging results in the steric shielding of polynucleotides
from nucleases in the blood stream. Serum stability is also affected by the net charge of
the complex. Neutral complexes often aggregate when placed in physiological
conditions. Conversely, net anionic and cationic complexes remain soluble but introduce
problems in the intracellular delivery of the gene.
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One current area of scrutiny is the effect of the polycation/polynucleotide ratio on
the size, stability, and formation of polyelectrolyte complex. Typically the N/P (nitrogen
to phosphate) ratio is used to determine the net charge of the complex. N/P ratios are
often less than or greater than one in order to confer water solubility. However,
electrostatic repulsions between the negatively charged complexes and the cell membrane
(also negatively charged) prevent transfection. Conversely, positively charged
complexes associate with cell membranes via strong electrostatic interactions leading to
nonspecific cellular uptake through adsorptive endocytosis.207 Furthermore, this strong
interaction often leads to membrane disruption resulting in cell death. Even if positive
complexes could be targeted to specific cells, negative proteins found in the blood can
associate with the complex resulting in clearance by phagocytic cells.113,208,209 Neutral
complexes (N/P=1) can in principle circumvent the problems associated with negative
and positive complexes, but often have low solubility leading to precipitation.
In addition to imparting favorable properties to the complex before cellular
uptake, the polymeric carrier must also provide components which promote successful
delivery once internalized by the cell. Commercially available cationic polymers, such as
poly(L-lysine) (PLL) or poly(ethylenimine) (PEI) (Figure I-9), are typically used for gene
delivery studies because of widespread availability, and the fact that PEI containing
complexes promote endosomal escape via the ―proton sponge‖ effect.113,114,183,210,211
Though PEI-based complexes are able to escape the endosome, these polymers were not
originally designed for gene delivery and hence have suboptimal properties, including
high cytotoxicity, inherently broad molecular weight distributions, and little structural
uniformity (e.g. linear or branched). If other architectures are desired, such as blocks,
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extra synthetic steps are required. For further information regarding commercially
available polymers for gene delivery, the reader is referred to thorough reviews by Pack
et al.,113 Kissel et al.,166 and Kim et al.114
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Figure I-9. Structures of poly(L-Lysine) (PLL) and branched poly(ethylenimine) (PEI)
used in the formation polyelectrolyte complexes with polynucleotides.

Rapid advancements in polymerization techniques, including CRP, have provided
researchers with the tools necessary to synthesize potential gene carriers. It is anticipated
that both extra- and intracellular barriers can be overcome through the intelligent and
rational design of polymeric carriers. For this reason, the use of well-defined polymers
synthesized by CRP techniques offers an attractive alternative to commercially available
polymers. Utilizing CRP methods, hydrophilic-b-cationic copolymers can be synthesized
thus yielding a carrier which can form neutral, stable complexes solving stability and
circulation problems seen in the aforementioned systems. Electrostatic interactions
through the cationic block stabilize the polynucleotide while the hydrophilic block
provides steric stabilization of the entire complex. The water soluble, biocompatible, and
nonimmunogenic PHPMA or PEO are usually used as the hydrophilic block, while the
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cationic block generally consists of tertiary or quaternary amines.7 In principle, the
binding/release properties of the carrier can be tailored by choice of cationic monomer
and polymer block architecture. For example, quaternization of tertiary amines with
varying alkyl groups or the random copolymerization of the cationic block with a neutral
monomer will result in polymers with different binding strengths.
Though promising, the reports of CRP polymers synthesized specifically for use
in gene delivery through polyelectrolyte complexation are limited. The delivery of
siRNA, a messenger RNA (mRNA) down-regulator, via polyelectrolyte complexation
has recently moved to the forefront of gene delivery and will be discussed in a
subsequent section. The following examples pertain only to condensing DNA or
oligonucleotides via cationic containing (co)polymers. Oupicky and coworkers212
synthesized homopolymers of NIPAM (M3) via RAFT polymerization, utilizing a CTA
with -terminal carboxylic functionality. The carboxylic acid was activated by
carbodiimide chemistry and subsequently linked to branched PEI. The ability of the
NIPAM-co-PEI (M3-co-PEI) copolymer to complex with plasmid DNA and
subsequently transfect cells was studied. The complexation between the copolymer and
the plasmid DNA at various N/P ratios was monitored by ethidium bromide exclusion
assay. It was found that as the N/P ratio was increased above 2.5, no further ethidium
bromide exclusion was observed; the fluorescence intensity decreased indicating that
ethidium bromide was unable to intercalate the condensed DNA. When compared to
conventionally synthesized PNIPAM, the RAFT PNIPAM exhibited wider phase
transitions. The authors attributed this to the aminolysis of the thiocarbonylthio group
when in the presence of the amine containing cell culture medium or amine-functional
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PEI. Therefore, PNIPAM synthesized by conventional free radical polymerization was
used for the remainder of the studies. The copolymer complexes had cytotoxicity similar
to PEI/DNA complexes at temperatures above the LCST, while cytotoxicity decreased at
temperatures below the LCST. The PNIPAM-PEI/DNA complexes had lower levels of
cellular uptake and transfection as compared to the PEI/DNA complexes when
temperatures were below the LCST and increased to PEI/DNA complex levels above the
LCST. Even though the remainder of the studies used a conventionally polymerized
PNIPAM, the -terminal thiocarbonylthio of the RAFT generated polymer might be
easily modified in future work.29,201
Mallapragada and coworkers213 synthesized a pentablock copolymer utilizing
ATRP. A difunctional PEO-block-poly(propylene oxide)-block-PEO (PEO-b-PPO-bPEO) macro-initiator was used in the polymerization of the cationic monomer 2[(diethylamino)ethyl]methacrylate (DEAEMA, M12). The pentablock was capable of
condensing plasmid DNA. The polyelectrolyte complex displayed lower cytotoxicity as
compared to linear PEI, while maintaining the ability to protect the plasmid DNA from
enzymatic degradation. At low N/P ratios (e.g. 3/1 and 4/1), the polymer/DNA complex
was able to transfect cells with efficiencies similar to that of linear PEI, but at higher
ratios the complex became more cytotoxic. In addition, the pentablock copolymer
displayed thermo-reversible gelation behavior due to the presence of the PPO block. This
thermoresponsive behavior may be advantageous for local delivery of genes or other
therapeutic agents administered by subcutaneous injections.
Wooley and coworkers214 also demonstrated the ability to package and protect
DNA using a cationic SCL micelle. The styrene-b-4-vinylpyridine (S-b-4VP; S-b-M10)
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cationic copolymer self-assembled in aqueous solution creating a hydrophobic PS core
and a solvated P4VP hydrophilic shell.215 The resulting micelle was cross-linked through
a radical oligomerization process, ―locking‖ the micelle conformation. The cationically
charged SCL micelles were then loaded with plasmid DNA and studied using atomic
force microscopy (AFM), DLS and enzymatic degradation studies. Although these
polymers were synthesized using anionic polymerization, the same monomers could be
synthesized in less stringent conditions using CRP methods and should have potential
applications in gene delivery.
Phosphorylcholine-based polymers reduce nonspecific protein adsorption216 and
have therefore been used as biomaterials.217,218 Stolnik et al.219 synthesized a series of
block copolymers via ATRP comprised of the cationic monomer 2[(dimethylamino)ethyl]methacrylate (DMAEMA; M11) and the zwitterionic monomer 2(methacryloyloxyethyl phosphorylcholine) (MPC; M22) capable of condensing DNA.
An optimal block composition of the DMAEMA-b-MPC (M11-b-M22) copolymers was
found necessary in order to obtain stable colloids and prevent non-specific cellular
binding even though the MPC moiety slightly inhibited DNA binding.
Cellular uptake of polyelectrolyte complexes can be increased by exploiting the
over-expression of folate receptors on cancer cells. In order to maintain high transfection
efficiency while eliminating non-specific uptake, Armes and coworkers,132 synthesized
folic acid conjugated DMAEMA-b-MPC (M11-b-M22) copolymers, via ATRP, through
post-polymerization modification. Preliminary studies showed that the folic acid
conjugated block copolymer/DNA complexes were preferentially taken up in specific cell
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lines. However, to the best of our knowledge, these and subsequent studies with this
block copolymer have not been published to date.
Although there are few reports on the conjugation of targeting species to RAFT
synthesized polymers, the techniques mentioned earlier for polymeric prodrugs could be
utilized easily to target gene carriers to specific sites. For example two routes that can be
adapted for the facile modification of RAFT synthesized polymers include reaction of the
carboxylic group built in to the CTAs shown in Figure I-2 or the reduction of the
thiocarbonylthio -terminal chain end to a thiol. Carboxylic groups and thiols are widely
used in biochemistry and can react readily with primary amines, thiols, maleimides, as
well as other reactive functionalities.
The systems mentioned above have shown promise in the future delivery of
polynucleotides, but many unresolved issues must be addressed. These include
developing successful conjugation techniques for attaching targeting moieties to the
carriers via methods discussed above, enhancing cellular uptake, optimizing
interpolyelectrolyte binding strength and endosomal release. The development of
tailored copolymers, via CRP methods, for construction of polyelectrolyte complexes as
well as polymer-bioconjugate systems have recently shown promise in delivery of a
newly discovered RNA therapeutic, siRNA.6-12

Small Interfering Ribonucleic Acid (siRNA)
siRNA was first discovered by Mello and Fire in 1998 220 as the effector molecule
that leads to gene suppression in the RNA interference (RNAi) pathway.221-224 siRNA
consists of two complementary RNA strands, a sense strand and an anti-sense strand.
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The siRNA duplex typically consists of 21 to 23 base pairs in the central part with two 3’
nucleotide overhangs from each strand.222-225 siRNAs can be derived from long double
stranded RNA (dsRNA), short hairpin RNA (shRNA), or other modified double stranded
RNAs that have been introduced to the cell.223
In the first step of the RNAi pathway (Scheme I-9), the delivered modified-, dsor shRNA is processed into siRNA by an RNase III-type endoribonuclease termed
DICER.222,223 The siRNA is then bound to a multi-protein complex known as the RNA
induced silencing complex (RISC). RISC facilitates the unwinding of the siRNA duplex
and helps direct the anti-sense strand to the complementary sequence found on mRNA.
This interaction causes mRNA cleavage by RISC between the 10th and 11th nucleotides
from the 5’ end of the incorporated siRNA strand leading to the down-regulation of the
encoded protein.223,226 siRNA is attractive for genetic-based therapeutics because it can
reduce gene expression with limited dosage and less toxicity than other oligonucleotide
treatments such as anti-sense oligodeoxyribonucleic acids (ODNs), DNAzymes or
ribozymes.223,225 However, several factors affect the efficacy of siRNA delivery
including, delivery method, delivery to specific tissues, chemical modifications, and its
susceptibility to enzymatic degradation.13,223,225 These factors must be taken into
consideration when designing a vehicle for siRNA delivery.
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DICER
Double-stranded RNA

ATP
Argonaute,
Effector molecules
Cleavage of dsRNA
into siRNA by DICER

RNAi-induced
silencing complex (RISC)
Complementary
mRNA

Protein
Expression

Cleaved mRNA

Target mRNA Cleavage Site

Scheme I-9. General mechanism for siRNA gene down-regulation via the RNAi
pathway.

siRNA Delivery
Since the discovery of the RNAi pathway, a number of carrier systems have been
developed for the delivery of siRNA.6-9,11,69,190,227-233 Although siRNA delivery can also
be achieved through intracellular transcribing of DNA vectors, only exogenous non-viral
delivery systems will be discussed. Delivery by non-viral systems can be broken into
conjugated as well as non-conjugated systems. Conjugated systems (Figure I-10) include
protein-siRNA, lipophile-siRNA, polymer-siRNA, aptamer-siRNA, antibody-siRNA, and
nanoparticle-siRNA conjugates, while non-conjugated systems generally employ
positively charges molecules, such as cationic liposomes or cationic polymers that
electrostatically interact with siRNA. Either of these systems can be modified with
targeting ligands for cell specific delivery.
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Lipophile-siRNA conjugates (Figure I-10) have been explored for the potential
treatment of liver specific diseases, such as hepatitis C, since the liver is involved with
lipid and steroid metabolism.229,234,235 For example Hadwiger et al,234 reported the 5’ end
modification of an siRNA sense strand with cholesterol. This siRNA was targeted
against E. coli β-galactosidase mRNA. The translated protein of this mRNA is
responsible for the breakdown of lactose. The resulting activity of β-galactosidase was
measured after treatment and siRNAs that were modified with cholesterol had enhanced
gene down-regulation as compared to unmodified siRNAs. Other carriers that have
gained significant interest for the delivery of siRNA are transition metal nanoparticles
functionalized with siRNA because they can serve the dual purpose of diagnostic
(contrast agents) and therapeutic agents.228,236,237 Mirkin and coworkers 228 recently
reported the functionalization of gold nanoparticles with both thiolated-PEG and/or thiolPEGylated siRNA. It was demonstrated that the siRNA-functionalized nanoparticles
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could be delivered to HeLa cells (cervical cancer) in the absence of a transfection agent.
Non-specific uptake was attributed to serum protein association with the siRNAfunctionalized nanoparticle which facilitates endocytosis. These siRNA nanoparticles
caused gene down-regulation of the targeted mRNA over a four day period leading to a
higher efficiency than cells treated with unmodified siRNA. This increased
―knockdown‖ efficiency was attributed to enhanced siRNA stabilization/protection by the
gold nanoparticle.
Perhaps one of the most popular routes to enhance siRNA delivery is the chemical
modification of siRNA with (co)polymers. Due to PEGs commercial availability and
biocompatibility, most literature reports utilize PEG for siRNA conjugation (Figure I10).230,232,238-242 For example, PEG has been conjugated directly to thiol modified siRNAs
through disulfide exchange chemistry to produce PEG-S-S-siRNA conjugates thus
allowing release of siRNA from the polymer under intracellular reducing
conditions.230,232,238,239 Typically, these PEGylated siRNAs are electrostatically
complexed with PEI for similar reasons discussed in the preceding Polyelectrolyte
Complexes section. However, the same drawbacks (i.e., cytotoxicity and non-specific
uptake) for the delivery of DNA with cationic complexes are also applicable to siRNA.
Many laboratories,6-12 including our own, are now employing RAFT polymerization for
the tailored synthesis of well-defined (co)polymers suitable for siRNA delivery.
RAFT Polymers as Carriers in siRNA Delivery
Recently, RAFT polymerization has been exploited as a synthetic tool to
rationally design siRNA carriers.6-12 In 2006, Scales and coworkers reported the first use
of RAFT copolymers (HPMA-b-DMAPMA; (M4-b-M7)) for the complexation and
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potential delivery of siRNA (Scheme I-10).6 The ability of the block copolymers to form
neutral (N/P = 1), stable complexes was studied. The effect of DMAPMA block length
on complexation properties could also be assessed due to the high level of control using
RAFT polymerization. Results indicated that the DMAPMA block length was the major
factor affecting the stabilization of the bound siRNA (43 nucleotides). Block copolymers
with DMAPMA lengths of 13 and 23 had the highest percentage of stabilized siRNA and
displayed siRNA protection from enzymatic degradation under physiological conditions.
siRNA protection was demonstrated by monitoring the absorbance at 260 nm in the
presence of nuclease RNase A (Figure I-11). The unprotected control was rapidly
hydrolyzed as shown by an increase in the absorbance while the polymer-bound siRNA
showed little degradation.

HPMA-b-DMAPMA

siRNA

HPMA
DMAPMA

Scheme I-10. Idealized representation of the interpolyelectrolyte complexation of
HPMA-b-DMAPMA (M4-b-M7) copolymer with siRNA.6
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Figure I-11. Enzymatic degradation of free siRNA and HPMA258-b-DMAPMA23 (M4258b-M723) copolymer complexed with siRNA.6
Shortly following the initial report of implementing RAFT polymers for siRNA
delivery, Convertine et al.7 reported the synthesis of block copolymers containing repeat
units of butyl methacrylate (BMA), PAA and DMAEMA (M11) via RAFT
polymerization. The resulting DMAEMA-b-(DMAEMA-co-PAA-co-BMA) (M11-b(M11-co-PAA-co-BMA)) copolymers were studied for the ability to complex and deliver
siRNA. The cationic DMAEMA block was used for siRNA complexation, while the
endosomal releasing block was comprised of BMA and equal molar amounts of
DMAEMA and PAA. It was shown that the endosomal releasing block led to hemolysis
of red blood cells upon decreasing the pH from physiological conditions, pH 7.4, to
endosomal conditions (pH 6.6-5.8). This activity is attributed to the protonation of the
PAA repeats at lower pH leading to an increase in overall hydrophobicity. This increase
allows penetration of the BMA and protonated PAA units into the amphiphilic lipid
bilayer thus causing membrane disruption. It was reported that a larger mol % of BMA
led to greater hemolytic activity. This observation has also been reported for other
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systems containing hydrophobic moieties.243 siRNA delivery to HeLa cells was also
confirmed using fluorescence microscopy and gene down-regulation experiments.
Similarly, higher gene transfection was observed for the copolymer with the highest
BMA content. Over 80% gene down-regulation was reported for DMAEMA-b(DMAEMA-co-PAA-co-BMA) copolymer/siRNA complexes utilizing an N/P ratio of 4
after a 48 h period.
Modified siRNAs can also be directly conjugated to RAFT-synthesized
(co)polymer end or pendent groups. As discussed above, RAFT polymers can be easily
modified at either the - or α-chain ends making coupling of modified siRNA
straightforward. For example, Maynard and coworkers, in 2008, demonstrated α-chain
end functionalization of poly(PEG acrylate) with 5’ thiol-modified siRNA.8 This was
achieved through the utilization of a CTA (C16) containing an activated thiol R group
(Figure I-12). Since most polymer chains are initiated by the R group in RAFT
polymerization, the resulting poly(PEG acrylate) was successfully functionalized with
thiol modified siRNA as determined by gel electrophoresis. However, a large excess of
polymer (~ 25 times) with low molecular weight (< 10,000 g/mol) was required to
achieve conjugation efficiency close to 90 %.
S
O
S

S

N

S
S

O

C16

Figure I-12. Pyridyl disulfide functionalized CTA used for siRNA conjugation.
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Similarly, the -terminal chain end of RAFT-synthesized (co)polymers can be
modified upon reduction of the thiocarbonylthio moiety to a polymeric thiol (Scheme I-7
and I-8). For example, Bulmus et al. demonstrated the modification of an HPMA (M4)
homopolymer with siRNA utilizing a dithioester CTA.11 This was achieved by reducing
the thiocarbonylthio group in the presence of DTP yielding an activated thiol (pyridyl
disulfide) at the -terminal that was subsequently reacted with thiol modified siRNA. In
addition, the α-chain end was modified with a dendritic mannose that potentially allows
for biorecognition events. However, this route also was limited to low molecular weight
polymers (< 10,000 g/mol) and required 20 times excess of polymer for high degrees of
siRNA conjugation.
Although RAFT polymerization is emerging as a tool for the rational synthesis of
siRNA carriers, the current systems rely heavily on the EPR effect or cationic interactions
(universal transfection) with the cellular membrane to achieve endocytosis/uptake
indicating a need to develop well-defined targeted siRNA carriers. In addition, the
conjugation of siRNA to RAFT (co)polymers has been limited to the end-groups of low
molecular weight polymers requiring large excesses of polymer relative to siRNA for
high conjugation efficiencies. The background our laboratories have in preparing welldefined copolymers with precise architectures and dimensions via RAFT polymerization
and the minimal reports on well-defined copolymers for siRNA complexation and
targeted delivery provides impetus for the research detailed in this dissertation.
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CHAPTER II
OBJECTIVES OF RESEARCH
Precisely synthesized copolymers with advanced architectures, narrow molecular
weight distributions, and reactive functionalities offer unprecedented scaffolds for
construction of vehicles for effective drug/gene delivery. Until recently, limitations (i.e.,
poor control over molecular weight and architecture) of traditional polymerization
methods impeded progress toward tailored, rational design of polymeric carriers in these
applications. Within the past decade, advances in CRP have addressed many drawbacks
by providing facile routes for the synthesis of functional (co)polymers with complex
architectures and predetermined pendent and terminal (α and ) functionality. RAFT
polymerization is arguably the most versatile of the CRP methods given its ability to
control the polymerization of a wide variety of unprotected functional vinyl-based
monomers under mild conditions (without requiring often toxic transition metal
catalysts). Since the discovery of RAFT polymerization in 1998, the McCormick
research group has focused significant efforts on the aqueous RAFT polymerization of
several water soluble monomers to prepare functional/responsive block and/or statistical
copolymers for utility in biomedical applications. Most recently, research in RAFT
polymerization has focused on developing bioconjugation methods between RAFTsynthesized copolymers and biorelevant species in order to prepare polymer-biomolecule
conjugates with specific architectures/dimensions and narrow polydispersities for
therapeutic delivery.
The overall goal of this research is to exploit the RAFT process to prepare welldefined biocompatible copolymers, develop bioconjugation methods for chain end and
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side chain post-polymerization functionalization, and investigate the utility of these
polymeric bioconjugates in targeted siRNA delivery.
The specific objectives of this research are to:
(1)

Prepare well-defined hydrophilic-b-cationic copolymers of HPMA and
DMAPMA via aqueous RAFT polymerization

(2)

Adapt the aqueous RAFT process to synthesize well-defined terpolymers
comprised of an HPMA-s-APMA (hydrophilic/primary amine) statistical block
and a DMAPMA cationic block

(3)

Modify well-defined statistical copolymers of HPMA-s-APMA to contain both
thiol (pyridyl disulfide) and amine reactive pendent functionality

(4)

Characterize all (co)polymers in terms of molecular weight, polydispersity, and
composition

(5)

Develop bioconjugation methods to the α- and -chain ends of RAFT-synthesized
HPMA-b-DMAPMA copolymers and subsequently determine degree of
conjugation

(6)

Develop bioconjugation conditions to couple active folate, cellular targeting
groups, in this case to pendent groups of RAFT-synthesized (HPMA-s-APMA)-bDMAPMA copolymers and to subsequently characterize the resulting conjugate
via UV-vis spectroscopy, NMR, and MALDI-ToF MS

(7)

Prepare neutral electrostatic complexes between folate functionalized HPMA-sAPMA-b-DMAPMA copolymers and siRNA and subsequently characterize in
terms of size and charge
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(8)

Conduct fluorescent microscopy and gene down-regulation experiments by in
vitro treatment of cancerous cell lines that over-express folate receptors with
folate functionalized (HPMA-s-APMA)-b-DMAPMA/siRNA complexes

(9)

Develop bioconjugation conditions to couple both siRNA and folate to pendent
groups of RAFT-synthesized HPMA-s-APMA copolymers with both activated
thiol and amine functionality

(10)

Characterize siRNA and folate multiconjugates via UV-vis spectroscopy and gel
electrophoresis and monitor siRNA release from copolymer backbone under
simulated intracellular conditions
The first three objectives are possible through the careful selection of the RAFT

polymerization parameters including CTA, solution pH, temperature, and initiator halflife. In the synthesis of primary amine containing copolymers maintaining an acidic pH
is critical in order to retain the integrity of the CTA throughout the polymerization
process. The objectives associated with bioconjugation of folate and/or siRNA are
possible through the rational design of copolymers and appropriate post-polymerization
reaction conditions for robust and facile modification of chain end and pendent groups.
The successful synthesis of these copolymer conjugates allows the targeted delivery of
siRNA to cancerous cells and subsequent gene down-regulation. Factors that affect
successful targeted siRNA delivery and subsequent gene down-regulation include
complex/conjugate preparation conditions (i.e., pH, salinity, N/P ratio, number of
folates/siRNAs) and siRNA release (i.e., ion exchange, reducible linkages) upon cellular
uptake. The successful completion of these objectives is outlined in Chapter IV of this
dissertation.
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CHAPTER III
EXPERIMENTAL
Materials
All reagents were purchased from Aldrich (Milwaukee, WI) and used without
further purification unless otherwise stated. 4,4’-Azobis(4-cyanopentanoic acid) (V-501)
and azobisisobutyronitrile (AIBN), a gift from Wako Pure Chemicals Industries, Ltd.,
was recrystallized from methanol. 6-(Fluorescein-5-carboxamido)hexanoic acid,
succinimidyl ester (5-SFX) was purchased as a single isomer from Invitrogen Molecular
Probes. N-(3-Aminopropyl)methacrylamide hydrochloride (APMA, M9) was purchased
from PolySciences (Warrington, PA). N-[3-(Dimethylamino) propyl] methacrylamide
(DMAPMA, M7) was purified by vacuum distillation. N-succinimidyl 3-(2pyridyldithio) propionate (SPDP) was purchased from Thermo Scientific (Rockford, IL)
and used as received. Folic acid linked to poly(ethylene glycol) (PEG) (1500 g/mol) with
an amine-terminal chain end (FA-PEG34-NH2, Mn =1950 g/mol) was provided by Dr.
Huang’s laboratory from the University of Southern Mississippi. Both the sense and
antisense strands of a 59-nucleotide (nt) model small interfering ribonucleic acid (siRNA)
against human survivin were chemically synthesized and labeled with fluorescein (FAM)
and cyanine-3 (Cy3) separately. Unlabeled, FAM-labeled, and 5’-thiolated sense strand,
5’-AGCCCUUUCUCAAGGACCACCGCAUCU-3’, was synthesized by Integrated
DNA Technologies. Unlabeled and Cy3-labeled antisense strand, 3’UUUCGGGAAAGAGUUCCUGGUGGCGUAGAGGA-5’ was synthesized by
Biosynthesis Inc. A549 cells (human lung cancer cells) and KB cells (human epidermal
cancer cells) were purchased from American Type Culture Collection (Manassas, VA).
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Synthesis of N-(2-Hydroxypropyl)methacrylamide (HPMA, M4)
1-amino-2-propanol (2.0 moles, 153.1 g) was added to 1.2 L of cold acetonitrile at
0 °C and mechanically stirred. Methacryloyl chloride (1.04 moles, 108.2 g) was added
drop-wise using an addition funnel over 2 h while maintaining the temperature of the
reaction below 5 °C. Upon complete addition of methacryloyl chloride, the monomer
solution was allowed to stir for 3 h between 0 and 5 °C. The resulting white precipitate,
1-amino-2-propanol HCl salt, was filtered off. The acetonitrile filtrate was then
concentrated to approximately 800 mL via roto-evaporation and placed in a deep freezer
at -40 °C and allowed to crystallize overnight. The resulting HPMA monomer crystals
were filtered off and recrystallized twice from acetone and dried in vacuo (mp = 67 °C).
1

H NMR (300 MHz, CDCl3):  (ppm) 1.15 (d, -CH2CH(OH)CH3, J = 6.3 Hz), 1.93 (s,

CH2C(CH3)C(O)-), 3.13 (m, NH-CH2CH(OH)), 3.43 (m, NH-CH2CH(OH)), 3.90 (m,
CH2CH(OH)CH3), 5.31 (s, CH2C(CH3)), 5.70 (s, CH2C(CH3)).

O
+
Cl

NH2

acetonitrile

NH

HO

0 °C

O

Methacryloyl
Chloride

+

NH3+ ClHO

1-amino-2-propanol

1-amino-2-propanol HCl Salt
HO

HPMA (M4)

Scheme III-1. Synthetic pathway for the synthesis of N-(2 hydroxypropyl)
methacrylamide (HPMA, M4).
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Synthesis of 4-Cyanopentanoic Acid Dithiobenzoate (C1)
Synthesis of dithiobenzoic acid (DTBA). DTBA was prepared by a modification
of the method of Becke and Hagen. To a thoroughly dried 1 L, three-necked roundbottomed flask equipped with a magnetic stir bar, addition funnel (250 mL),
thermometer, and rubber septum for liquid transfers, sodium methoxide was added (30%
solution in methanol, 180 g, 1.0 mol). Anhydrous methanol (250 g) was added to the
flask via cannula, followed by rapid addition of elemental sulfur (32 g, 1.0 mol). Benzyl
chloride (63 g, 0.5 mol) was then added dropwise via the addition funnel over a period of
1 h, at room temperature under a dry nitrogen atmosphere. The reaction mixture was
heated in an oil bath at 67 °C for 10 h. After this time, the reaction mixture was cooled to
7 °C using an ice bath. The precipitated salt was removed by filtration, and the solvent
was removed in vacuo. Deionized water (500 mL) was added to the residue. The solution
was filtered a second time and then was transferred to a 2 L separatory funnel. The crude
sodium dithiobenzoate solution was washed with diethyl ether (3 × 200 mL). Diethyl
ether (200 mL) and 1.0 M HCl (500 mL) were added, and dithiobenzoic acid was
extracted into the ethereal layer. DI water (300 mL) and 1.0 M NaOH (600 mL) were
added, and sodium dithiobenzoate was extracted to the aqueous layer. This washing
process was repeated two more times to finally yield a solution of sodium dithiobenzoate.
Note: dithiobenzoic acid is unstable and should be used immediately.
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Scheme III-2. Synthesis of dithiobenzoic acid (DTBA).

Synthesis of di(thiobenzoyl)disulfide. Dithiobenzoic acid was oxidized to the
corresponding di(thiobenzoyl)disulfide using a K3Fe(CN)6 catalyst in a 1:1 ratio with
dithiobenzoic acid. The reaction was conducted under alkaline conditions at room
temperature and produced a purple precipitate upon formation of product.

S
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S
K3Fe(CN)6

2
-

+

S Na

S

S

H2O

Scheme III-3. Synthesis of di(thiobenzoyl)disulfide.

Synthesis of 4-cyanopentanoic acid dithiobenzoate (CTP) (C1). A 250 mL roundbottomed flask, equipped with a condenser, was charged with ethyl acetate (80 mL), dry
V-501 (I3) (5.84 g, 21.0 mmol), and di(thiobenzoyl)disulfide (4.25 g, mmol). The
reaction solution was heated at reflux for 18 h and then was cooled to room temperature
before removing the ethyl acetate in vacuo. The crude product was isolated by column
chromatography (silica gel 60, 70-230 mesh) using ethyl acetate/hexane (2/3 v/v) with
0.5% v/v acetic acid as the eluent. Fractions that were red in color were combined and
dried over anhydrous sodium sulfate overnight. The solvent mixture was removed in
vacuo, and the red oily residue was placed in a freezer at -20 ºC, whereupon it

68
crystallized. The target compound, CTP (C1), was recrystallized from benzene. 1H
NMR (300 MHz, CDCl3):  1.95 (s,3H), 2.78-2.40 (m, 4H), 7.40 (t, 2H), 7.57 (t, 1H),
7.91 (d, 2H). 13C NMR (300 MHz, CDCl3):  24.2, 29.5, 33.0, 45.6, 118.4, 126.7, 128.6,
133.1, 144.5, 177.0, 222.1.
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Scheme III-4. Synthesis of 4-Cyanopentanoic Acid Dithiobenzoate (C1).

Synthesis of Di-N-Hydroxysuccinimide-Folate (diNHS-FA)
The carboxylic groups of folic acid (FA) were activated using standard
carbodiimide chemistry. First, 1 g (2.26 mmol) of FA was dissolved in 15 mL of DMSO
in a 50 mL round-bottomed flask equipped with a stir bar. Once the FA was completely
dissolved, 4.67 g (22.6 mmol) of DCC and 1.3 g (11.3 mmol) of NHS were added to the
FA solution to synthesize diNHS-FA. Each solution was allowed to react at 21 °C for 40
h in the dark. After the reaction was complete, a white precipitate was filtered from the
solution and the activated FA was precipitated and washed repeatedly in cold anhydrous
diethyl ether. The product was then dried in vacuo overnight to yield 1.35 g of product
(94%) and used without further purification. 1H NMR (300 MHz, DMSO-d6):  (ppm)
8.65 (s, PtC7H, 1H), 8.59–8.57 (d, -CONHCHCO-OSu, 1H, J = 7.2 Hz), 7.70–7.67 (d,
Ph-C2H and Ph-C6H, 2H, J = 8.7 Hz), 6.90 (br s, NH2, 2H), 6.68–6.65 (d, Ph-C3H and
Ph-C5H, 2H, J = 8.7 Hz), 4.91–4.84 (m, -CONHCHCO-OSu, 1H), 4.51–4.49 (d, PtC6CH2NH-Ph, 2H, J = 5.7 Hz), 2.96–2.91 (t, -CH2CH2CO-OSu, 2H, J = 6.9 Hz), 2.82 (s, -
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NHCHCO-OSuC3H2 and -NHCHCO-OSuC4H2, 4H), 2.82 (s, -CH2CH2CO-OSuC3H2 and
-CH2CH2CO-OSuC4H2, 4H), 2.31–2.26 (m, -CHCH2CH2CO-OSu, 2H).
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Scheme III-5. Synthetic pathway for the synthesis of di-N-hydroxysuccinimide-folate
(diNHS-FA).

Polymerizations and Polymer Modifications
Aqueous RAFT Polymerization of HPMA
HPMA (M4) macroCTAs were prepared employing V-501 (I3) as the primary
radical source and CTP (C1) as the chain transfer agent at 70°C. A [M]o/[CTA]o ratio of
800/1 was used while the CTA to initiator ratio ([CTA]o/[I]o) was kept at 5/1. HPMA258
macroCTA (P1) (Mn = 37,000 g/mol, PDI = 1.15) was prepared by dissolving HPMA
(28.64 g, 200 mmol) and CTP (70.0 mg, 0.250 mmol) in 50 mL of an aqueous acetic
buffer (pH 5.2, 0.27 M acetic acid and 0.73 M sodium acetate). Once dissolved the
resulting solution was diluted to 200 mL to a final [M]o = 1M. V-501 (14 mg, 50 µmol)
was then added to the monomer/CTA solution. The round-bottomed flask was then
septa-sealed and purged with nitrogen for 1 h and subsequently placed in a water bath at
70 °C. HPMA250 macro CTA (P2) (Mn = 35,700 g/mol, PDI = 1.08) was prepared under
the same conditions except the final volume was 50 mL. HPMA macroCTAs were
isolated by dialysis (pH 3-4) at 4 °C followed by lyophilization. Characteristic polymer
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1

H NMR shifts (300 MHz, D2O):  (ppm) 0.7-0.9 (br, 3H), 0.9-1.1 (br, 3H), 1.5-2.0 (br,

2H), 2.8-3.2 (br, 2H), 3.6-3.9 (br, 1H).
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Figure III-1. Structures of HPMA258 (P1) and HPMA250 (P2) macro CTAs.
Synthesis of HPMA-s-APMA Copolymers via Aqueous RAFT Polymerization
HPMA-s-APMA (M4-s-M9) macroCTAs were prepared employing V-501 (I3) as
the primary radical source and CTP (C1) as the chain transfer agent at 70°C. A
[M]o/[CTA]o ratio of 800/1 was used while the [CTA]o/[I]o was kept at 5/1. The initial
feed composition was either 90 or 95 mol% HPMA and 5 or 10 mol% APMA. A typical
polymerization is as follows: HPMA315-s-APMA13 macroCTA (P3) (Mn = 47,400 g/mol,
PDI = 1.10) was prepared by dissolving HPMA (4.08 g, 28.5 mmol), APMA (0.268g, 1.5
mmol), and CTP (10.5 mg, 37.6 µmol) in 7.5 mL of an aqueous acetic buffer (pH 5.2,
0.27 M acetic acid and 0.73 M sodium acetate). Once dissolved the resulting solution
was diluted to 30 mL to a final [M]o = 1 M. V-501 (2.10 mg, 7.5 µmol) was then added
to the monomer/CTA solution. The round-bottomed flask was septa-sealed and purged
with nitrogen for 45 min and subsequently placed in a water bath at 70 °C. HPMA320-sAPMA33 macro CTA (P4) (Mn = 51,800 g/mol, PDI = 1.13) and HPMA252-s-APMA10
macro CTA (P5) (Mn = 37,900 g/mol, PDI = 1.05) were prepared under the same
conditions except P4 was prepared with 90 mol% HPMA and 10 ml % APMA.

All
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polymerizations were quenched at predetermined time intervals by immersion in liquid
nitrogen. HPMA-s-APMA macroCTAs were isolated by dialysis (pH 3-4) at 4 °C
followed by lyophilization. Characteristic polymer 1H NMR shifts (300 MHz, D2O),
number of protons per peak depends on composition of the copolymer, are as follows: 
(ppm) 0.6-0.9 (br), 0.9-1.1 (br), 1.4-2.0 (br), 2.7-3.2 (br), 3.6-3.9 (br).
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Figure III-2. Structures of HPMA315-s-APMA13 (P3), HPMA320-s-APMA33 (P4), and
HPMA252-s-APMA10 (P5) macro CTAs.
Synthesis of HPMA-b-DMAPMA and (HPMA-s-APMA)-b-DMAPMA Block Copolymers
via Aqueous RAFT Polymerization
HPMA (P1 or P2) or HPMA-s-APMA (P3, P4, or P5) macroCTAs were chain
extended with DMAPMA (M7) utilizing V-501 (I3) as the radical source. DMAPMA
(stock solution 1.25 M) and the appropriate macroCTA were added to a round-bottomed
flask, dissolved in DI water, and subsequently titrated to a pH between 4-5 to give [M]o=
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1 M. The round-bottomed flask was septa-sealed and subsequently purged with nitrogen
for 30 min. Block copolymers were prepared with a [M]o/[CTA]o ratio of 200/1, while the
[CTA]o/[I]o was kept at 5/1. Block polymerization solutions containing HPMA250
macroCTA (P2) and DMAPMA were divided into multiple round-bottomed flasks and
placed in a 70 °C water bath. Each polymerization was terminated at predetermined time
intervals by rapid cooling and exposure to air. All block copolymers were isolated by
dialysis (pH 3-4) at 4 °C followed by lyophilization. HPMA258-b-DMAPMA13 (P6) (Mn
= 39,700 g/mol, PDI = 1.06) and HPMA250-b-DMAPMAn (P7; n = 15, 32, or 56) were
characterized via aqueous size exclusion chromatography and 1H NMR. 1H NMR was
used to determine the block copolymer composition by comparing the methyne-proton
resonance of HPMA at 3.75 ppm to that of the dimethyl-proton resonances from
DMAPMA at 2.80 ppm.
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Figure III-3. Structures of HPMA258-b-DMAPMA13 (P6) and HPMA250-b-DMAPMAn
(P7; n = 15, 32, or 56) block copolymers.

HPMA-s-APMA macroCTAs were chain extended with DMAPMA also using V501 (I3) as the radical source at 70 °C. DMAPMA (stock solution 1.25 M) and HPMA-sAPMA copolymer were added to a round-bottomed flask, dissolved in DI water, and
subsequently titrated to a pH between 5-6 to give [M]o= 1M. The round-bottomed flask
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was septum-sealed and subsequently purged with nitrogen for 45 min. Block copolymers
were prepared with a [M]o/[CTA]o = 200, while the [CTA]o/[I]o was kept at 5/1. Each
polymerization was terminated at predetermined time intervals by exposure to air and
rapid cooling in liquid nitrogen. The (HPMA-s-APMA)-b-DMAPMA copolymers were
purified by dialysis (pH 3-4) at 4 °C and dried by lyophilization. (HPMA315-s-APMA13)b-DMAPMA23 (P8) (Mn = 51,300 g/mol, PDI = 1.14), (HPMA320-s-APMA33)-bDMAPMA34 (P9) (Mn = 57,600 g/mol, PDI = 1.13) and (HPMA252-s-APMA10)-bDMAPMAn (P10) were characterized via aqueous size exclusion chromatography
(ASEC) and 1H NMR.
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Thiocarbonylthio End Group Removal from RAFT Copolymers
Thiocarbonylthio functionalities from RAFT generated copolymers (P4, P7, P8,
P9, P10) were removed using a previously reported procedure by Perrier and
coworkers.244 Briefly, RAFT copolymer was added to a 10 mL round-bottomed flask and
dissolved with N,N-dimethylformamide (DMF) to give a final copolymer concentration
of 2 mM. AIBN was then added to the flask giving an AIBN:copolymer ratio of 20:1
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(40 mM AIBN). The solution flask was septum-sealed and purged with nitrogen for 45
min and submersed in a water bath at 70 °C for 4 h. The resulting copolymer was
precipitated from DMF in cold anhydrous diethyl ether and washed repeatedly. This step
was repeated in triplicate and the copolymer was dried in vacuo overnight. Quantitative
removal of thiocarbonylthio group was determined with UV-vis spectroscopy.
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Figure III-5. Structures of copolymers after thiocarbonylthio end group removal through
reaction with AIBN. For P12 n = 15, 32, 56 and for P15 n = 11 and 17.
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Thiol Activation of HPMA-s-APMA Copolymer (P11) with SPDP
Activated thiols were introduced along the copolymer backbone of P11 through
the reaction of N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) with the pendent
functional primary amine groups of APMA (M9). 24 mol % (8 of the available 33)
APMA units were targeted for functionalization with SPDP. First, 20 mg (0.39 mol) of
end-capped (no thiocarbonylthio group) P11 was dissolved in 335 L of anhydrous
DMSO. 48 L of a 20 mg/mL stock solution of SPDP in anhydrous DMSO (0.97 mg,
3.1 mol) was then added to the copolymer solution. Triethylamine (TEA) (3.5 L, 25
mol) was added to serve as a catalyst and ensure deprotonation of primary amines, thus
giving a final concentration of 1 mM and 8 mM for copolymer P11 and SPDP,
respectively. The resulting solution was allowed to react for 4 h at room temperature.
Following reaction, thiol activated copolymer P16 was precipitated in cold anhydrous
diethyl ether and dried overnight in vacuo. The dried copolymer was then dissolved in
deionized (DI) water and lyophilized for 24 hours. As determined by UV-vis and 1H
NMR spectroscopy (DMSO-d6), 7 out of 33 APMA groups (20 mol %) were converted to
activated thiols (pyridyl disulfides). Polydispersity index was 1.18 as determined by
ASEC-MALLS.
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Polymer Conjugation Reactions

-Chain End Amine Functionalization of HPMA258-b-DMAPMA13 (P6)
HPMA258-b-DMAPMA13 copolymer (P6) -end groups were amine
functionalized with cystamine. HPMA258-b-DMAPMA13 (40.6 mg) was added to a 1.85
mL vial equipped with a micro stir bar. The polymer was diluted with 183 L of 2 M
sodium borohydride (NaBH4) and allowed to react for 2 h yielding the reduced polymer.
The reduced polymer was then dialyzed against DI water for 3 days and subsequently
lyophilized. The reduced polymer was then functionalized with a primary amine through
the reaction with excess dihydrochloride cystamine. Reduced HPMA258-b-DMAPMA13
(22.4 mg) was dissolved in 100 L of 4 M cystamine in Tris buffer (pH 9.5) to give a
final polymer concentration of 5.6 mM. This reaction was carried out at 70 °C for 92 h.
The solution was then dialyzed against DI water for 3 days followed by lyophilization.
The amine content of the resulting polymer was determined by ninhydrin assay (UV-vis
spectroscopy) and the polymer was again dialyzed for 3 more days against DI water and
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subsequently lyophilized yielding a , primary amine functionalized copolymer (P17) .
A second ninhydrin assay indicated a constant amine concentration.
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Figure III-7. Structure of , primary amine functionalized HPMA258-b-DMAPMA13
copolymer (P17).

5-SFX Fluorophore Conjugation to Amine Functionalized HPMA258-b-DMAPMA13 (P17)
Amine functionalized polymer (P17) was fluorescently labeled with 5-SFX. 11.5
mg (0.29 mol) of P17 was added to a 1.5 mL microcentrifuge tube and diluted with 97
L of a 15 mM solution of 5-SFX in anhydrous DMF to give a final polymer
concentration of 3 mM, or a 5-SFX to polymer ratio of 5:1. A catalytic amount of
triethylamine (TEA) was also added to the solution. The reaction solution was allowed to
react in the dark at 60 °C for 15 h. The solution was then dialyzed in the dark against DI
water for 3 days and subsequently lyophilized. The dried, fluorescently labeled polymer
(P18) was then analyzed via UV-vis spectrometry indicating that free fluorophore was
still present. The labeled polymer was then dissolved in 20 mM phosphate/ 0.1 M NaCl
buffer (pH 7.4) and purified using 10,000 molecular weight cut-off (MWCO) Microcon
centrifuge tubes in order to remove free fluorophore. This was repeated until minimal
absorbance was observed. The sample was then washed repeatedly with DI water to
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remove the buffer solution. The retentate was diluted with DI water and lyophilized.
The percent conjugation was then determined using UV-vis spectroscopy.
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Figure III-8. Structure of , 5-SFX fluorescently labeled HPMA258-b-DMAPMA13
copolymer (P18).
FA-PEG34-NH2 Conjugation to -Terminal Carboxylic Group of HPMA250-b-DMAPMAn
(P12) Copolymers
Following removal of the dithioester -chain end and isolation of end-capped
HPMA250-b-DMAPMAn (P12) block copolymers, the -terminal carboxylic group of
HPMA250-b-DMAPMAn was activated using carbodiimide coupling. A typical reaction
is as follows: HPMA250-b-DMAPMAn, N-hydroxysuccinimide (NHS),
diisopropylcarbodiimide (DIPC), and triethylamine (TEA) were dissolved in DMF to a
final polymer concentration of 3 mM. DIPC and NHS were used with a 10 times molar
excess and TEA was used with a 5 times molar excess. The resulting solution was
allowed to react for one week. The activated polymer was precipitated in cold diethyl
ether and dried in vacuo.
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NHS-Activated copolymers of P12 were reacted with FA-PEG34-NH2. In a
typical reaction NHS-activated P12 was dissolved in DMF to a final polymer
concentration of 3 mM followed by the addition of excess FA-PEG34-NH2 (6mM) and a
catalytic amount of TEA. The reaction proceeded at room temperature for 72 h. Folic
acid-PEG labeled HPMA250-b-DMAPMAn (P19) was isolated by dialysis against DI
water followed by lyophilization. In addition to 1H NMR spectroscopy and MALDI-ToF
mass spectrometry, the presence of folic acid was confirmed by UV-vis spectroscopy
(350 nm).
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Figure III-9. Structure of folic acid-PEG labeled HPMA250-b-DMAPMAn copolymers
(P19).

DiNHS-Folate Conjugation to (HPMA-s-APMA)-b-DMAPMA (P13, P14, P15) Block
Copolymers
Following isolation of the chain terminated block copolymer the pendent
functional primary amine groups from the incorporated APMA (M9) were labeled with
diNHS-FA. A typical reaction is as follows: 30 mg (0.585 mol) of (HPMA315-sAPMA13)-b-DMAPMA23 (P13) copolymer was dissolved in 200 L to give a final
concentration of 2.92 mM. 130 times excess diNHS-FA (58 mg) was then dissolved in
350 L of DMSO and (HPMA315-s-APMA13)-b-DMAPMA23 copolymer solution was

CN
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added to the activated FA solution at a rate of 20 L every 20 minutes. TEA was added
to serve as a catalyst. The resulting solution was allowed to react overnight or for 48 h at
room temperature. Following reaction, excess ammonium hydroxide (100% by volume)
was added to quench the remaining activated esters of the activated FA. The resulting
reaction mixture was then directly placed in 12-14K MWCO dialysis tubing and was first
dialyzed against 0.6 M NaCl solution followed by dialysis against DI water for 3 days.
The multivalent folate-block copolymer conjugates (P20, P21 and P22) were isolated via
lyophilization. Degree of conjugation was determined by a combination of 1H NMR,
UV-vis spectrosocpy and/or MALDI-ToF mass spectrometry. MALDI-ToF mass
spectrometry was utilized for P20 and P21, not P22. Near quantitative conversion was
obtained for P20 and P22, while the degree of conjugation for P21 was approximately 70
%.
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HS-RNA Sense Strand Conjugation to Thiol Activated HPMA-s-APMA (P16) via
Disulfide Exchange
Prior to RNA conjugation, the chemically synthesized 5’ thiolated sense strand
RNA purchased from Integrated DNA Technologies was treated with dithiothreitol
(DTT) to remove the disulfide protecting group, thus giving an RNA with reactive thiol
functionality. The protected RNA was first dissolved in nuclease free water to a final
concentration of 1 mM. Disulfide cleavage was performed by incubating 50 µL of the
RNA with 100 mM DTT and 20 mM sodium phosphate buffer (pH 8.0, total volume 60
µL) for 30 min at room temperature. Following disulfide cleavage, 40 µL of nuclease
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free water, 20 µL of 3 M sodium acetate buffer (pH 5.2), and 360 µL ethanol were added
to the solution to promote RNA precipitation. After cooling the sample for 30 min at -20
°C, the sample was centrifuged for 6 min at 14,000 rpm. After careful removal of the
supernatant, the RNA pellet was redissolved in 100 µL of nuclease free water. The
solution was then loaded onto a Microcon 10 kDa MWCO centrifuge tube and spun at
14,000 rpm for 20 min at room temperature. 100 µL nuclease free water was added to the
membrane filter and was subsequently centrifuged for 20 min at 14,000 rpm. Finally, the
recovered 5’ thiolated sense strand RNA (HS-RNA) concentration was determined by
UV-vis spectroscopy.
Conjugation of HS-RNA to thiol activated copolymer P16 was performed through
a disulfide exchange reaction (Scheme IV-6). In a typical reaction, 29 L of 700 M HSRNA (20 nmol) was added to 57 L of 0.2 M phosphate buffer (pH 8.0). Second, 14 L
of a 100 M thiol activated copolymer P16 solution (1.4 nmol polymer, 10 nmol pyridyl
disulfide) was then added to the RNA solution bringing the final volume to 100 L and
ratio of pyridyl disulfides to HS-RNA 1:2. This reaction was carried out at room
temperature for 3 h. The reaction was repeated four times and a degree of conjugation
was determined to be 89 ± 4 % using polyacrylamide gel electrophoresis (PAGE). This
corresponds to 6.3 repeats (2 mol%) of RNA along the copolymer backbone.
RNA conjugated copolymer P23 was isolated and purified through PAGE. The
reaction mixture was first concentrated to 15 L using a 30 kDa MWCO Microcon
centrifuge tube. Gel-loading buffer containing 15 L of 0.2% bromophenol blue, 8 M
urea, and 1X TBE buffer (Trisborate-EDTA) was added to the reaction tube. The sample
was then loaded onto an 8% denaturing polyacrylamide gel and run for 50 min at 15 W.
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Location of the RNA conjugated copolymer P23 on the gel was determined using UV
light and the corresponding band was cut out and crushed inside a 1.5 mL centrifuge
tube. Compound P23 was extracted through washing of the crushed gel with nuclease
free water (400 L) and heating at 70 °C for 5 min. This step was repeated in triplicate to
increase product recovery. The resulting product was concentrated using a 30 kDa
MWCO Microcon centrifuge tube. For UV-vis spectroscopic analysis, 1 L of the
recovered product was diluted in 1 mL of 20 mM phosphate buffer (pH 7.4) and the
absorbance at 260 nm was recorded to determine the RNA concentration. The resulting
concentration of RNA conjugated copolymer P23 was 23 M giving a total RNA
concentration of 146 M. The recovery yields via PAGE extraction for the RNA
conjugated copolymer P23 and the unreacted HS-RNA were 48 % and ~80 %,
respectively.
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NHS-Folate Conjugation to RNA Conjugated Copolymer P23 (P24)
Following the isolation of RNA conjugated copolymer P23, the remaining APMA
(M9) pendent functionalities (APMA functionalities not reacted with SPDP) were labeled
with NHS-activated folate (Scheme IV-6). First, the nuclease free water was removed in
vacuo from the copolymer P23 solution using a Speed Vac for 3h. Following complete
water removal, copolymer P23 was dissolved in 10 L of anhydrous DMSO followed by
the addition of 4 L of 80 mM (0.32 mols) NHS activated folate. 1 L of TEA was
added as a catalyst bringing the total reaction volume to 15 L giving a copolymer P23
concentration of 46.0 M, an RNA concentration of 290 M and an NHS activated folate
concentration of 20 mM (1:6.3:435). This reaction was allowed to proceed at room
temperature for 2 h. The reaction mixture was then diluted to 500 L using 100 mM
phosphate buffer (pH 8.0). Excess folic acid was removed using a 30 kDa MWCO
Microcon centrifuge tube. The product (P24) was washed four times with 200 L of 40
mM phosphate buffer (pH 8.0) and once with 100 L nuclease free water. RNA/folate
conjugated copolymer P24 was concentrated to a final volume of 50 L. For UV-vis
spectroscopic analysis 2 L of the recovered product was diluted in 0.5 mL with 20 mM
phosphate buffer (pH 7.4) and the absorbance was recorded. It was determined through
UV-vis spectroscopy that 81 ± 2 % of the remaining APMA units coupled with folate.
This results in a multiconjugated copolymer that is 91 mol% HPMA, 2 mol % RNA and
6 mol % folate. The remaining 1 mol % would be comprised of unmodified APMA
units.
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Anti-sense RNA Strand Hybridization (P25)
Following the synthesis of multiconjugate copolymer P24, the hybridization
between the copolymer conjugated RNA sense strand and the RNA anti-sense strand was
performed (Scheme IV-6). Typical hybridization conditions are as follows: 15 L of
11.9 M RNA/folate conjugated copolymer P24, 75 M RNA (1.13 nmols of RNA), was
added to 11.3 L of a 100 M (1.13 nmols) solution of anti-survivin RNA anti-sense
strand. The resulting solution was added to 15 L of 0.39 M NaCl/60 mM phosphate
buffer (pH 7.0) and diluted to 45 L with nuclease free water giving a final RNA
concentration of 25 M and salt concentration of 0.15 M. The two RNA strands were
annealed at 72 °C for 2 min and allowed to cool back down to room temperature resulting
in the siRNA conjugated copolymer P25. Quantitative hybridization to the resulting antisurvivin siRNA was confirmed by PAGE.
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Analytical Techniques
Aqueous Size Exclusion Chromatography for HPMA macroCTAs
All HPMA polymers were characterized by aqueous size exclusion
chromatography (ASEC) using an eluent of 20% acetonitrile/80% 0.05 M Na2SO4(aq) at
a flow rate of 0.3 mL/min at 35 °C; TOSOH Biosciences TSK-gel columns (G3000
PWXL (<50 000 g/mol, 200 Å) and G4000 PWXL (2000-300 000 g/mol, 500 Å)), a
Polymer Labs LC1200 UV/Vis detector, a Wyatt Optilab DSP interferometric
refractometer ( = 690 nm), and a Wyatt DAWN-EOS multiangle laser light scattering
(MALLS) detector ( = 690 nm). Monomer conversions were determined by comparing
the area of the monomeric UV signal detected at 274 nm at t0 to the area at tx using a
Polymer Labs LC1200 UV/Vis detector. Absolute molecular weights and
polydispersities were calculated using the Wyatt OmniSEC software.
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Aqueous Size Exclusion Chromatography for Amine Containing Copolymers
All copolymers with cationic functionality were characterized by aqueous size
exclusion chromatography (ASEC) utilizing an eluent of 1 wt% acetic acid/0.10 M
Na2SO4 (aq) at a flow rate of 0.25 mL/min at 35 °C, Eprogen, Inc. CATSEC columns
(100, 300, and 1000 Å), a Polymer Labs LC1200 UV/Vis detector, a Wyatt Optilab DSP
interferometric refractometer ( = 690 nm), and a Wyatt DAWN-DSP multiangle laser
light scattering (MALLS) detector ( = 633 nm). Absolute molecular weights and
polydispersities were calculated using the Wyatt OmniSEC software. dn/dc
measurements were performed with a Wyatt Optilab DSP interferometric refractometer
( = 690 nm) at 35 °C and determined using OmniSEC software. Monomer conversions
were determined by comparing the area of the monomeric UV signal detected at 274 nm
at t0 to the area at tx using a Polymer Labs LC1200 UV/Vis detector. Removal of the
thiocarbonylthio functionality was confirmed by monitoring the UV signal at 310 nm
before and after removal.
1

H NMR Spectroscopy of Copolymers
Copolymer compositions were determined with a Varian MercuryPLUS 300 MHz

spectrometer in D2O or DMSO-d6 with a delay time of 2 s. 1H NMR was used to
determine the copolymer composition by integration of the relative intensities of the
peaks associated with comonomers.
Determination of Amine Functionalization to HPMA258-b-DMAPMA13 (P6)
Amine functionalization of HPMA258-b-DMAPMA13 (P6) was determined using a
ninhydrin assay. Ninhydrin assay solution was prepared by dissolving 200 mg of
ninhydrin in 5 mL of ethylene glycol and 8 mg of SnCl2H20 into 5 mL of 0.2 M citrate
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buffer (pH 5) and mixing the resulting two solutions. 3.2 mg of amine functionalized
polymer was diluted with 29 L of DI water to give a 3 mM polymer solution. The
solution (6L 3mM polymer) was then diluted with 200 L of ninhydrin assay solution
and was vortexed to ensure homogenous mixing. The resulting solution was then placed
at 100 °C for 20 minutes. The solution was then diluted to 600 L using DI water and
the absorbance at 570 nm was measured using a JASCO V-530 UV-vis
spectrophotometer. The amine functionalized polymer was analyzed after 3 and 6 days
of dialysis against DI water to ensure the complete removal of excess cystamine. To
determine amine functionalization, a calibration curve was constructed using hexylamine.
Four different aliquots of 3 mM hexylamine were diluted with 200 L of ninhydrin assay
solution and placed at 100 °C for 20 minutes. Each solution was diluted to 600 L using
DI water and the absorbance at 570 nm was measured to create a calibration curve.
Determination of Fluorescent Labeling to amine functionalized HPMA258-b-DMAPMA13
(P17)
Determination of percent conjugation of 5-SFX to amine functionalized
HPMA258-b-DMAPMA13 (P17) was determined using a JASCO V-530 UV-vis
spectrophotometer. The fluorescently labeled polymer was dissolved in 209 L of DI
water to yield a polymer concentration of 0.5 mM. 5 L of 0.5 M solution was then
diluted with 600 L of 20 mM phosphate/ 0.1 M NaCl buffer (pH 7.4). The absorbance
of the polymer conjugate, at 494 nm, was then measured and the concentration of 5-SFX
was calculated using the reported extinction coefficient of 68,000 M-1 cm-1.245,246 This
measurement was performed in quadruplet to ensure accuracy.
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Characterization of Folate-Conjugated Block Copolymers
Conjugations of FA to (HPMA-s-APMA)-b-DMAPMA) copolymers (P20, P21
and P22) were verified by 1H NMR and UV-vis spectroscopy. Due to difficulty in
characterizing FA conjugated polymers via ASEC-MALLS, these spectroscopic
techniques were used to show the copolymers before and after FA conjugation. 1H NMR
was performed on a Varian MercuryPLUS 300 MHz spectrometer in DMSO-d6 with delay
times of 2s. The amount of FA conjugated to the polymer backbone of (HPMA315-sAPMA13)-b-DMAPMA23 (P20) was estimated by integration of the methyne-proton
resonance of HPMA at 3.75 ppm and the proton resonance of FA at 8.64 ppm (s, PtC7H,
1H). These values were estimated employing a Lorentzian/Gaussian line fit using
MestReC NMR data processing software version 4.7.
UV-vis spectroscopy was carried out using a JASCO V-530 UV-vis
spectrophotometer for FA conjugated (HPMA-s-APMA)-b-DMAPMA block copolymers
(P20, P21 and P22). An average extinction coefficient of 8000 M-1cm-1 for free FA in
phosphate buffer solution (20 mM Pi / 0.1 M NaCl pH 7.4) was used to determine the
number of FA units for (HPMA-s-APMA)-b-DMAPMA copolymers.
MALDI-ToF Mass Spectrometry for Folate Conjugation
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass
spectrometry was used to show molecular weights before and after FA conjugation for
P20 and P21. MALDI-ToF mass spectra were obtained using a Bruker Daltonics
Microflex equipped with a 337 nm N2 laser in linear mode with a 20 kV acceleration
voltage. 2,5-Dihydroxybenzoic acid (DHB) dissolved in HPLC H2O (10mg/mL) was
employed as the matrix and all samples (1 mg/mL in HPLC H2O) were charged with
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trifluoroacetic acid. Polymer samples were mixed with DHB matrix solution in a 50/50
ratio by volume and 2 L of each sample were then spotted onto a stainless steel target.
An external protein calibration standard (Bruker, protein standard II) was employed for
accurate measurements of polymers before and after conjugation. Over 2000 laser shots
on average were taken for each sample and peak molecular weight values were
determined by Microflex analysis software.
Dynamic Light Scattering and Zeta Potential of Block Copolymer/siRNA Complexes
Dynamic light scattering (DLS) and zeta potential measurements of block
copolymer/siRNA complexes under aqueous conditions were performed using a
Malvern-Zetasizer Nano Series DLS detector with a 22 mW He-Ne laser operating at λ =
632.8 nm, an avalanche photodiode detector with high quantum efficiency, and an
ALV/LSE-5003 multiple  digital correlator electronics system. DLS measurements
were carried out at a FA-block copolymer or complex concentration (siRNA + FA-block
copolymer) of 0.1 mg mL-1 in phosphate buffer saline solution (20 mM Pi / 0.1 M NaCl
pH 7.4). Data analysis of DLS measurements was performed using the CONTIN method.
Zeta potential measurements were carried out at a complex concentration of 0.8 mg mL-1
in 20 mM NaCl solution at pH 7.4 in a zeta folded capillary cells purchased from
Malvern Instruments. A higher concentration for zeta potential measurements was
required because 0.1 mg mL-1 concentration was too dilute for instrument detection.
Samples were vortexed immediately to ensure homogenous mixing and equilibrated for
10 min at 25 °C. To remove dust, samples were centrifuged at 14,000 RPM for 10
minutes prior to characterization via DLS and zeta potential. Both DLS and zeta potential
measurements were performed in triplicate.
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Preparation of Block Copolymer/siRNA Complexes for Fluorescence Microscopy
FA labeled (HPMA-s-APMA)-b-DMAPMA/siRNA complexes were prepared
with a nitrogen/phosphate (N/P) ratio equal to 1. A typical preparation is as follows: 0.6
L of 10 M dual-labeled (Cy3-siRNA-FAM) or unlabeled siRNA was mixed with 1.7
L or 1.1 L of 10 M FA conjugated (HPMA315-s-APMA13)-b-DMAPMA23 (P20) or
un-conjugated (HPMA315-s-APMA13)-b-DMAPMA23, respectively. All samples were
immediately vortexed to ensure homogenous mixing. Block copolymer/siRNA
complexes were equilibrated at room temperature for 10min before adding to a 12-well
plate where each well contained 600 L of cell media.
Fluorescence Microscopy
Fluorescence cell images were taken using a Nikon fluorescence microscope
(Eclipse 80i, Plan Fluor 40X/0.75 DIC M/N2 lens). The images were processed utilizing
Image-Pro Plus software. Multiple fields were examined for each sample to ensure
uniform distribution of block copolymer/siRNA and lipofectamine/siRNA complexes
throughout. Each cell treatment was repeated in triplicate to show reproducibility of the
observed results.
2,4,6-Trinitrobenzene Sulfonic Acid (TNBS) Primary Amine Assay
A TNBS assay on copolymer P11 was performed in order to confirm the presence
of primary amines. This assay was performed according to literature procedure by
Snyder and Sobocinski.247 D-Alanine was utilized to construct a calibration curve before
the amine content of copolymer P11 was determined. First, D-Alanine was dissolved in
sodium tetraborate buffer (0.1 M, pH 9.3) at a concentration of 100 µM with a total
volume of 1 mL. A 5% w/v solution of TNBS in methanol (obtained from Aldrich) was
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diluted 5-fold with sodium tetraborate buffer. 25 µL of the resulting TNBS solution was
added to the 100 µM D-Alanine solution giving an approximate TNBS concentration of
750 µM. The reaction was then allowed to proceed for 30 min at 37 °C. Following
reaction, the absorbance at 420 nm was measured for D-Alanine concentrations of 5, 10,
15, 20 and 25 µM to construct a calibration curve. Baselines were corrected for each
concentration by measuring the absorbance for a solution without amines present (i.e. a
750 µM TNBS solution in sodium tetraborate). An extinction coefficient of 9920 M-1
cm-1 was determined using a linear fit by Origin 7.0. Following the construction of the
calibration curve, a 1 mL, 3.03 µM solution of copolymer P11 in 0.1 M sodium
tetraborate was prepared. Assuming 33 amines per polymer chain, as determined by 1H
NMR, a primary amine concentration of 100 µM is calculated. A TNBS assay was then
performed on the resulting solution as described above. The reaction solution was then
diluted ([copolymer P11] = 0.454 µM or [amine] = 15 µM ) and the absorbance at 420
nm was measured. UV-vis analysis was in 99 % agreement with the calibration curve
and 1H NMR thus confirming the presence of 33 APMA repeats per polymer chain. The
absorbance at 420 nm versus amine concentration for D-Alanine and copolymer P11 with
the fitted calibration curve can be seen in Figure IV-23. UV-vis spectroscopy for the
TNBS assay was carried out using an Agilent 8453 UV-Visible spectrophotometer with a
photodiode array.
Determination of SPDP Functionalization to HPMA-s-APMA Copolymers
The thiol activation of copolymer P11 with SPDP was verified by 1H NMR and
UV-vis spectroscopy. 1H NMR was performed with a Varian MercuryPLUS 300 MHz
spectrometer in DMSO-d6 utilizing delay times of 2s. The amount of SPDP reacted with
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the APMA (M9) functionalities of copolymer P11 was estimated to be 7 out of 33 (20
mol %) of the APMA units by integration of the methyne-proton resonance of HPMA at
3.7 ppm and the proton resonance of the SPDP pyridyl ring at 8.4 ppm. These integration
values were estimated employing a Lorentzian/Gaussian line fit using MestReC NMR
data processing software version 4.7. UV-vis spectroscopy was carried out using a
Varian Cary 50 Bio spectrophotometer for copolymer P4, P11 and P16 to demonstrate
thiocarbonylthio removal and the presence of pyridyl disulfide functionalities. All UVvis measurements were repeated in triplicate.
Characterization of Copolymer P23 and Copolymer P24 Multiconjugates
Conjugation of RNA sense strand to copolymer P16 and subsequent folate
conjugation was verified by PAGE and/or UV-vis spectroscopy. All gel electrophoresis
was carried out using 8% polyacrylamide denaturing gel using 1X TBE buffer/Urea as
running buffer. All gels were stained with ethidium bromide (EtBr) for band
visualization and imaged by a BIO-RAD Molecular Imager FX using Quantity One
software package version 4.2.2. For analysis of RNA conjugated copolymer P23, 2 L
of the reaction solution was diluted to 16 L with gel-loading buffer containing 0.2%
bromophenol blue, 8 M urea, and 1X TBE buffer. 2 L (approx. 50 pmol RNA) was then
loaded onto the gel and run for 10 min at 15 W. The degree of conjugation of HS-RNA
was determined using BIO-RAD Molecular Analyst software package version 1.5
through the comparison of the product band (RNA conjugated copolymer P23) to that of
free/unreacted HS-RNA using Equation 9 and was found to be 89 ± 4 %.
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝐶𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 % =

𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐶𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒 𝐵𝑎𝑛𝑑
𝑇𝑜𝑡𝑎𝑙 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦

× 2 × 100%

The 2 in Equation 9 is due to the fact that two times excess HS-RNA was employed.

(9)
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For gel analysis of purified copolymer P23, RNA/folate conjugated copolymer
P24, and hybridization (siRNA/folate conjugated copolymer P25), all sample solutions
were diluted to approximately 25 M RNA concentration and 1 L of the resulting
solution was diluted to 2 L with gel-loading buffer containing 0.2% bromophenol blue,
8 M urea, and 1X TBE buffer. The samples were loaded immediately and allowed to run
for 12 min at 15 W, with the exception of the hybridization reaction which was run for 30
min at the same wattage. For samples involving DTT reduction 1 L of the above
sample solutions were diluted with 1 L of 0.2 M DTT/80 mM phosphate buffer (pH 8.0)
and allowed to incubate at 37 °C for 30 minutes. Following reduction the resulting
samples were diluted with 2 L of gel-loading buffer containing 0.2% bromophenol blue,
8 M urea, and 1X TBE buffer. The samples were loaded immediately and allowed to run
under the same conditions as above.
UV-vis spectroscopy was carried out using a Varian Cary 50 Bio
spectrophotometer for RNA conjugated copolymer P23 and RNA/folate conjugated
copolymer P24. An extinction coefficient () of 250,000 M-1 cm-1 for polynucleotides at
260 nm was used to determine the RNA concentration for the RNA conjugated
copolymer P23. Conjugation of NHS activated folate to RNA conjugated copolymer P23
was determined by comparing the absorbance at 260 nm (maxima for RNA) to 281 nm
(maxima for folate). Extinction coefficients for free folic acid in 40 mM phosphate
buffer (pH 8.0) at 260 and 281 nm are 16,600 M-1 cm-1 and 30,300 M-1 cm-1, respectively.
Extinction coefficient for RNA at 281 nm is 107,500 M-1 cm-1. Using the following two
equations, the concentration of RNA and folate linked to the copolymer was determined:
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260
260
𝐴260 = 𝐶𝑅𝑁𝐴 𝜀𝑅𝑁𝐴
+ 𝐶𝐹𝐴 𝜀𝐹𝐴

(10)

281
281
𝐴281 = 𝐶𝑅𝑁𝐴 𝜀𝑅𝑁𝐴
+ 𝐶𝐹𝐴 𝜀𝐹𝐴

(11)

where A is the absorbance at either 260 or 281 nm, C is the concentration of either RNA
of folate (FA) and  is the extinction coefficient for RNA or FA at either 260 or 281 nm.
All UV-vis measurements were repeated in triplicate. It is important to note that the
absorbance due to the copolymer at the measured concentrations is negligible at both 260
and 281 nm.
siRNA Release via Glutathione from P25
siRNA release from siRNA/folate conjugated copolymer P25 was carried out in
the presence of glutathione to simulate intracellular conditions. First, 4 L of a 4 M
siRNA/folate conjugated copolymer P25 solution (25 M anti-survivin siRNA) was
added to 4 L of a 10 mM glutathione / 40 mM phosphate buffer (pH 7.4) solution
bringing the final concentration of glutathione to 5 mM and siRNA to 12.5 M. The
resulting solution was incubated at 37 °C and 1 L aliquots were taken at increasing time
intervals and subsequently diluted with 2 L of gel-loading buffer containing 0.2%
bromophenol blue, 8 M urea, and 1X TBE buffer. The resulting samples were loaded and
run on an 8% polyacrylamide denaturing gel using 1X TBE buffer/Urea as the running
buffer for 20 min at 15 W. The percent release of anti-survivin siRNA was determined
using BIO-RAD Molecular Analyst software package version 1.5 where the intensity of
the released siRNA band was directly compared to the remaining conjugate band.
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In Vitro Cell Studies
Cell Culture
KB and A549 cells were maintained and proliferated in folate free RPMI 1640
(Gibco, #27016) cell media supplemented with 10% fetal calf serum (FCS), 100units mL1

penicillin, 100 g mL-1 streptomycin at 37 ºC in 95% air humidified atmosphere and 5%

CO2.
Copolymer Cytotoxicity Assay
Cell viability tests were performed utilizing a CellTiter 96 Aqueous one solution
cell proliferation assay (Promega). 5000 KB cells were seeded into the 96-well
microplate (Nunclon) one day before treatment. Various amounts of FA conjugated
(HPMA315-s-APMA13)-b-DMAPMA23 (P20) stock solution were added to the wells
bringing the total volume of medium to 300 µL and the concentration of P20 was varied
from 10 nM to 6 µM. Tests were run in triplicate in 3 separate wells. Cells were cultured
for 2 days and subsequently 20 µL of CellTiter reagent was added to each well and
incubated for 2 hours before measuring the absorbance at 490 nm using a Synergy2
(BioTek) and Gen5 software. Cells were cultured at 37 ºC in a humidified, 5% CO2
atmosphere.
Cell Treatment with Block Copolymer/siRNA Complexes and Lipofectamine for
Fluorescence Microscopy
Prior to treatment, KB and A549 cells were seeded on cover-glasses in a 12-well
plate with 600 L of folate-free RPMI1640 cell media supplemented with 10% FCS and
were cultured for 24 h. Block copolymer/siRNA complexes were then added to the cell
media and incubated for 1 h. After treatment the cells were fixed with 4%

98
paraformaldehyde and washed with phosphate buffered saline (PBS) prior to imaging.
The cells were then stained with 4',6-diamidino-2-phenylindole (DAPI) in 12 L of
mounting gel. The cover glasses were then placed on precleaned microscope slides for
analysis. For lipofectamine 2000 (Invitrogen) control group, the transfection was carried
out according to manufacturer recommendations. 50 L of Opti buffer was mixed with
1ul lipofectamine and added to 50 L Opti buffer with 0.6 L of 10 M Cy3-siRNAFAM and mixed for 20min. The resulting solution was then added to 500 L of media
(total 600ul) and the cells were treated for 3 hours. After treatment the cells were fixed
with 4% paraformaldehyde and washed with PBS and then stained with DAPI in 12 L
of mounting gel. The cover glass was then placed on precleaned microscope slides for
analysis.
Cell Treatment with Block Copolymer/siRNA Complexes for Gene Down-Regulation
KB cells and A549 cells (3 x 104 cells per well) were seeded in 24-well plates
(Flow Laboratories, Inc. McLean, VA) in folate free RPMI 1640 (Gibco, Carlsbad, CA)
supplemented with 10% FCS (HyClone, Logan, UT) one day before experiments. Cells
were treated with either free siRNA or block copolymer/siRNA complexes. In addition,
KB cells were treated block copolymer/siRNA complexes in the presence of free folic
acid (1mM). All cell experiments contained 200 nM anti-survivin siRNA and were
treated for 4 hours, followed by replacement with fresh media. After 2 days, total RNA
was extracted with TriZol (Invitrogen) following the manufacture’s protocol. Reverse
transcription was performed with MMLV transcriptase (Promega, Madison, WI). Finally,
real time reverse transcription PCR (RT-PCR) was carried out with SYBR (SigmaAldrich, St. Louis, MO) on MX3000P PCR system (Stratagene). The primer pairs for
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detecting the survivin gene were 5'-AGCCCTTTCTCAAGGACCAC and 5'TCCTCTATGGGGTCGTCATC. PCR primers for beta-actin gene were 5'CATGTACGTTGCTATCCAGGC and 5'-CTCCTTAATGTCACGCACGAT. Gene
down-regulation experiments were repeated in triplicate to ensure accuracy of results.
The passage numbers of KB and A549 cells are 12 and 4, respectively.
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CHAPTER IV
RESULTS AND DISCUSSION
Work accomplished during this doctoral research has been divided into three
sections. The first section describes the successful aqueous RAFT polymerization of
hydrophilic-b-cationic block copolymers and subsequent chain end conjugation. Welldefined HPMA-b-DMAPMA (M4-b-M7) block copolymers were synthesized in the
presence of the carboxylic acid containing CTA, CTP (C1), and the initiator V-501 (I3).
Following characterization of these block copolymers, bioconjugation methods to both
the α- and -chain ends were developed for potential use in siRNA delivery. Initial
modification of the thiocarbonylthio -chain end of HPMA-b-DMAPMA copolymers to
a primary amine allowed facile and efficient modification with an amine reactive
fluorescein fluorophore. The carboxylic acid α-chain ends of the block copolymers were
activated via carbodiimide chemistry to form an activated ester that was subsequently
modified with an amine and folate containing PEG. However, poor conjugation yields to
the α-terminal chain ends led to the development of an alternate synthetic pathway for
folate conjugation.
The second section of this research concerns the synthesis of well-defined
terpolymers containing a DMAPMA cationic block to form neutral (N/P = 1) electrostatic
complexes with siRNA, and an HPMA-s-APMA statistical amine functional block that
confers water solubility and provides sites for conjugation of folic acid. These
multivalent folate-block copolymer conjugates were then utilized for complexation and
targeted delivery of a double stranded 59-nucleotide siRNA to cancerous cell lines that
over-express folate receptors. The specific siRNA sequence employed in this research
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was able to down-regulate Human Survivin, a protein required to regulate the cell cycle
and prevent apoptosis (i.e., cell death). After observation of siRNA delivery through
fluorescence microscopy, gene down-regulation was confirmed by monitoring the Human
Survivin mRNA level.
In the third section, conditions to conjugate both a gene therapeutic, siRNA, and a
cancer cell targeting moiety, folic acid, to RAFT-synthesized HPMA-s-APMA (M4-sM9) copolymers were developed. After isolating HPMA-s-APMA, a small fraction of
the pendent primary amines were subsequently converted to activated thiols, utilizing Nsuccinimidyl 3-(2-pyridyldithio)-propionate (SPDP), providing a copolymer with two
distinct reactive sites for both thiol containing compounds and activated esters.
Bioconjugation of both thiolated siRNA and modified folic acid were performed in two
separate steps, allowing the characterization of intermediates by ASEC-MALLS and 1H
NMR and UV-vis spectroscopy. It was demonstrated that this pathway provides a facile
and robust route for producing well-defined targeted siRNA delivery vehicles. In
addition, siRNA release through disulfide cleavage was demonstrated under intracellular
conditions, while the presence of attached folates allows for site-directed delivery to
cancer cell lines that over-express folate receptors. Conjugation reactions and subsequent
siRNA release were confirmed by polyacrylamide gel electrophoresis and UV-vis
spectroscopy.
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Section I. Development of Conjugation Methods to Both the α- and -Chain Ends of
RAFT-Synthesized HPMA-b-DMAPMA Copolymers
Overview
RAFT polymerization has proven to be a facile method to synthesize polymers
with controlled molecular weights, precise polymer architectures, and predetermined α
and  end group functionality. The CTA provides an α end group, dictated by the R
group, and a thiocarbonylthio -terminal chain end, both of which can be modified by
post-polymerization conjugation to drugs, peptides, proteins, oligonucleotides, targeting
moieties, nanoparticles, or fluorescent dyes.8,10,11,80,81,198,199,203-205,248,249 Reduction of the

-terminal thiocarbonylthio group with reducing agents, such as amines10,49,249,250 or
sodium borohydride (NaBH4),203-205,251 provides a polymeric thiol that is easily coupled to
biological compounds that contain or have been modified with thiols, enes (i.e.,
maleimides, vinyl), and iodoacetamides. Alternatively, end group conjugation to the αterminal/R group either prior to or after polymerization is also an attractive strategy. For
example, CTAs containing α-terminal carboxylic acid moieties, such as C1, C7, C8, C9
and C10 (Figure I-2), are commonly employed because they can be modified through
carbodiimide chemistry, activated with NHS, or transformed to an acid
chloride.79,80,199,202
Although reports on end group modification of RAFT-synthesized copolymers are
now common, literature reports were minimal at the time the research discussed in this
section was being conducted. Furthermore, at the same time our laboratory reported a
fluorescent labeling procedure for the -chain end of RAFT-synthesized poly(NIPAM)
(poly(M3)) with maleimide fluorophores.203 However, this procedure was not successful
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in labeling RAFT polymers synthesized with α-methyl-substituted monomers.
Unsuccessful labeling was attributed to the lower reactivity of tertiary thiols (α-methyl
derivatives) versus secondary thiols (non α-methyl derivative) towards maleimides. Due
to this poor reactivity, an alternative synthetic allowing for facile transformation of
polymeric tertiary thiols to primary amines was developed.82 This transformation allows
shorter reaction times and lower molar quantities for conjugation to expensive peptides,
proteins, and fluorescent dyes. Building on the success of this end group conjugation and
our group’s prior success for electrostatically stabilizing and enzymatically protecting
siRNA,6 we then focused on the conjugation of folate, a cancer cell targeting moiety, to
the α-terminal chain end of HPMA-b-DMAPMA (M4-b-M7) copolymers for targeted
siRNA delivery. Therefore, the work contained in this section focuses on 1) the
preparation and characterization of well-defined HPMA-b-DMAPMA copolymers via
aqueous RAFT polymerization and 2) the development of bioconjugation methods to
both the α- and -chain ends of these HPMA-b-DMAPMA copolymers.
Synthesis of HPMA-b-DMAPMA Copolymers for α- or -Chain End Modification
HPMA-b-DMAPMA copolymers were prepared by chain-extension of an HPMA
macroCTA with DMAPMA (M7) under acidic aqueous conditions, pH 5.2, at 70 °C
(Scheme IV-1). Aqueous, cationic SEC-MALLS chromatograms for HPMA250
macroCTA (P2) and the HPMA250-b-DMAPMAn (P7) copolymer series are shown in
Figure IV-1. The unimodal nature of the chromatograms in combination with the shift to
lower elution volume indicates efficient chain extension. Molecular weight properties
and chromatograms for HPMA258 macroCTA (P1) and HPMA258-b-DMAPMA13 (P6)
were reported previously by our laboratory.6 Conversion, molecular weight, and
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polydispersity data for each block copolymer are listed in Table IV-1. 1H NMR was
utilized to determine the block compositions for each copolymer through comparison of
the integrated resonance of the HPMA methyne-proton at 3.75 ppm to that of the
DMAPMA methylene at 2.70 ppm (Figure IV-2). As shown in Table IV-1, theoretical
molecular weights (Mn,th) and experimental molecular weights (Mn,exp) are in reasonable
agreement with each other.
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Scheme IV-1. Synthetic pathway for aqueous RAFT-synthesized HPMA-b-DMAPMA
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Figure IV-1. Aqueous, cationic SEC-MALLS traces demonstrating the efficient blocking
of HPMA250 macroCTA with DMAPMA (M7), A) HPMA250 macroCTA (P2),
B) HPMA250-b-DMAPMA15 (P7; n= 15), C) HPMA250-b-DMAPMA32 (P7; n= 32), and
D) HPMA250-b-DMAPMA56 (P7; n= 56).
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Table IV-1. Conversion (), Composition, Molecular Weight (Mn), and Polydispersity
(PDI) Values for a Series of HPMA-b-DMAPMA Copolymers Prepared Via Aqueous
RAFT Polymerization.

Sample
HPMA258 macroCTA*
(P1)
HPMA258-b-DMAPMA13*
(P6)
HPMA250 macroCTA
(P2)
HPMA250-b-DMAPMA15
(P7; n= 15)
HPMA250-b-DMAPMA32
(P7; n= 32)
HPMA250-b-DMAPMA56
(P7; n= 56)
a

a
(%)

Compositionb

Mn,th
(kDa)c

Mn,exp
(kDa)

PDId

----

----

----

37.0 d

1.15

9

95 : 5

40.7

39.7 b

1.06

----

----

----

35.7d

1.08

5

94 : 6

35.9

38.6b

1.04

13

89 : 11

41.1

42.3b

1.05

25

82 : 18

46.0

47.2b

1.05

Conversions were determined by comparison of the UV signal at 274 nm of the
monomer at t0 to that at tx. b As determined by 1H NMR. c Theoretical Mn (Mn, th)
Calculated from conversion () using Mn, th = ([M]o/[CTA]o )Mw, monomer  + Mw, CTA .
d
As determined by aqueous SEC-MALLS. * These polymers were previously reported
by our laboratories.6
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Figure IV-2. 1H NMR spectrum with chemical shift assignments for HPMA250-bDMAPMA15 copolymer (P7; n = 15).
This series of block copolymers was designed for siRNA complexation and
subsequent cellular delivery based on previous results obtained by our laboratories.6 In
the previous report, the presence of the hydrophilic, biocompatible HPMA block allowed
neutral complexes to be formed (i.e., nitrogen/phosphate ratio (N/P) of 1) while
maintaining solution stability of the polymer/siRNA complexes. Furthermore, it was
found that DMAPMA block lengths having a degree of polymerization (DP) below 60
were optimal for siRNA complexation. Copolymer/siRNA complexes of this nature led
to minimal precipitation, leaving most of the complexes solubilized under physiological
conditions (20 mM phosphate/0.1 M NaCl, pH 7.4). Therefore, DMAPMA block lengths
in this work were maintained near or below a DP of 60, while substantial HPMA block
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lengths (i.e., DP > 200) were targeted to maintain solution stability of the neutral
copolymer/siRNA complex.

, Primary Amine Functionalization of HPMA258-b-DMAPMA13 (P6) Copolymer
Directly in Water
The synthetic pathway for the amine functionalization and the fluorescent labeling
with 5-SFX for HPMA258-b-DMAPMA13 (P6) block copolymer is outlined in Scheme
IV-2. The dithioester chain end of the copolymer is first reduced through the use of the
strong reducing agent NaBH4. After reduction and subsequent purification the reduced
polymer contains free tertiary thiols and disulfide coupled polymer chains.
Unfortunately, this polymeric tertiary thiol is of low reactivity and needs to be modified
to a more reactive functionality. Therefore, a more reactive primary amine functionality
was introduced through the addition of excess cystamine at basic pH. This results in a
disulfide exchange reaction between the polymer chain ends and cystamine, thus,
yielding a primary amine at the -chain end of the polymer. Primary amines are key to
transformation in the biosciences, allowing facile reactions with activated carboxylic
acids as well as other functional groups. Primary amine functionalization was
determined via a ninhydrin assay by monitoring the absorbance at 570 nm. Figure IV-3
shows the absorbance of the amine activated HPMA258-b-DMAPMA13 (P17) block
copolymer at 570 nm along with a calibration curve for the model amine compound,
hexylamine. The percent of reduced HPMA258-b-DMAPMA13 copolymer reacted with
cystamine was found to be 91.7  0.3 %.
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Scheme IV-2. Synthetic pathway for the amine functionalization (P17) and fluorescent
labeling (P18) of HPMA258-b-DMAPMA13 (P6) block copolymer with 6-(fluorescein-5carboxamido)hexanoic acid, succinimidyl ester (5-SFX).
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Figure IV-3. Absorbance of ninhydrin at 570 nm versus amine concentration for
hexylamine (○), amine activated polymer (P17; 29.7 M) (■) and fitted calibration curve
(—).

5-SFX Fluorophore Conjugation to Amine Activated HPMA258-b-DMAPMA13 (P17)
The presence of a free amine at the RAFT polymer chain ends allows for easy
conjugation between the polymer and the activated fluorophore 5-SFX (P18). The
primary amine, a more reactive group than a tertiary thiol, allows smaller quantities of
fluorescent dyes to be used. For example, the ratio of fluorescent dye to polymer in this
report was 5:1; while in our group’s previous study,203 a molar ratio of 150:1 was needed
for sufficient reaction between a secondary thiol and a maleimide. After conjugation of
5-SFX to the polymer, excess fluorescent dye was evident even after dialysis against DI
water. This was attributed to the fact that the block copolymer contains a cationic block
and 5-SFX is anionically charged at neutral pH, causing the free fluorophore to be bound
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to the cationic groups of the DMAPMA block. In order to remove excess 5-SFX the
polymer was dissolved in 20 mM phosphate/ 0.1 M NaCl buffer (pH 7.4) to promote ion
exchange and ultimately release the bound 5-SFX. Excess 5-SFX was then removed
using a centrifugal membrane filtration device. Figure IV-4 shows the absorbance of the
fluorescently labeled polymer before and after centrifugal membrane filtration. The
decrease in maximum absorbance is clearly visible between the two absorbance spectra.
The degree of 5-SFX conjugation to HPMA258-b-DMAPMA13 copolymer was obtained
by comparing the concentration of 5-SFX, determined by measuring the maximum
absorbance at 494 nm, to the concentration of the copolymer (Figure IV-4). The degree
of conjugation was found to be 80.1  2.6 %.
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Figure IV-4. Absorbance spectrum of fluorescently labeled HPMA258-b-DMAPMA13
(P18) copolymer. Inlay shows magnified region of absorbance due to 6-(fluorescein-5carboxamido)hexanoic acid (5-SFX) before (----) and after (—) membrane filtration.
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Folic Acid Conjugation to the α-Chain End of HPMA-b-DMAPMA Copolymers
Prior to modifying the α-chain end of HPMA-b-DMAPMA copolymers with folic
acid, the thiocarbonylthio groups at the -terminus were removed through a standard
literature procedure involving the reaction of the block copolymers with a large excess of
azobisisobutyronitrile (AIBN).244 Removal of the thiocarbonylthio eliminates unwanted
side reactions between primary amines and the -terminus. The removal processes were
monitored by measuring the thiocarbonylthio characteristic absorbance at 310 nm with a
UV-vis detector in-line with ASEC instrumentation and directly comparing the
absorbance of HPMA250-b-DMAPMAn before (P7) and after (P12) end group removal.
Over a 90% reduction in the UV-vis chromatograms absorbance/area verified end group
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removal (Figure IV-5).
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Figure IV-5. UV-vis absorbance @ 310 nm before () and after (---) the removal of the
thiocarbonylthio functionality from A) HPMA250-b-DMAPMA15 (P7; n = 15) and B)
HPMA250-b-DMAPMA32 (P7; n = 32).
In order to address the problem of trafficking therapeutic carriers to the intended
location, a folic acid derivative (FA-PEG34-NH2) was conjugated to HPMA250-bDMAPMA15 (P12; n =15) and HPMA250-b-DMAPMA32 (P12; n =32) copolymers for
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the targeting and treatment of cancerous tissues with siRNA based therapeutics. FAPEG34-NH2 (Mn = 1950 g/mol) was conjugated to the -terminal chain end as shown in
Scheme IV-3. As determined by MALDI-ToF MS (Figure IV-6), UV-vis and 1H NMR
spectroscopy (data not shown) FA-PEG34-NH2 was conjugated to both HPMA250-bDMAPMA15 and HPMA250-b-DMAPMA32 copolymers. The MALDI-ToF spectra for
HPMA250-b-DMAPMA32 before and after conjugation can be seen in Figure IV-6.
Through comparison of the peak molecular weight values before and after reaction with
FA-PEG34-NH2 it was determined that HPMA250-b-DMAPMA15 and HPMA250-bDMAPMA32 had peak molecular weight shifts of 700 m/z and 1200 m/z, respectively.
However, quantitative conjugation of FA-PEG34-NH2 to these copolymers should have a
peak-to-peak shift near 1950 m/z (the Mn of FA-PEG34-NH2). Only conjugation
efficiencies of 36 % and 62 % for HPMA250-b-DMAPMA15 and HPMA250-bDMAPMA32, respectively, were obtained. This incomplete coupling suggests that the use
of carbodiimide chemistry with these macromolecules has low efficacy and other
synthetic routes for bioconjugation are warranted. One such route was reported by
Sumerlin and coworkers in which ―click‖ chemistry was utilized to conjugate folic acid
to the -terminal chain end of RAFT synthesized polymers.81 However, it has also been
suggested by Kataoka and coworkers that the number and distribution of folic acid
ligands on the carrier is significant.252 The synthetic route used by Sumerlin et al. only
allows for one folic acid to be linked per chain, which may be desired when using block
copolymers capable of undergoing micellization, as demonstrated by this group.
However, due to controlling the HPMA and DMAPMA block lengths and thus the
registry between the cationic block and the siRNA anionic backbone, as is the case in this
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research, the number of polymer chains per siRNA is much lower than the number of
chains found in a typical polymeric micelle. In such a case an alternate route is needed to
increase the number of targeting moieties per chain, such as conjugation along the
polymer backbone.
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Section II. Synthesis and Characterization of Multivalent Folate-Block Copolymer
Conjugates for Targeted Delivery of siRNA and Gene ―Knockdown‖
Overview
Most reports in the literature implement commercially available cationic polymers
(i.e., PEI, poly(amidoamine) dendrimers, PLL), due to the widespread availability, to
protect and deliver oligo- and polynucleotides for gene delivery. Since these polymers
were not designed for such applications, it is not surprising that commercial cationic
polymers are suboptimal for delivery applications. Various drawbacks include high
cytotoxicity, ill-defined architectures, and inherently broad molecular weight
distributions.13,253,254 Furthermore, transfection relies on adsorptive endocytosis due to
the cationically charged complex which leads to treatment of both healthy and unhealthy
tissues. Therefore, a significant need exists for the development of a well-defined neutral
polymeric gene carriers with tunable properties that can be targeted to specific cellular
receptors.
Typically, macromolecular species accumulate via the EPR effect in tumoral
tissue because of poor lymphatic drainage.116,124,190,255 This increased accumulation gives
a higher probability that the macromolecular carrier will be internalized into the cell
through endocytosis. In the case of cationic gene carriers this can result in various
deleterious side effects. However, it has been demonstrated that the conjugation of a
targeting moiety, such as folic acid, to a non-viral carrier can increase cellular uptake as
compared to carriers that solely rely on the EPR effect.117,256,257
Research presented in this section is a direct extension of the work performed by
Scales et al. from our laboratories in 2006, where we successfully demonstrated how to
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prepare solution-stable, neutral polyelectrolyte complexes between a hydrophilic-bcationic copolymer, HPMA-b-DMAPMA, and a model 49 nt hairpin siRNA.6 That
report established optimal cationic block lengths (DP ≤ 60) for complex solution stability
and demonstrated siRNA protection from enzymatic degradation. However, utilizing
these copolymer/siRNA complexes for gene delivery applications would solely rely on
the EPR effect, a passive targeting method. Therefore, we sought to develop a polymeric
carrier that still encompasses the attributes of our previous system but also allows for
targeted delivery of copolymer/siRNA complexes to specific cellular receptors. This
requires the synthesis of a polymeric carrier with well-defined architecture and multiple
reactive pendent functionalities for conjugation. The work contained in this section
demonstrates the facile synthesis of a novel, well-defined, multivalent terpolymer capable
of forming neutral complexes with siRNA (less potential for adverse side effects) while
providing multiple targeting moieties for cell specific delivery. The use of aqueous RAFT
polymerization affords control over the block length and number of conjugation sites
incorporated along the polymer backbone. The cationic block of the polymer forms an
electrostatic complex with siRNA, while a statistical amine functional block confers
water solubility and provides sites for conjugation of folic acid (FA). As demonstrated
through zeta potential, fluorescence microscopy, and gene knockdown studies, this
tailored polymer allows the formation of neutral complexes that can be delivered
specifically to cancer cells over-expressing folate receptors.
Synthesis of (HPMA-s-APMA)-b-DMAPMA Block Copolymers
HPMA-s-APMA macro chain transfer agents (macroCTAs) were prepared via
aqueous RAFT polymerization (Scheme IV-4) (P3, P4, and P5). These reactions were
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carried out in acetate buffer (pH 5.2) at 70 °C utilizing 4-cyanopentanoic acid
dithiobenzoate (CTP; C1) and 4,4’-azobis(4-cyanopentanoic acid) (V-501; I3) as the
CTA and initiator, respectively. Two HPMA-s-APMA macroCTAs were synthesized
containing either 5 or 10 mol% APMA (M9) in the monomer feed. The resulting HPMAs-APMA macroCTAs were successfully chain extended with DMAPMA (M7) under
similar conditions (Scheme IV-4) yielding the statistical block copolymers (HPMA315-sAPMA13)-b-DMAPMA23 (P8) and (HPMA320-s-APMA33)-b-DMAPMA34 (P9). Both
polymers displayed polydispersities (PDIs) below 1.15 as determined by aqueous size
exclusion chromatography (ASEC). ASEC chromatograms are shown in Figure IV-7
before and after chain extension with DMAPMA. The unimodal nature of the
chromatograms in combination with the shift to lower elution volume indicates efficient
chain extension. Low molecular weight tailing is apparent in the GPC chromatograms
which is a typical observation in RAFT polymerizations and has been attributed to
premature termination and/or loss of the CTA thiocarbonylthio moiety.6,20 However,
GPC chromatograms indicate that the presence of low molecular weight species is
minimal suggesting that the majority of chain ends retain the CTA functionality allowing
for efficient chain extension.

118
S

O
O

O

HO

CTP, V-501

HN

HN

S

Acetate Buffer (pH = 5.2)
70 °C

HO

y

x

NC

O

O
HN

HN
HO

H3N Cl-

+

HPMA

H3N Cl-

+

APMA

1. DMAPMA,V-501
DI H2O (pH = 5.4)
70 °C

2. Excess AIBN
DMF, 70 °C

O

O
HO

x

NC

y

O
HN

HN

CN

z

O
HN

HO

x

NC

O

HO
H3N Cl-

O
HN

HN

diNHS-FA
DMSO, 21 °C, 48 h

+

y

CN

z

O
HN

O

HO
H3N Cl-

+

NH+ Cl-

NH+ Cl-

Scheme IV-4. Reaction pathway for the synthesis of (HPMA-s-APMA)-b-DMAPMA
copolymers and subsequent conjugation of folic acid (FA).

B
RI Response

RI Response

A

6.5

7.0

7.5

8.0

Elution Volume (mL)

8.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

Elution Volume (mL)

Figure IV-7. Aqueous, cationic SEC-MALLS traces demonstrating blocking of HPMAs-APMA macroCTAs with DMAPMA (M7). A) () HPMA315-s-APMA13 (P3)
macroCTA and (---) (HPMA315-s-APMA13)-b-DMAPMA23 (P8) and B) () HPMA320-sAPMA33 (P4) macroCTA and (---) (HPMA320-s-APMA33)-b-DMAPMA34 (P9).
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Copolymer molecular weights, PDIs, compositions and dn/dc measurements are
shown in Table IV-2. 1H NMR (Figure IV-8) was utilized to determine copolymer
composition through the integration and comparison of the relative intensities of the
methyne-proton resonances of HPMA at 3.75 ppm to the methylene resonances of
APMA between 2.80 to 3.20 ppm for HPMA-s-APMA macroCTAs (Figure IV-8 A) or
the DMAPMA methylene-resonance at 2.70 ppm for (HPMA-s-APMA)-b-DMAPMA
copolymers (Figure IV-8 B). MacroCTA copolymer compositions are in agreement with
theoretical values, Table IV-2. As indicated in Table IV-2, the experimental molecular
weights (Mn, exp) are in close agreement with the theoretical molecular weights (Mn, th). A
positive deviation was observed in the Mn, exp with respect to Mn, th, which has been
previously observed in our laboratories as well as others.17,43,48,72,77,91 This ―overshoot‖ in
the molecular weight of the (HPMA-s-APMA) macroCTAs and in (HPMA-s-APMA)-bDMAPMA copolymers may be attributed to a loss of CTA (e.g. irreversible coupling
reactions, aminolysis or hydrolysis) in the early stages or during the
polymerization.6,49,77,258 Nevertheless, narrowly dispersed copolymers with precise
architecture and reactive pendent functionality were obtained allowing for FA
conjugation, siRNA complexation and subsequent delivery.
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Table IV-2. Conversion (), Composition, Molecular Weight (Mn), Polydispersity (PDI),
and dn/dc Values for the Preparation of (HPMA-s-APMA)-b-DMAPMA ((M4-s-M9)-bM7) Copolymers by Aqueous RAFT Polymerization.
a

Sample
HPMA315-s-APMA13
(P3)
HPMA320-s-APMA33
(P4)
(HPMA315-s-APMA13)b-DMAPMA23 (P8)
(HPMA320-s-APMA33)b-DMAPMA34 (P9)

Comp.
(Theory)
(%)

Comp.
(exp)b

38

95 : 5

40

Mn,th
(kDa)

Mn,exp
(kDa)

PDId

dn/dce

96 : 4

44.3

47.4d

1.10

0.167

90 :10

90 : 10

46.7

51.8d

1.13

0.169

6

----

90 : 4 : 6

49.4

51.3b

1.14

----

9

----

83 : 8 : 9

54.8

57.6b

1.13

----

c

a

Conversions were determined by comparison of the UV signal at 274 nm of the
monomer at t0 to that at tx. b As determined by 1H NMR. c Theoretical Mn (Mn, th)
Calculated from conversion () using Mn, th = ([M]o/[CTA]o )Mw, monomer  + Mw, CTA .
d
As determined by aqueous, cationic SEC-MALLS. e Determined by Wyatt Optilab DSP
interferometric refractometer ( = 690 nm).
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Figure IV-8. 1H NMR spectra and chemical shift assignments for A) HPMA315-sAPMA13) (P3) and B) HPMA315-s-APMA13)-b-DMAPMA23 (P8) copolymers.
The novelty of these copolymers lies in the incorporation of three monomer
components that address various issues related to effective siRNA delivery. The
packaging and protection of the siRNA is accomplished by the incorporation of a cationic
block that can form an electrostatic complex with siRNA, while the aqueous stability and
targeted delivery of siRNA is accomplished by the incorporation of a statistical block that
contains a hydrophilic monomer and a primary amine monomer providing conjugation
sites. RAFT polymerization allows control over the number of conjugation sites and the
block lengths for construction of narrowly dispersed polymers designed specifically for
siRNA delivery.
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Folate Conjugation to (HPMA-s-APMA)-b-DMAPMA Block Copolymers
In order to prevent unwanted side reactions during the conjugation of FAderivatives, the thiocarbonylthio groups at the -terminus of all polymers were removed
according to a standard literature procedure involving the reaction of the block
copolymers with a large excess of AIBN (Scheme IV-4).244 The removal of the
thiocarbonylthio functionalities was confirmed by monitoring the thiocarbonylthio
absorbance at 310 nm with a UV-vis detector in-line with our ASEC instrumentation

Normalized Absorbance @ 310 nm

(Figure IV-9).
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Figure IV-9. UV-vis absorbance @ 310 nm before (P8; ) and after (P13;---) the
removal of the thiocarbonylthio functionality from (HPMA315-s-APMA13)-bDMAPMA23.
The carboxylic groups of FA were amidated to prevent intrapolymer
complexation with the cationic block of the copolymer. The carboxylic acid groups were
first activated with N-hydroxysuccinimide (NHS) yielding a diNHS-FA. DiNHS-FA was
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successfully conjugated to the (HPMA-s-APMA)-b-DMAPMA copolymers (Scheme IV4) via the reaction of the APMA primary amine functionality with a large excess of
diNHS-FA. Following diNHS-FA conjugation, excess ammonia was added to quench
the remaining activated esters to prevent intrapolymer electrostatic interactions.
Successful conjugation of FA to the polymer was confirmed by UV-vis and 1H NMR
spectrosocpy, and MALDI-ToF mass spectrometry.
UV-vis spectroscopy was used to confirm the presence of FA. The absorbances at
350 nm and 280 nm confirm that FA was indeed conjugated to the backbone of the
polymer. As shown in Figure IV-10, the absorbance spectrum for free FA is almost
identical to that of FA conjugated (HPMA-s-APMA)-b-DMAPMA suggesting successful
conjugation of diNHS-FA to the polymer backbone. Based on an average extinction
coefficient for free FA at pH 7.4, UV-vis spectroscopy indicates conjugation of 11 FA
units out of 13 possible for (HPMA315-s-APMA13)-b-DMAPMA23 (P20) and 23 FA units
out of 33 for (HPMA320-s-APMA33)-b-DMAPMA34 (P21). Due to the similarity of UVvis spectra of the synthesized copolymers, only (HPMA315-s-APMA13)-b-DMAPMA23 is
illustrated in Figure IV-10.
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Figure IV-10. UV-vis spectra for A) free folic acid (FA) and B) FA conjugated
(HPMA315-s-APMA13)-b-DMAPMA23 (P20) measured in phosphate buffer pH 7.4.
1

H NMR spectroscopy further proved the conjugation of folate along the

backbone of the (HPMA-s-APMA)-b-DMAPMA copolymers. Figure IV-11 shows the
spectra of free FA (Figure IV-11 A), the block copolymer (HPMA315-s-APMA13)-bDMAPMA23 (P13) prior to conjugation (Figure IV-11 B) and the FA conjugated
copolymer (P20) after neutralization of the folic acid with ammonium hydroxide (Figure
IV-11 C). Chemical shifts from folic acid 8.64 ppm (s, PtC7H, 1H), 7.66-7.63 (d, Ph-C2H
and Ph-C6H, 2H, J = 8.4 Hz) and 6.64-6.61 (d, Ph-C3H and Ph-C5H, 2H, J = 8.4 Hz) are
visible in the 1H NMR spectrum shown in Figure IV-11 C suggesting the successful
conjugation of FA to the polymer backbone. The amount of FA conjugated to the
polymer backbone of (HPMA315-s-APMA13)-b-DMAPMA23 was estimated by integration
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of the methyne-proton resonance of HPMA at 3.75 ppm and the proton resonance of FA
at 8.64 ppm (s, PtC7H, 1H) and was found to be approximately 12-13 FA units per chain.
Due to the amount of sample synthesized, the 1H NMR spectrum was only obtained for
FA conjugated (HPMA315-s-APMA13)-b-DMAPMA23.

c

O
N

g HN
H2N

N

N

h

O

b

O

S
N
H

OH

i

a

HO

x
NC

y
HN

HN

d

HO

z
O

O

O

O

f
c b

N
H

S

O

OH

HN

e
+

Folic Acid

NH+ Cl-

H3N Cl-

(HPMA-s-APMA)-b-DMAPMA
amide peak

C)

d
b

a

g

c

h

f

A)

a

d

e

c

b

h

g

f

9

i
amide peak

B)

e

i

8

7

6

5

4

Chemical Shift (ppm)
Figure IV-11. 1H NMR spectra in d6-DMSO for A) free folic acid (FA), B) (HPMA315-sAPMA13)-b-DMAPMA23 (P8) block copolymer, and C) FA conjugated (HPMA315-sAPMA13)-b-DMAPMA23 (P20).
In addition to UV-vis and 1H NMR, MALDI-ToF mass spectrometry (Figure IV12) was also utilized to confirm FA conjugation to both (HPMA315-s-APMA13)-bDMAPMA23 (P13)and (HPMA320-s-APMA33)-b-DMAPMA32 (P14). A clear shift to
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higher molecular weight indicates successful conjugation of approximately 8-9 FA
molecules per polymer chain for (HPMA315-s-APMA13)-b-DMAPMA23 (Figure IV-12 A)
and 16 FA molecules for (HPMA320-s-APMA33)-b-DMAPMA34 (Figure IV-12 B). The
number of FA units was estimated by comparing peak molecular weight values before
and after FA conjugation. While the low molecular weight species is hardly discernible in
the SEC chromatograms (Figure IV-7), it appears disproportionately in the MALDI-ToF
mass spectra due to the method’s higher sensitivity to low molecular weight species
(Figure IV-12).Quantification using MALDI-ToF is difficult and was not possible with
these samples. Therefore the relative abundance of low molecular weight species is
unknown, but is assumed to be minimal as suggested by SEC prior to conjugation (Figure
IV-7). Given the higher percentage of FA conjugation to (HPMA315-s-APMA13)-bDMAPMA23 (P13), as indicated by the spectroscopic techniques utilized, only
(HPMA315-s-APMA13)-b-DMAPMA23 was studied for complexation with siRNA and
subsequent cellular treatment for fluorescence microscopy and gene suppression
experiments.
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Figure IV-12. MALDI-ToF mass spectra for A) (HPMA315-s-APMA13)-b-DMAPMA23
and B) (HPMA320-s-APMA33)-b-DMAPMA34 before () and after () conjugation with
diNHS-FA.
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Dynamic Light Scattering and Zeta Potential Experiments
Neutral FA conjugated block copolymer/siRNA complexes were prepared
according to our previously reported method which showed siRNA stabilization and
protection from enzymatic degradation.6 The complexes used in these studies were
characterized via dynamic light scattering (DLS) and zeta potential at 25 °C (Figure IV13). Prior to siRNA complexation, the hydrodynamic diameter (Dh) of the FA
conjugated block copolymer was 10.8 ± 0.3 nm and the zeta potential was +25.4 ± 0.7
mV. Given the required need of siRNA for subsequent cellular experiments and the
concentration and volume required for an accurate measurement of the Dh of free siRNA,
DLS experiments were not performed. However, as reported previously by our
laboratories the Dh of a siRNA containing 49 nt was determined via DLS and was found
to be 2.95 ± 0.34 nm.6 It is practical to assume that a slightly larger but similar Dh would
be expected for the siRNA used in these studies which contains 59 nt. The Dh of the
complex as determined by DLS was 15.2 ± 2.4 nm and the zeta potential of the complex
was -3.88 ± 0.21 mV. Zeta potential measurements and DLS indicate that the complexes
are near neutral but remain sterically stable due to the presence of the hydrophilic block.
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Figure IV-13. Hydrodynamic diameters and zeta potential measurements of () folate
conjugated (HPMA315-s-APMA13)-b-DMAPMA23 (P20) and (---) FA conjugated block
copolymer/siRNA complexes. Hydrodynamic diameters were measured at physiological
conditions (20 mM phosphate/0.1 M NaCl, pH 7.4) and zeta potential measurements
were performed in 20 mM NaCl pH 7.4 solution.

Cellular Delivery of Multivalent Folate-Block Copolymer/siRNA Complexes
Prior to siRNA delivery the cytotoxicity of FA conjugated (HPMA315-sAPMA13)-b-DMAPMA23 copolymer (P20) was measured utilizing a cell viability assay
with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS). MTS is directly converted to formazan by dehydrogenase enzymes
which can only be accomplished if cells are metabolically active. Therefore, the
absorbance of formazan at 490 nm is a direct measurement of cell viability. KB cells
were first seeded into a 96 well plate and incubated for 24 h prior to introduction of FA
conjugated (HPMA315-s-APMA13)-b-DMAPMA23 copolymer. Five different FA
copolymer concentrations ranging 10 nM to 6 µM were tested and allowed to incubate
for 2 days. Wells containing only KB cells and no FA copolymer were utilized as a
control. After incubation was complete, a solution of MTS was added and incubated for
two additional hours followed by measuring the absorbance at 490 nm. All results were
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directly compared to the control. As shown in Figure IV-14, FA conjugated (HPMA315s-APMA13)-b-DMAPMA23 copolymer has very low to negligible toxicity over the
complete range of concentrations tested, suggesting that the copolymer is biocompatible
and suitable for gene delivery applications. Each FA copolymer concentration was
repeated in triplicate.
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Figure IV-14. Percent cell survival of KB cells at increasing concentrations of FA
conjugated (HPMA315-s-APMA13)-b-DMAPMA23 copolymer (P20). All experiments
were done in triplicate and error bars represent ± S.D.

siRNA delivery to cancer cells using FA conjugated (HPMA-s-APMA)-bDMAPMA copolymers was followed by fluorescence microscopy (Figure IV-15). A
dual, fluorescently-labeled (Cy3 and FAM) anti-human survivin siRNA was mixed and
vortexed with block copolymers before cell treatment. Human survivin is a protein that
regulates the cell cycle and is commonly over-expressed in cancer cell lines. Cells treated
with copolymer/siRNA complexes were washed with PBS after 1 hour to remove free
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complexes prior to imaging. KB cells, which are known to over-express folate receptors,
were used to show efficient, cell specific delivery of neutral multivalent FA-complexes
(Figure IV-15). For direct comparison, KB cells in Figure IV-15 C were treated with
block copolymer/siRNA complexes prior to FA conjugation while cells in Figure IV-15 E
were treated with FA-conjugated copolymer. The strong Cy3 fluorescence in Figure IV15 E indicates successful folate receptor binding, demonstrating the viability of this
terpolymer system to effectively deliver siRNA to folate-receptor expressing cell lines.
To further prove cell specific delivery, the human lung cancer cell line A549,
which has low folate receptor expression,259 was treated with both un-conjugated (Figure
IV-15 D) and FA conjugated complexes (Figure IV-15 F). Neither image showed Cy3
fluorescence providing evidence of cell specificity. The low folate receptor expression in
the A549 cell line was confirmed by running real time reverse transcription-PCR (RTPCR) experiments and comparing the folate receptor expression levels of the A549
versus the KB cell line. For positive controls both cell lines were treated with
lipofectamine/siRNA complexes (Figure IV-15 A and IV-15 B), where lipofectamine is a
nonspecific transfection agent. The nuclei were stained with 4',6-diamidino-2phenylindole (DAPI) for nuclei location (blue fluorescence).
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A)

B)

C)

D)

E)

F)

Figure IV-15. Fluorescent microscope images of small interfering RNA (siRNA)
(Cyanine-3 and fluorescein (FAM) labeled) delivery to KB cells (A, C, E) and A549 cells
(B, D, F). Lipofectamine (A, B) (+ control), un-conjugated (HPMA315-s-APMA13)-bDMAPMA23 (P13; C, D) (- control), and folic acid conjugated (HPMA315-s-APMA13)-bDMAPMA23 (P20; E, F). Nuclei were stained with 4',6-diamidino-2-phenylindole (blue).
For clarity FAM fluorescence is not shown. Scale bars = 50 m.
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Gene Down-Regulation
To demonstrate that these neutral carriers can lead to cell specific gene downregulation, KB cells and A549 cells were treated with FA conjugated (HPMA315-sAPMA13)-b-DMAPMA23 (P20)/siRNA complexes (siRNA concentration = 200 nM) for
4 hours, followed by 48 hours incubation. Additionally, KB cells were treated with FA
conjugated (HPMA315-s-APMA13)-b-DMAPMA23/siRNA complexes in the presence of
free FA (1 mM) to show inhibition of cellular uptake due to the competition of folate
receptor binding between free FA and FA conjugated copolymer/siRNA complexes.
Survivin mRNA was then quantified by RT-PCR analysis (Figure IV-16). As shown in
Figure IV-16, approximately 60% mRNA down-regulation was observed in the KB cell
line, while no mRNA down-regulation was in the A549 cell line, which has low folate
receptor expression. The presence of free FA led to negligible mRNA down-regulation
indicating minimal cellular uptake of FA conjugated (HPMA315-s-APMA13)-bDMAPMA23/siRNA complexes. These results indicate that FA conjugated (HPMA315-sAPMA13)-b-DMAPMA23/siRNA complexes can deliver siRNA through folate receptormediated endocytosis leading to the down-regulation of human survivin in KB cells.
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Figure IV-16. Quantitative RT-PCR analysis of cell specific down-regulation of human
survivin messenger RNA (mRNA) by anti-survivin small interfering RNA (siRNA). The
control contained either KB cells/siRNA or A549 cells/siRNA. The other three
experiments (marked KB, KB/Free FA and A549) were treated with folate conjugated
(HPMA315-s-APMA13)-b-DMAPMA23 (P20)/siRNA complexes in the presence (KB/Free
FA) or absence (KB, A549) of 1 mM free folic acid (FA). All experiments were done in
triplicate and error bars represent ± S.D.

After demonstrating successful gene down-regulation with the above system, FA
conjugated (HPMA-s-APMA)-b-DMAPMA copolymers with shorter DMAPMA block
lengths were synthesized in an attempt to increase the efficacy of the carrier. In theory,
as the DMAPMA block decreases the number of polymers per siRNA increases.
Therefore, dissociation of complexes formed with polymers containing short DMAPMA
blocks should result in a higher entropic gain than complexes formed with long
DMAPMA blocks. In other words, release of the siRNA can potentially be increased by
employing polymers with short DMAPMA block lengths. With this in mind, neutral FA
conjugated block copolymer/siRNA complexes were prepared utilizing newly
synthesized FA conjugated (HPMA252-s-APMA10)-b-DMAPMAn copolymers (P22; n =
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11 or 17) (Table IV-3). However, increased gene-down regulation was not observed in in
vitro cellular experiments. Due to these results, an alternate polymeric carrier was
developed in order to address issues associated with intracellular release.

Table IV-3. Conversion (), Composition, Molecular Weight (Mn), Polydispersity (PDI),
Degree of FA Conjugation (% FA), and Human Survivin mRNA Suppression Values for
(HPMA252-s-APMA10)-b-DMAPMAn (P10, n = 11 or 17) Copolymers Prepared by
Aqueous RAFT Polymerization.

Sample
HPMA252-s-APMA10 (P5)
(HPMA252-s-APMA10)-bDMAPMA11 (P10; n = 11)
(HPMA252-s-APMA10)-bDMAPMA17 (P10; n = 17)
a

a
(%)

Comp.
(exp)b

Mn,exp
PDIc
(kDa)

% FAb

% mRNA
Suppressiond

25

96 : 4

37.9c

1.05

----

----

6

92 : 4 : 4

39.8b

1.06

88

42

8

90 : 4 : 6

40.8b

1.06

95

50

Conversions were determined by comparison of the UV signal at 274 nm of the
monomer at t0 to that at tx. b As determined by 1H NMR. c As determined by aqueous,
cationic SEC-MALLS.d As determined by real time RT-PCR.
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Section III. Rational Design of Targeted Cancer Therapeutics through the
Multiconjugation of Folate and Cleavable siRNA to HPMA-s-APMA Copolymers
Overview
Ever since the influential ―depot‖ model of pharmacologically active polymers
introduced by Ringsdorf 35 years ago,1,107 researchers have aggressively pursued the
conjugation of therapeutic agents/targeting moieties to synthetic polymers.
Unfortunately, limitations of polymerization techniques at the time restricted progress.
These limitations included poor control over molecular weight, molecular weight
distributions, placement of terminal or pendent reactive groups, polymer architecture
(i.e., blocks, stars), and solubility in biologically relevant media.3,16,20 Traditional ―living‖
polymerization techniques, such as anionic, cationic, or group transfer, can address some
of these limitations, such as control over molecular weight and polymer architecture, but
have stringent reaction conditions and limited monomer selection that often require
protecting group chemistries for functional/reactive monomers. RAFT polymerization on
the other hand allows the controlled polymerization of a wide variety of unprotected
functional vinyl-based monomers under mild conditions. For example, various
laboratories, including our own, have reported the RAFT polymerization of monomers
containing primary amines,9,74,75,78,175 activated esters,155,158,170,171,173,174 activated
thiols,177,178 as well as other functionalities.180,260,261 The utility of RAFT polymerization
and the facile modification of pendent or end groups is not only attractive for small
molecule-polymer (i.e., fluorophores, drugs)9,10,82,177,178,203 coupling reactions, but also
biomacromolecule-polymer (i.e., oligonucleotides, proteins, peptides)8,10,11,80,173,198
conjugations.
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The work in this section focuses on the rational design of a polymeric carrier that
encompasses the attributes suggested by Ringsdorf through the incorporation of two
reactive functionalities for multiconjugation of therapeutics (siRNA) and cancer cell
targeting moieties (folate) (Schemes IV-5 and IV-6). To achieve carriers with precise
architectures, predetermined structopendant and structoterminal functionalities, and
narrow polydispersities, RAFT polymerization was utilized in the synthesis of a HPMAs-APMA copolymer. HPMA was chosen as the primary polymer component (90 mol %)
due to its nonimmunogenic, hydrophilic nature, while APMA was statistically
incorporated (10 mol %) to provide pendent primary amine functionalities. A small
fraction of the pendent primary amines were subsequently converted to activated thiols,
providing a copolymer with two distinct reactive sites. This allows for selective and
specific conjugation of thiolated-siRNAs and cancer cell targeting moieties (folate).
siRNA release through disulfide cleavage was demonstrated under intracellular
conditions, while the presence of attached folates would allow for site-directed delivery
of the siRNA carrier to cancer cell lines that over-express folate receptors.
Synthesis of Thiol Activated HPMA-s-APMA (P16)
The polymeric platform utilized for multiconjugation reactions, was designed to
contain 90 mol % hydrophilic HPMA (M4) repeats and 10 mol % primary amine pendent
APMA (M9) units distributed statistically along the polymer backbone. The statistical
copolymer, shown as compound P4 in Scheme IV-5, was prepared utilizing aqueous
RAFT polymerization with 4-cyanopentanoic dithiobenzoate (CTP; C1) and 4,4’azobis(4-cyanopentanoic acid) (V-501; I3) as the CTA and initiator, respectively
(Scheme IV-5). As determined by ASEC-MALLS the resulting copolymer had a number
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average molecular weight (Mn) of 51,800 g/mol and a polydispersity index (PDI) of 1.13.
The copolymer composition, HPMA320-s-APMA33 (P4), was determined by 1H NMR
(Figure IV-17). Low molecular weight tailing is apparent in the ASEC chromatogram
(Figure IV-18 a) which is typically observed in RAFT polymerizations and has been
attributed to premature termination and/or loss of the CTA thiocarbonylthio moiety.6,20
Nevertheless, the chromatogram is unimodal and narrow, representative of a controlled
polymerization.
The -thiocarbonylthio functionality was then removed to avoid aminolysis by
the pendent primary amine functionalities of APMA (Scheme IV-5). This removal was
carried out via addition of excess AIBN according to a literature procedure developed by
Perrier and coworkers244 yielding copolymer P11 illustrated in Scheme IV-5. The
removal of the thiocarbonylthio functionality was confirmed to be quantitative by
comparing the absorbance at 310 nm before and after removal (Figure IV-19). Further
evidence is provided by monitoring the thiocarbonylthio absorbance at 310 nm with a
UV-vis detector in-line with ASEC instrumentation (Figure IV-20 A). The ASEC
chromatogram (RI response) for end-capped HPMA320-s-APMA33 (P11) is unimodal with
no detectable byproducts (Figure IV-18 b). The Mn and PDI obtained from ASECMALLS (Mn = 51,600 g/mol, PDI = 1.10) are similar to those of copolymer P4 prior to
end group removal. Although, other methods for the removal of thiocarbonylthio groups
are available3,29,201 the utilized method proved to be satisfactory.
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Figure IV-17. 1H NMR spectrum and chemical shift assignments for HPMA320-sAPMA33 (P4) copolymer.
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Figure IV-18. Aqueous SEC-MALLS traces of (a) HPMA320-s-APMA33 (P4), (b)
HPMA320-s-APMA33 after thiocarbonylthio removal (P11) and (c) thiol activated
copolymer P16 after reaction with N-succinimidyl 3-(2-pyridyldithio)-propionate
(SPDP). Analysis was conducted at pH 3.0.
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Figure IV-19. UV-vis spectra of () HPMA320-s-APMA33 (P4), (  ) HPMA320-sAPMA33 after thiocarbonylthio removal (P11) and (----) thiol activated copolymer P16
after reaction with N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) in 20 mM
phosphate buffer (pH 7.4).
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Figure IV-20. A) UV-vis absorbance @ 310 nm before () and after (---) the removal
of the thiocarbonylthio functionality from HPMA320-s-APMA33 (P4) and B) UV-vis
absorbance @ 280 nm before (---) and after () thiol activation of HPMA320-s-APMA33
(P11) with N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP).
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Following thiocarbonylthio removal, copolymer P11 was reacted with the amineand sulfhydryl-reactive molecule N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP)
(Scheme IV-5) to yield the thiol activated copolymer P16. By modifying a portion of
pendent amines with SPDP, a copolymer containing both pyridyl disulfide sites and
primary amine sites was prepared. The introduction of these two types of functionality
allows copolymer P16 to be modified with both thiol and amine reactive compounds,
which is beneficial for conjugation of multiple chemically-distinct therapeutics and
targeting moieties.
Stoichiometries were used such that only 24 mol % of the available APMA repeat
units (8 of 33) would be converted to activated thiols when reacted with SPDP. The
successful reaction of SPDP with copolymer P11 was confirmed by both UV-vis (Figure
IV-19) and 1H NMR spectroscopy (Figure IV-21). Based on an extinction coefficient of
5100 M-1 cm-1 for pyridyl disulfide at 280 nm,262 the number of pyridyl disulfide groups
reacted with copolymer P11 was determined to be 7.1, indicating that 20 mol % of the
available APMA units were reacted with SPDP. The significant increase in absorbance at
280 nm is shown in Figure IV-19. Additionally, 1H NMR spectroscopy (Figure IV-21)
was utilized to confirm the presence of pyridyl disulfide functionalities in copolymer P16
as evidenced by the appearance of aromatic protons at 8.4 ppm and 7.6-7.8 ppm. The
amount of conjugated SPDP was estimated by comparing the pyridyl resonance at 8.4
ppm to that of the methyne-proton of HPMA at 3.7 ppm. This analysis indicates that 20
mol % of the APMA units were modified (6.9 pyridyl disulfide groups), thus
corroborating the results obtained by UV-vis spectroscopy. For comparison, the 1H NMR
spectrum for copolymer P11, along with integrations, can be seen in (Figure IV-22). In
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addition, a 2,4,6-trinitrobenzene sulfonic acid (TNBS) primary amine assay was
performed on copolymer P11 to determine the number of APMA units and verify the
result determined by the combination of 1H NMR and SEC (33 APMA units). As
expected, upon measuring the absorbance at 420 nm due to reacted TNBS, 32.9 ± 0.6
APMA units were found (Figure IV-23).
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Figure IV-21. 1H NMR spectra (d6-DMSO) showing the successful thiol activation of
copolymer P11 with N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP).
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Figure IV-23. Absorbance of reacted TNBS at 420 nm versus amine concentration for
alanine (■), end-capped HPMA320-s-APMA33 (P11) copolymer (0.454 M) (○), and the
fitted calibration curve (—).

In addition, ASEC-MALLS was utilized to demonstrate that thiol activated
copolymer P16 remained narrowly dispersed. As shown in Figure IV-18 c, the
chromatogram remained unimodal and narrowly dispersed with a PDI of 1.18 suggesting
minimal side reactions. Further characterization was provided by monitoring the pyridyl
disulfide absorbance at 280 nm with a UV-vis detector in-line with our ASEC
instrumentation (Figure IV-20). The Mn of copolymer P16 was estimated to be 53,000
g/mol based on the results of 1H NMR and UV-vis spectroscopy that 20 mol% of the
APMA units were modified by SPDP. ASEC-MALLS, UV-vis, and 1H NMR
spectroscopy data corroborate the successful synthesis of the target, dually reactive
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(amines and activated thiols) copolymer (P16) allowing for subsequent conjugation of
both RNA and folate.
siRNA and Folate Conjugation to Thiol Activated Copolymer P16
Following the successful preparation of copolymer P16, a 5’-thiolated RNA sense
strand (HS-RNA) was then introduced via a disulfide exchange reaction between pendent
pyridyl disulfides and HS-RNA to yield RNA conjugated copolymer P23 as shown in
Scheme IV-6. The disulfide exchange reaction was successfully carried out at pH 8.0
with a molar ratio of pendent pyridyl disulfide groups to HS-RNA of 1:2. Successful HSRNA conjugation was evidenced using polyacrylamide gel electrophoresis (PAGE)
(Figure IV-24 A & B) and UV-vis spectroscopy (Figure IV-25).
Linkage of HS-RNA to copolymer P16 is shown by PAGE through the
appearance of a high molecular weight band (Figure IV-24). Using Equation 9 from the
Experimental Section, the degree of conjugation of HS-RNA was determined by
comparing the intensity of the unreacted HS-RNA and RNA dimer band to that of the
conjugate band. From four replicates and standard gel imaging, the degree of conjugation
was found to be 89 ± 4 %. This implies that 6.3 of the 7 pendent pyridyl disulfides
participated in the disulfide exchange reaction. This coupling efficiency yields an RNA
conjugated copolymer (P23) which contains 2 mol% pendent RNA groups, 91 mol%
HPMA and 7 mol% APMA (Scheme IV-6).
Control reactions with copolymer P11 and P16 and HS-RNA were carried out to
verify that the HS-RNA was indeed attached via a disulfide linkage and not merely
associated with the polymer through non-covalent interactions (Figure IV-24 A). Lane 1
in Figure IV-24 A shows the incubated product of copolymer P11 with HS-RNA while
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lane 2 shows the results from incubation of thiol activated copolymer P16 with unthiolated RNA. These control reactions were carried out under identical conditions of the
RNA conjugation reaction. No appreciable conjugate formation is evidenced in lanes 1
& 2 (Figure IV-24 A) when compared to lane 3 which shows specific conjugation
between thiol activated copolymer P16 and HS-RNA. Weak electrostatic associations
between the copolymer and RNA may be attributed to the statistical nature of the
copolymer and to the large excess of HS-RNA compared to primary amine pendent
groups (nitrogen/phosphate = 0.07). Since HS-RNA is used, a dimer band is visible
above the unreacted HS-RNA which is attributed to disulfide formation between two HSRNA strands. RNA attachment to the copolymer backbone through a disulfide linkage
was established by showing RNA cleavage under reducing conditions (0.1 M DTT for 30
min) which led to the disappearance of the conjugate band (Figure IV-24 A, lane 4) as
well as the HS-RNA dimer band.
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Figure IV-24. Polyacrylamide gel electrophoresis (PAGE) of (A) control reactions, (B)
RNA conjugated copolymer P23 and RNA/folate conjugated copolymer P24 and (C)
hybridization of RNA/folate copolymer conjugate P24 with RNA anti-sense strand to
yield small interfering RNA (siRNA)/folate conjugate P25. A) Lane 1 – copolymer P11
with 5’-thiolated RNA sense strand (HS-RNA), Lane 2 – thiol activated copolymer P16
with unmodified RNA sense strand, Lane 3 – thiol activated copolymer P16 reacted with
HS-RNA and Lane 4 – components of lane 3 treated with 0.1 M dithiothreitol (DTT). B)
Lane 1 – HS-RNA, Lane 2 – thiol activated copolymer P16 reacted with HS-RNA, Lane
3 – purified RNA conjugated copolymer P23, Lane 4 – folate conjugated to copolymer
P11 (contains no RNA), Lane 5 – Purified RNA/folate conjugated copolymer P24, Lane
6 – lane 5 components treated with 0.1 M DTT. C) Lane 1 – RNA anti-sense strand,
Lane 2 – RNA/folate conjugated copolymer P24 hybridized with RNA anti-sense strand
yielding siRNA/folate conjugate P25, Lane 3 – lane 2 components treated with 0.1 M
DTT, Lane 4 – double stranded anti-survivin siRNA. All images were stained with
ethidium bromide (EtBr) and the run direction is from the top to bottom of images.
Intensity differences between lane 1 and 4 in C) are due to intercalation efficiency of
EtBr for double stranded RNA versus single stranded, not concentration.
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Figure IV-25. UV-vis spectra normalized by their extinction coefficients at 260 nm for
() free RNA sense strand, (---) RNA conjugated copolymer P23 and (  ) RNA/folate
conjugated copolymer P24 carried out in 20 mM phosphate buffer (pH 7.4).
The current method provides a facile and robust route for the coupling of multiple
RNAs to RAFT-synthesized copolymers utilizing low molar ratios and relatively fast
reaction times under mild conditions. The introduction of multiple thiol reactive sites
renders attachment of modified RNAs/oligonucleotides to high molecular weight
polymers straightforward with the potential to couple multiple gene targets to the same
carrier. Due to low molar ratios, purification of the RNA copolymer conjugate P23 is
facile and allows for isolation and subsequent modifications with targeting moieties.
Therefore, this pathway is advantageous for producing well-defined targeted gene
delivery vehicles as compared to previously reported methods for reacting modified
oligonucleotides to the end groups of RAFT generated polymers.8,10,11 Those methods
required 20 to 50 times excess of polymer relative to siRNA/oligonucleotide and long
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reaction times (18-20 h) to achieve high degrees of end-group conjugation. Furthermore,
these higher molar ratios may further complicate purification steps if conjugation to high
molecular weight polymers (> 10,000 g/mol) is desired due to difficulty in separating two
high molecular weight species (i.e. the polymer and the polymer-oligonucleotide
conjugate) by dialysis or membrane filtration separation methods. However, separation
of excess polymer or RNA when employing end group modification methods is possible
via HPLC. Additionally, molecular weights below 10,000 g/mol were used to achieve
high coupling efficiency whereas molecular weights above this led to low or incomplete
coupling efficiency even when excess polymer was present. A possible explanation for
this low degree of conjugation to higher molecular weight polymers is that the RAFT
polymers utilized contained only one reactive site at either the α or  terminus (i.e.
monofunctional). This could lead to poor collision frequency or proper orientation
between two reactive functionalities, thus further complicating an already difficult
reaction between two macromolecular species. Another possible reason is incomplete
chain end functionalization during platform synthesis, thus resulting in a lower degree of
oligonucleotide conjugation.11
In contrast to previously reported methods which required 20 to 50 times excess
of active site to thiol-oligonucleotide to obtain high yields, a 2 times excess of HS-RNA
in our approach resulted in 90 % conjugation efficiency to a copolymer with Mn > 50,000
g/mol. Since two times excess HS-RNA is used relative to reactive copolymer sites, the
removal of unreacted HS-RNA from the RNA conjugated copolymer P23 is
straightforward.

This removal is evidenced by comparing lanes 2 and 3 in Figure IV-24

B showing the conjugate band visible only in lane 3. As a side note, the unreacted HS-
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RNA in these reactions can be recovered through extraction from the PAGE gel and
reused for future studies, which is beneficial given the high cost of modified
oligonucleotides. A similar recovery method could be employed for end group modified
RNA-RAFT copolymer conjugates. Following purification and recovery of RNA
conjugated copolymer P23, the concentration of RNA was determined by UV-vis
spectroscopy. As shown in Figure IV-25, the free RNA spectrum is analogous to that of
RNA conjugated copolymer P23 thus supporting the PAGE results. The slightly higher
absorbance present in the RNA conjugated copolymer P23 spectrum below 250 nm is
due to the absorbance of the copolymer repeating units.
Following isolation and subsequent analysis of RNA conjugated copolymer P23,
the remaining APMA groups (26 repeats, 7 mol%) were reacted with excess NHSactivated folate (NHS-FA) for 2 h as illustrated in Scheme IV-6. Any excess or
unreacted folate was removed by membrane filtration. After purification and recovery,
RNA/folate conjugated copolymer P24 was analyzed by UV-vis spectroscopy. As shown
in Figure IV-25 (dotted line) the absorbance increase is due to conjugated folate. The
shoulder peaks that appear near 350 and 310 nm are also due to the presence of folate.
Given the higher extinction coefficient for folate at 281 nm (30300 M-1 cm-1) versus 350
nm (8000 M-1 cm-1)9 and the low concentration of the measured sample, the former
extinction coefficient was used for a more accurate analysis. Using Equations 10 and 11
(Experimental Section), the relative concentrations of both RNA and folate were
calculated. The number of conjugated folates was determined to be approximately 21 out
of 26 available sites, yielding a coupling efficiency of 81 ± 1 %. Similarly, using the
extinction coefficient for folate at 350 nm, it was estimated that 19 sites contained folate,
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which is in close agreement to the results obtained from Equations 10 and 11. The
resulting copolymer consists of 91 mol% HPMA, 2 mol% RNA, and 6 mol% folate. The
remaining 1 mol% can be assigned to unmodified APMA units.
RNA/folate conjugated copolymer P24 was also analyzed by PAGE (Figure IV24 B, lane 5) to verify that the coupled RNA was unaffected by the folate reaction. As a
control, lane 4 of Figure IV-24 B contains folate conjugated to copolymer P11 (no RNA)
to show that the copolymer or folate cannot be stained by EtBr and that neither fluoresce
under standard gel imagining techniques. Importantly, lane 6 in Figure IV-24 B indicates
that the disulfide-linked RNA can still be released in the presence of 0.1 M DTT.
Additionally, our studies revealed that the order of reaction is important. Reaction of
NHS-FA followed by HS-RNA led to substantially lower degrees of RNA conjugation
(30-40%), determined via gel electrophoresis, as compared to the synthetic pathway
described above. Decreased yields are attributed to pendent folates sterically blocking
activated thiol sites or secondary interactions between multiple folates, lowering the
number of accessible activated thiol sites for reaction with HS-RNA. Given the lower
degree of HS-RNA conjugation, reactions by this alternative route were not further
explored.
In the last step, illustrated in Scheme IV-6, the conjugated RNA strand was
hybridized with its complementary anti-sense strand to form double stranded siRNA.
The siRNA model chosen for this work was an anti-survivin siRNA which our
laboratories have used previously due to its potential in cancer treatment.9 PAGE was
employed in order to confirm hybridization as shown in Figure IV-24 C. Lane 1
indicates only the anti-sense strand while lane 2 shows the hybridized product. As
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indicated in lane 2 of Figure IV-24 C, no band is present for the anti-sense strand
indicating quantitative hybridization. The release of the siRNA from the copolymer
backbone under reducing conditions (0.1 M DTT) is visualized in lane 3 of Figure IV-24
C and for comparison lane 4 shows unmodified anti-survivin siRNA. The slightly slower
migration of the released siRNA in lane 3 as compared to the reference unmodified
siRNA in lane 4, Figure IV-24 C, is attributed to high salt concentration (150 mM) used
during the hybridization step. The unmodified siRNA used as a reference in lane 4
contains no salt. A longer running time was used (30 versus 10 min) for the gel in Figure
IV-24 C compared to that in Figure IV-24 A to compensate for the faster migration of
double stranded siRNA (59 nt) versus single stranded RNA with a similar number of
nucleotides (e.g. the RNA dimer (54 nt) in Figure IV-24 A). This difference arises from
the RNA chain confirmation in solution (i.e. random coil versus double helix). Although
it was demonstrated that the siRNA could be released in the presence of 0.1 M DTT,
subsequent studies were conducted to verify siRNA release under conditions similar to
those in the cytoplasm of the cell.
siRNA Release Under Intracellular Conditions
Effective gene delivery requires an intracellular release mechanism of the
therapeutic agent from the carrier. The reducing environment in the cytoplasm of cells
attributed to the presence of glutathione renders disulfide linkages attractive for
intracellular therapeutic release. In fact, several research groups are using disulfides as a
means to conjugate siRNA, thus exploiting intracellular reducing
conditions.8,10,11,178,230,232,263,264 Typical glutathione concentrations in the intracellular
compartment of mammalian cells range from 1-10 mM.265,266 Therefore, we sought to
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demonstrate that the attached oligonucleotide can be released not just under the artificial
conditions (0.1 M DTT) demonstrated above, but also under more typical cytoplasmic
conditions. The synthesized siRNA/folate copolymer conjugate P25 was incubated at 37
°C in the presence of 5 mM glutathione (pH 7.4). The profile of siRNA released versus
time and the PAGE image can be seen in Figures IV-26 A & B. Approximately 60 %
release was achieved in 4 hours with an estimated half-life of 200 min. These
experiments demonstrate that the siRNA/folate copolymer conjugate P25 can indeed
release siRNA under these conditions.
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Figure IV-26. Release of siRNA from siRNA/folate copolymer conjugate P25 incubated
in the presence of 5 mM glutathione (pH 7.4). A) Percent release of siRNA versus time
and B) polyacrylamide gel electrophoresis (PAGE) of siRNA/folate copolymer conjugate
P25 incubated with glutathione at increasing time intervals (left to right).
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CHAPTER V
CONCLUSIONS
Section I. Development of Conjugation Methods to Both the α- and -Chain Ends of
RAFT-Synthesized HPMA-b-DMAPMA Copolymers
Synthetic pathways for labeling both the α- and -chain ends of RAFTsynthesized copolymers have been developed. First, a facile method to functionalize the
-chain end of the RAFT copolymer HPMA258-b-DMAPMA13 (P6) with a primary
amine and subsequently label with an amine reactive dye was accomplished. The
reduction of the dithioester chain end, using NaBH4, yields a tertiary polymeric thiol with
low reactivity. To circumvent this problem, the reduced polymer was functionalized with
a primary amine via a disulfide exchange with dihydrochloride cystamine. The degree of
functionalization was measured using a ninhydrin assay by measuring the maximum
absorbance at 570 nm. The degree of functionalization was found to be 91.7 ± 0.3%. The
primary amine at the -chain end of the RAFT polymer, which is more reactive than a
tertiary thiol, allows for facile conjugation between HPMA258-b- DMAPMA13 copolymer
and the fluorescent dye, 5-SFX. The degree of conjugation was found using a UV-vis
spectrometer by measuring the maximum absorbance at 494 nm, giving a degree of
conjugation of 80.1 ± 2.6%. The facility by which RAFT-generated polymers can be
functionalized as described in this work points to future utility in drug delivery, gene
delivery, biodiagnostics, as well as other areas of biotechnology.
The ability to precisely control block length via RAFT polymerization was
demonstrated by the synthesis of HPMA-b-DMAPMA copolymers (P7). In addition,
FA-PEG34-NH2 was successfully conjugated to HPMA250-b-DMAPMA15 (P19; n = 15)
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and HPMA250-b-DMAPMA32 (P19; n = 32) through the use of carbodiimide chemistry.
However, the poor conjugation efficiency (< 62 %) of -terminal chain ends by this
synthetic route and the advantages of incorporating multiple targeting moieties led to the
development of an alternate copolymer for siRNA delivery applications.

Section II. Synthesis and Characterization of Multivalent Folate-Block Copolymers for
Targeted Delivery of siRNA and Gene ―Knockdown‖
The facile synthesis of a novel, well-defined, multivalent terpolymer capable of
forming neutral complexes with siRNA and providing multiple targeting moieties for cell
specific siRNA delivery has been demonstrated. These copolymers consist of a
biocompatible statistical hydrophilic block that provides amine functionality for
bioconjugation and a cationic block that promotes electrostatic complexation with
siRNA. Well-defined, narrowly dispersed, HPMA-s-APMA macroCTAs and (HPMA-sAPMA)-b-DMAPMA block copolymers were successfully prepared via aqueous RAFT
polymerization in acetate buffer (pH 5.2). Direct polymerization of the primary amine
monomer, APMA, without protecting group chemistries, demonstrates the usefulness of
RAFT polymerization in preparing reactive/functional copolymers. The resulting APMA
repeat units of the terpolymer were then successfully reacted with NHS-activated folate
to prepare multivalent folate-block copolymer conjugates. Prior to siRNA complexation
and delivery, it was established that these multivalent folate-block copolymer conjugates
have negligible cytotoxicity. These multivalent folate-block copolymer conjugates were
then employed in the successful complexation and subsequent cellular delivery of a 59 nt
siRNA against human survivin.
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Folate conjugated (HPMA315-s-APMA13)-b-DMAPMA23 (P20) was chosen for
dynamic light scattering and zeta potential measurements. Upon complexation with
siRNA, the size of the complex was found to be 15.2 nm, consistent with previous
findings by our laboratories. In addition, the zeta potential decreased from + 25.4 mV for
P20 alone to -3.88 mV for the copolymer/siRNA complex indicating that close to neutral
complexes were formed.
Cell specific delivery of a Cy3-labeled siRNA utilizing P20 was demonstrated via
fluorescence microscopy. Complexes prepared with folate conjugated (HPMA315-sAPMA13)-b-DMAPMA23 showed positive delivery to KB cells, which over-express
folate receptors, while delivery to A549 cells, which have negligible folate receptor
expression, was negative. Importantly, cellular uptake of complexes prior to folate
conjugation was not visible in the KB cell line. Additionally, these multivalent FA-block
copolymer/ siRNA complexes proved to be successful at gene down-regulation as
evidenced by reduced mRNA levels of human survivin in KB cells. Significantly, the
presence of excess free folate in the KB cell media prior to treatment with multivalent
FA-block copolymer/ siRNA complexes resulted in minimal gene down-regulation due to
limited accessibility of folate receptors.

Section III. Rational Design of Targeted Cancer Therapeutics through the
Multiconjugation of Folate and Cleavable siRNA to HPMA-s-APMA Copolymers
A unique synthetic pathway allowing the conjugation of gene therapeutics and
targeting moieties to a well-defined polymeric platform has been reported. The
synthesized copolymer contains biocompatible segments provided by poly(HPMA) and
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both primary amine and activated thiol functionalities for post-polymerization
modification. In this case, the introduction of multiple reactive sites allows attachment of
multiple siRNAs and multiple folates for potential targeted delivery to cancerous cells
that over-express folate receptors. The degree of siRNA conjugation was determined to
be 89 ± 4% (6 siRNAs) and the coupling efficiency of folate was 80 ± 1% (21 folates).
The final molar composition of the siRNA/folate copolymer conjugate P25 was 91 mol
% HPMA, 2 mol % siRNA, and 6 mol % folate. To date, the conjugation of siRNA,
specifically to copolymers synthesized via CRP methods, has been limited to the end
groups of low molecular weight polymers.8,10,11 The current method addresses limitations
of previous methods by allowing (1) reaction of multiple siRNAs with lower molar ratios,
(2) coupling of targeting moieties, (3) conjugation to high molecular weight polymers, (4)
facile purification, and (5) short reaction times while still taking advantage of RAFT
polymerization. In addition, by linking siRNAs via disulfide bonds, release of siRNA
from the polymer was achieved under simulated intracellular conditions (5 mM
glutathione) demonstrating the potential utility of these carriers for future delivery to
cancer cells. Although attachment of siRNA and folate were demonstrated, multiple types
of bioagents with either thiol or amine reactive functionalities might also be envisioned
for various delivery and/or biodiagnostics purposes. By providing two reactive side chain
functionalities, this method has utility in the preparation of other well-defined
bioconjugate systems.
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CHAPTER VI
FUTURE RECOMMENDATIONS
Pioneering research in RAFT polymerization was largely focused on mechanistic
studies as well as the development of CTAs and reaction conditions for the
polymerization of a variety of monomers.16,17,20 Thanks to the establishment of these
conditions, current researchers in the area of RAFT polymerization have redirected their
efforts towards the preparation of novel, water soluble, functional copolymers and the
investigation of these materials in various bioapplications. Control over molecular
weight, PDI, polymer composition and placement of chemical functionality by RAFT
polymerization allows for manipulation and fine tuning of molecular properties.85 This
not only provides opportunities to prepare novel functional copolymers, but also to study
polymer structural and/or compositional manipulations that can provide invaluable
information that facilitates the design of polymeric systems for advanced applications.
Although RAFT polymerization has recently been exploited in preparing water soluble
copolymers for siRNA delivery,6-12,267 composition and structural effects on siRNA
stabilization and binding as well as the effect of the number of targeting moieties per
polymer chain on cellular delivery remains relatively unexplored.
The work presented in this dissertation has established a strong foundation in
regards to constructing functional/reactive biorelevant copolymers via RAFT
polymerization. Bioconjugation routes for the synthesis of pendent and end group
modified copolymers have been developed, facilitating the design of actively-targeted
siRNA/copolymer electrostatic complexes and copolymer-siRNA bioconjugates.
Building on this foundation, it is recommended that a systematic study be carried out of
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the effect of the cationic nature (i.e. side chain functionality), cationic block length, and
copolymer composition on siRNA stability and binding strength (Table VI-1, Entry 1).
Even though research presented in this dissertation utilized DMAPMA (M7) as the
cationic monomer, other cationic monomers such as DMAEMA (M11) would be of
interest due to structural and pKa differences. Table VI-I provides recommended molar
compositions for future experiments utilizing hydrophilic-b-cationic copolymers where
the hydrophilic portion is comprised of HPMA (M4) repeats. As an example, the
composition of the cationic block can be statistically modified with the hydrophilic
containing monomer HPMA, thus manipulating the binding strength between the cationic
block and siRNA. The resulting binding strengths may be measured through either
nanocalorimetry or qualitatively monitored through gel electrophoresis experiments. It is
suggested that the HPMA hydrophilic block be maintained at or above 250 repeat units
for siRNA stability and solubility of neutral (N/P = 1) complexes.

Table VI-1. Suggested Molar Compositions of Hydrophilic-b-Cationic Copolymers,
Synthesized Via RAFT Polymerization, for Future Studies of siRNA Complexation and
In Vitro Delivery to Folate Receptor-Positive Cell Lines. See Figure VI-1 for Generalized
Copolymer Structure.

Entry

HPMA-s-Folate Block
(w : x)

1

100:0

2

97.5:2.5, 95:5, 92.5:7.5.
90:10. 87.5:12.5. 85:15

HPMA-s-Cationic Block
(y : z)

Total Cationic
Repeats (DP)

0:100, 10:90, 20:80, 30:70,
40:60, 50:50
0:100, Optimized
Composition from Entry 1

Varied between 10
and 60
Varied between 10
and 60
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Figure VI-1. Generalized block copolymer structure for recommended studies.

Further studies on the effect that the number of conjugated folates per polymer
chain has on siRNA delivery to cancerous cell lines are also warranted. It has been
shown in the literature that multivalent carriers have an effect not only on uptake
efficiency but also endosomal release and subsequent gene down-regulation.130,131,252,268
Suggested molar compositions of folate in the HPMA hydrophilic block are given in
Entry 2 of Table VI-1. For example, if the degree of polymerization of HPMA is held
near 250 repeats than the amount of folate repeats will be varied between 6 and 38. Entry
2 in Table VI-1 would be used to elucidate the relationships among the number of FA
conjugated units, the solubility of FA conjugated copolymer/siRNA complexes and
siRNA delivery efficiency.
Other opportunities exist for studying the folate targeted delivery process of
siRNA through in vitro experiments. This can be achieved by complexing Cy3 labeled
siRNA, where Cy3 has an emission maximum near 570 nm, with an (HPMA-s-APMA)b-DMAPMA copolymer that is first conjugated to an NHS-activated black hole quencher
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dye, BHQ-2 (Figure VI-2). BHQ-2 can be easily conjugated to one of the APMA (M7)
repeats of the copolymer at a 1:1 molar ratio of BHQ-2:copolymer.269 BHQ-2 dye has an
absorption range of 550-650 nm and an absorption max at 579 nm. Following
conjugation of BHQ-2, the remaining APMA units are reacted with excess diNHS-FA as
detailed in Chapter III. The large overlap in the emission spectrum of Cy3 (donor) and
the absorption spectrum of BHQ-2 (acceptor) allows for efficient fluorescence resonance
energy transfer (FRET), when the donor-acceptor pair are within 10 nm. The
complexation of a BHQ-2 and folate labeled (HPMA-s-APMA)-b-DMAPMA copolymer
with Cy3 labeled siRNA and subsequent treatment of various cancer cell lines will allow
the release of siRNA to be visualized under in vitro conditions. Upon siRNA release,
energy transfer from the donor to the acceptor is abated and emission from the donor, in
this case Cy3, is restored. This study will give insight into the location of siRNA release
from the copolymer complex. Furthermore, FRET studies are also recommended using a
fluorometer to gain information on the complexation, and therefore the binding strength,
between the block copolymer and siRNA and the release of siRNA under simulated
physiological conditions.
OCH3
O2N

N

N
N

N

N

H3CO
O

O
N

O
O

Figure VI-2. Structure of NHS activated black hole quencher dye (BHQ-2).
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Additional possibilities include preparing novel functional monomers that can be
polymerized via RAFT polymerization. For example, the controlled polymerization of a
guanidine containing monomer would be of interest because of its similarity to the amino
acid arginine. It has been demonstrated in literature that cell penetrating peptides are rich
in arginine repeats and have the ability to cross cellular membranes through an
endocytotic independent pathway, although this is still under debate.270 These peptides
are typically less than 20 amino acids, and have been shown to deliver macromolecules
(i.e., DNA, polymers) to numerous mammalian cells.270,271 To date, there has only been
one report on the synthesis and polymerization of a methacrylate monomer with an
arginine-resembling pendent group.272 The cell penetrating properties as well as the
DNA condensing ability of this guanidine containing polymer were investigated.
Following DNA condensation, polyelectrolyte complexes with N/P ratios near 5 were
shown to transfect COS-7 mammalian cells in the absence of serum. N/P ratios greater
than 5 were shown to have high cytotoxicity. A possible reason for this toxicity and less
than optimal transfection, when directly compared to cell penetrating peptides, is the use
of conventional free radical polymerization that led to poorly defined polymers with PDIs
in excess of 7.0. Therefore, a promising opportunity exists to prepare well-defined,
narrowly dispersed (co)polymers with arginine pendent functionalities via RAFT
polymerization. Studies on transfection and siRNA complexing capabilities of such
copolymers would be a logical extension of the work presented in this thesis. The control
provided by the RAFT process may be able to mimic the uniformity and thus structure
property relationships seen with typical cell penetrating peptides. Suggested synthesis of
a methacrylamide monomer with an arginine side group is illustrated in Scheme VI-1.
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Scheme VI-1. Recommended reaction pathway for the synthesis of N-(3guanadinopropyl)methacrylamide.
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